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ABSTRACT
Herpes simplex virus type 1 (HSV-1) is a DNA virus that is a ubiquitous pathogen of
humans. The hallmark of the HSV-lifecycle is infection of a mucosal surface with spread
to sensory neurons where the virus establishes a latent infection with periodic recurrences
for the life of the host. The most common course of symptomatic disease with HSV-1 is
the typical mucocutaneous lesion that is self-limiting. HSV-1 can also cause acute
encephalitis and ocular pathology on reactivation. Both of these manifestations of the
disease have severe consequences. Although ocular infection is less frequent, the
extensive prevalence of HSV makes it one of the most common infectious causes of
blindness in developed countries. Herpetic encephalitis causes significant morbidity and
mortality, particularly in the immunosuppressed or untreated individual. HSV-1 specifies
at least 11 glycoproteins that are expressed in the infected cells. The viral glycoproteins
are the first interface of the virus with a host cell and are therefore vitally important to
virus pathogenesis. Glycoproteins B, C, D, H, and L have been extensively studied and
found to be involved in initial attachment, fusion, and entry of the virus into a host cell.
Recent work in this laboratory has shown that glycoprotein K (gK) is also involved in the
fusion machinery of the virus, however, little was known about the role of gK in the
pathogenesis of the virus. To assess the role of gK in pathogenesis, mutant viruses were
used an experimental infection in a mouse eye model. In this investigation, gK was found
to have a critical role in the pathogenesis of the virus in the eye as well as in spread of the
infection to neurons and subsequent development of latency. Following this work, a
primary neuronal culture system was established to further define the role that gK played
in neuronal infection and transport. Using this system, gK was found to be a critical
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determinant for neuronal transport and pathology. Since gK deficient viruses appear
unable to infect neurons, defining this phenotype may assist in the eventual development
of a successful vaccine strain of the virus.
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CHAPTER I

INTRODUCTION

STATEMENT OF PROBLEM AND HYPOTHESIS

Herpes Simplex Viruses (HSV) are ubiquitous and represent the etiologic agents
responsible for a multitude of human ailments including mucocutaneous oral and genital
diseases, ocular disease, and viral encephalitis. The hallmark of the HSV-lifecycle is
infection of a mucosal surface with spread to sensory neurons where the virus establishes
a latent infection with periodic recurrences for the life of the host (Whitley, Kimberlin et
al. 1998a). The most common course of symptomatic disease with HSV-1 is the typical
oral mucocutaneous lesion that is self-limiting. Disease with HSV-1 is often considered a
quality of life issue rather than a potentially severe infection. However, HSV-1 can also
cause acute encephalitis and ocular pathology on reactivation and the impact of HSV can
be significant on healthy individuals as well as immunosuppressed people (Whitley
2001b). Although ocular infection is less frequent than mucocutaneous infection, the
marked prevalence of HSV in the population makes it one of the most common infectious
causes of blindness in developed countries (Liesegang, Melton et al. 1989a; Liesegang
2001). During the life cycle of HSV in its host, there are a number of distinct events
including initial attachment of the virus to a host cell membrane, fusion and entry of the
virus, viral protein and DNA production, assembly of capsids and DNA packaging of the
progeny virions, and acquisition of the final envelope and egress of the virus from the
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cell. Many of these individual facets of the virus life cycle are areas of intense
investigation. In many cases the constituents of this process are known. Herpes simplex
virus has a relatively large genome, for a virus, with approximately 152,000 bases (Kieff,
Bachenheimer et al. 1971). This allows HSV-1 to encode approximately 90 known gene
products and at least 84 transcriptional units participating in the production of proteins
(Roizman, Knipe et al. 2007).
In particular, HSV-1 specifies at least 11 glycoproteins that are expressed in the
infected cells (Roizman and Knipe 2001a). The viral glycoproteins are the first interface
of the virus with a host cell and are therefore vitally important to virus pathogenesis.
Glycoproteins B, C, D, H, and L have been extensively studied and found to be involved
in initial attachment, fusion, and entry of the virus into a host cell (Furth, Whitbeck et al.
1997; Whitbeck, Peng et al. 1997; Laquerre, Argnani et al. 1998; Warner, Geraghty et al.
1998; Krummenacher, Rux et al. 1999; Whitbeck, Muggeridge et al. 1999). These
proteins can control host cell range and even species range of infection.
The dogma often encountered with viruses with large genomes and many encoded
proteins is one of, one protein equals one function or one area of function, such as virion
attachment, entry, assembly, or egress. However, smaller viruses with smaller genomes
often have multifunctional proteins. In HSV, glycoprotein K (gK) appears to be
multifunctional. Glycoprotein K has been shown to have roles in virion egress,
envelopment, and viral fusion and syncytia formation (Ruyechan, Morse et al. 1979;
Bond and Person 1984; Pogue-Geile, Lee et al. 1984; Debroy, Pederson et al. 1985;
Jayachandra, Baghian et al. 1997; Laquerre, Argnani et al. 1998; Foster, Melancon et al.
2004a; Melancon, Luna et al. 2005; Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al.
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2010; Chouljenko, Kim et al. 2012). Recent work in this laboratory (cited above) has
shown that glycoprotein K (gK) is also involved in the fusion machinery of the virus,
however, little was known about the role of gK in the pathogenesis of the virus. The
overall hypothesis of the investigations described in this thesis, has been that gK plays a
significant role in viral pathogenesis. This hypothesis predicts that due to its many and
varied effects in the virus, a virus lacking gK will have a significant negative impact on
the pathogenesis of the virus in neurons and by extension ocular disease.

STATEMENT OF RESEARCH OBJECTIVES

The goal of this research was to investigate the role of Herpes Simplex Virus Type 1
glycoprotein K (gK) in relation to viral pathogenesis in the eye, nervous system and
individual neurons. The specific aims of this research were:

1. To assess the virulence and replication characteristics of gK-null viruses in
cell culture and the mouse eye model.
2. To develop a reproducible primary cell culture system amenable to
examination via microscopy and molecular techniques such as PCR.
3. To use the system developed in aim 2 to examine specific role of gK in
neuronal infection and anterograde and retrograde transport in neurons
without the influence of a host organism to potentially confound results.
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Overall, the results obtained from this research indicate that:
1. Glycoprotein K is critical to spread in the eye and for spread,
neuroinvasiveness, and the establishment of latency in an animal.
2. Glycoprotein K is a critical determinant in the infection of neurons at the level
of the axonal terminus.
3. Glycoprotein K is necessary for spread of the virus from a neuron to epithelial
cells in an anterograde manner.

The work is presented in individual chapters in a manuscript format having a specific title
for the central theme of each chapter.

Chapter 2: The Herpes Simplex Virus Type-1(HSV-1) Glycoprotein K(gK) is Essential
for Viral Corneal Spread and Neuroinvasiveness.
Chapter 3: A Mutant Herpes Simplex Virus Type-1 (HSV-1) McKrae Lacking the Glycoprotein
K (gK) Gene is Unable to be Transported in Axons in either the Anterograde or
Retrograde Manner.

LITERATURE REVIEW

History of Herpesviruses
Herpes was possibly first described in descriptions of lesions as early as the third
millennium BCE in a Sumerian tablet and the Ebers papyrus, 1500 BCE (Whitley 2001a).
Hippocrates used the Greek for “herpes”, or “herpein” to describe a lesion that creeps or
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crawls along the skin (Wildy 1973) and Pliny (the Elder) mentioned a syndrome that
could likely be shingles and called this syndrome “zoster” (Beswick 1962). These lesions
could have been the result of herpesvirus, other cutaneous infections or even cutaneous
neoplasms; however, herpes has been part of the human experience since prior to
recorded history. The three primary subfamilies of mammalian herpesviruses are
projected to have arisen about 200 million years ago and the two types of simplex virus
diverged as much as eight to ten million years ago, yet Homo sapiens sapiens are only
approximately 200,000 years old (McGeoch, Dolan et al. 1985; Gentry, Rana et al. 1988).
Herodotus is credited with realizing the association of fever and cutaneous lesions
in HSV (Whitley 2001a). While the Greek physician Galen recognized that recurrent
HSV lesions develop at the same sites in the second century A.D. (Whitley 2001a). By
the 18th century, study of the virus had progressed and the first description of genital
disease associated with herpes virus was published in De Morbis Veneris by John Astruc,
physician for King Louis XIV of France, after studying French prostitutes (Puellae
publicae) (Astruc 1736). In 1814, Bateman accurately describes both herpes labialis and
herpes preputialis as vesicular to ulcerative diseases often with heat, tingling, and pain
associated with the vesicles and spontaneous resolution and reoccurrence of the disease
(Bateman 1814). In the late 19th century, Vidal demonstrated that inocula from lesions
could transmit vesicular lesions from patient-to-patient and from one anatomic area to
another on the same patient, thereby proving the infectious nature of the virus (Vidal
1873; Longson 1978). Gruter, using rabbit studies, rather than human, showed that HSV
could be transmitted from one rabbit to another in likely the first use of an animal model
in the study of herpes (Gruter 1924). He is also given credit for first isolation of the virus
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by most of the virology community. In 1930, Andrewes and Carmichael showed that
recurrent disease could occur in people with significant levels of neutralizing antibodies,
which was contrary to popular beliefs in virology at the time (Andrewes 1928; Andrewes
1929; Andrewes and A. 1930).
By 1939, Burnet and Williams had resolved much of the current view on herpetic
latency; that the virus remains latent but various stimuli may awaken it from the latent
state to cause recurrence and lesions (Burnet 1939). As tissue culture techniques
emerged and evolved, isolation of other families of human herpesviruses became
possible. During the 1950’s, Varicella Zoster Virus (VZV, chickenpox) and
Cytomegalovirus (CMV) were isolated (Weller and Stoddard 1952; Rowe, Hartley et al.
1956; Craig, Macauley et al. 1957). By the end of the 1990’s T-cell lymphocyte culture
allowed the isolation of Human Herpesviruses 6A, 6B and 7 and Representational
Differential Analysis allowed the isolation of Human Herpesvirus 8 (Salahuddin, Ablashi
et al. 1986; Lopez, Pellett et al. 1988; Frenkel, Schirmer et al. 1990; Chang, Cesarman et
al. 1994). In 1962, Schneweiss demonstrated two distinct serotypes of Human
Herpesvirus (Schneweiss 1962). In 1971, the first International Committee on Taxonomy
of Viruses (ICTV) established the genus of Herpesvirus and by 1979 the committee had
elevated the herpesviruses to a family (Herpesviridae) and established the two serotypes
of herpes simplex virus (HSV) as Human Herpesvirus 1 and 2 (Davison 2010).

Taxonomy of Herpesviridae
Initially, identification of viruses, including Herpesviruses, was based on
epidemiologic factors, such as host range, and biologic properties, such as clinical course
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of disease and character of lesions. Developing technologies have shaped the
classification of viruses. With electron microscopy, Herpesviruses could be classified on
the basis of morphology. Biologic and chemical tests also allowed for characterization of
a virus based on antigens and biochemical properties. Therefore, all herpesviruses have
an icosahedral capsid of 162 capsomeres that surrounds a core filled with DNA and the
capsid is surrounded by a protein-rich tegument and a lipid envelope (Davison 2010).
Furthermore, biologic properties, like the establishment of latent infection in the natural
host, were included in the initial classification of herpesviruses into the Herpesviridae
family by the ICTV in 1979 (Matthews 1979; Davison 2010). Features of natural host
species, cell types infected, reproductive cycle, and antigens were used to further
subdivide the herpesviruses into the subfamilies of Alpha-, Beta- and
Gammaherpesvirinae (Roizman 1973; Roizmann, Desrosiers et al. 1992; Van
Regenmortel, Fauquet et al. 2000). During this time, a formal system for naming
herpesviruses was founded with various changes occurring over the following years, but
maintaining that herpesviruses are named after the family or subfamily to which the
primary host belongs; with the notable exception that human herpesviruses would
maintain human as a designation rather than hominid (Roizman 1973; Fenner 1976;
Matthews 1979; Roizman, Carmichael et al. 1981; Francki, Faquet et al. 1991;
Roizmann, Desrosiers et al. 1992; Davison 2010). Since the ancestral Herpesvirinae
subfamilies are projected to have appeared about 200 million years ago, it is not
surprising that DNA analysis has found many distantly related species of viruses in
animals (McGeoch, Dolan et al. 1985). With the discovery of many new herpesviruses,
the ICTV established the order Herpesvirales in 2009 (Davison 2010). This order
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contains three families: Herpesviridae, containing the viruses of mammals, birds and
reptiles; Alloherpesviridae, containing viruses of bony fish and frogs; and
Malacoherpesviridae, containing the bivalve herpes virus OsHV1 (Davison 2010). The
family Herpesviridae now contains the subfamilies of Alphaherpesvirinae,
Betaherpesvirinae and Gammaherpesvirinae. Type 1 simplex virus is an
alphaherpesvirus.
Due to the relatively rapidly mutating nature of viruses a couple definitions are
helpful to consider when discussing taxonomy of a virus. The ICTV defines virus
species as “a polythetic class of viruses that constitutes a replicating lineage and occupies
a particular ecological niche” (Van Regenmortel 1990). Herpes viruses are considered a
distinct species if “(a) their genomes differ in a readily assayable and distinctive manner
across the entire genome and not merely at a specific site, and (b) if the virus can be
shown to have distinct epidemiologic and biologic characteristics” (Roizmann, Desrosiers
et al. 1992). Members of the Alphaherpesvirinae subfamily have the following features
in common: variable host range, a generally short reproductive cycle in primary host,
rapid reproduction and spread in permissive tissue cultures, efficient lysis of infected
non-neuronal cells, and the ability to establish latent infections in neuronal cells,
primarily in sensory ganglia. The genera Simplexvirus (including HSV-1),
Varicellovirus, Marek’s disease-like virus, and Infectious laryngotracheitis-like virus are
members of the Alphaherpesvirinae subfamily (Roizmann, Desrosiers et al. 1992; Van
Regenmortel, Fauquet et al. 2000). Members of the Betaherpesvirinae subfamily have
the following features in common: a more restricted host range, long reproductive cycle
in host cells, slow infection progression and replication in tissue culture, cytomegaly
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(infected cells becoming enlarged) and latency is usually maintained in secretory glands,
lymphoreticular cells or kidneys. Cytomegalovirus, Muromegalovirus, and Roseolovirus
are members of the Betaherpesvirinae subfamily (Van Regenmortel, Fauquet et al. 2000).
Members of the Gammaherpesvirinae subfamily share the following characteristics: the
host range is limited to the family or order of the natural host, these viruses replicate in
lymphoblastoid cells in cell culture, some members of the subfamily cause lytic infection
in epithelial and fibroblastic cells, usually specific for either B or T lymphocytes, and
viral latency is usually maintained in lymphoid tissue. Lymphocryptovirus (EBV-Epstein
Barr virus), and Rhadinovirus are members of the Gammaherpesvirinae subfamily (Van
Regenmortel, Fauquet et al. 2000). Table 1.1 shows the family classification and
common names of the nine known human herpesviruses (denoted by an *) as well as
other commonly studies herpesviruses.

Table 1.1: The taxonomic classification of the nine known human herpesviruses
(denoted by *) as well as other commonly studied herpesviruses; adapted from
(Roizmann, Desrosiers et al. 1992; Van Regenmortel, Fauquet et al. 2000).
Table 1.1 Notable members of the Herpesviridae family
Subfamily
Designation
Vernacular Name
AlphaHuman herpesvirus 1 (HHV-1)*
Herpes simplex virus type 1 (HSV-1)
herpes- Human herpesvirus 2 (HHV-2)*
Herpes simplex virus type 2 (HSV-2)
Varicella-zoster virus (VZV),
virinae
Human herpesvirus 3 (HHV-3)*
chicken pox, shingles
Cercopithecine herpesvirus 1
Herpesvirus B, Simian Herpesvirus
(CeHV-1)
Gallid herpesvirus 1 (GaHV-1)
Infectious laryngotracheitis virus
Gallid herpesvirus 2 (GaHV-2)
Marek’s disease virus
Pseudorabies virus, Aujesky’s
Suid herpesvirus 1 (SuHV-1)
disease virus
Feline herpesvirus 1, Feline
Felid herpesvirus 1 (FeHV-1)
rhinotracheitis virus
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Ictalurid herpesvirus 1 (IcHV-1)
Bovine herpesvirus 1 (BoHV-1)
Bovine herpesvirus 2 (BoHV-2)
Equid herpesvirus 1 (EHV-1)
Equid herpesvirus 3 (EHV-3)
Equid herpesvirus 4 (EHV-4)
BetaHerpesvirinae

GammaHerpesvirinae

Human herpesvirus 5 (HHV-5) *
Human herpesvirus 6A (HHV-6A)
*
Human herpesvirus 6B (HHV-6B)
*
Human herpesvirus 7 (HHV-7) *
Murid herpesvirus 1 (MuHV-1)
Murid herpesvirus 2 (MuHV-2)
Suid herpesvirus 2 (SuHV-2)
Cercopithecine herpesvirus 5
(CeHV-5)
Cercopithecine herpesvirus 8
(CeHV-8)
Elephantid herpesvirus 1 (ElHV-1)
Human herpesvirus 4 (HHV-4) *
Human herpesvirus 8 (HHV-8) *
Alcelaphine herpesvirus 1 (AlHV1)
Canid herpesvirus 1 (CaHV-1)
Ovine herpesvirus 2
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Channel catfish herpesvirus
Infectious bovine rhinotracheitis
virus
Bovine mammillitis
Equine HV-1, Equine abortion virus
Equine coital exanthema
Equine HV-4, Equine
rhinopneumonitis virus
Cytomegalovirus (CMV)
Roseolovirus
Mouse CMV
Rat CMV
Inclusion-body rhinitis virus
African green monkey CMV
Rhesus monkey CMV
Endotheliotropic elephant
herpesvirus-1
Epstein-Barr virus (EBV)
Kaposi’s sarcoma associated
herpesvirus (KSHV)
Wildebeest herpesvirus, Malignant
catarrhal fever of European cattle
Canine herpesvirus
Sheep-associated malignant
catarrhal fever

Organization of the Herpes Viral Genome
The DNA of herpesviruses is arranged as a linear double strand. Rapidly after
entry into the nucleoplasm of an infected cell nucleus, the DNA circularizes to form a
double stranded circle. Herpesvirus DNA ranges from 120 kilobase pairs (kbp) to 250
kbp depending on the species of virus (McGeoch, Dalrymple et al. 1988a). Within
individual viruses, length of the genome can also vary due to variable copy numbers of
terminal and internal repeated sequences that can change the length within an individual
virus by 10 kbp. Herpes simplex virus DNA is composed of approximately 152,000
bases with a weight of approximately 100 x 106 Daltons and 67-69% cytosine/guanine
content (Kieff, Bachenheimer et al. 1971). Cytosine and guanine content of
herpesviruses ranges from 31% to 75% across the entire genome (Roizman and Pellett
2001). Among the herpesviruses, the architecture of the genome varies in the presence
and location of reiterated sequences. In HSV, there are sequences at each terminus of the
genome that are repeated in an inverted orientation. These are juxtaposed internally
within the genome. The genome is divided into two unique regions, the unique long (UL
or UL) and unique short (US or US) segments, separated by the apposed internal repeats
(Fig 1.1) (Roizman, Knipe et al. 2007). The UL region is approximately 108 kbp and
encodes at least 56 proteins, while the US region is approximately 13 kbp and encodes 12
proteins (McGeoch, Dalrymple et al. 1988b). The repeated segments are designated the
terminal long and short repeats (TRL and TRS respectively) and the internal long and
short repeats (IRL and IRS respectively) (Roizman and Pellett 2001). These four
components are able to invert relative to one another, making possible four different
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isomers that have been demonstrated in infected cells in equivalent populations arranged
in varying orientations (Roizman and Pellett 2001).

Figure 1.1: Schematic representation of the HSV genome. Schematic of the typical
HSV genome showing the relative positions of the terminal repeats designated (TR), the
unique long and short segments (designated UL and US respectively), and the internal
repeats both long and short (designated IRL and IRS respectively). The character of the
repeats (dotted or full black) denotes the positions of the related repeats.
The structure of most herpesvirus genes is a 50-200 bp promoter region followed
by a TATA box and an initiation site 20-25 bases downstream from the TATA box. 30300 bases later, this is followed by 5’ untranslated leader sequence, a major open reading
frame, a 3’ untranslated segment 10-30 bases long and a polyadenylation signal with
flanking sequences (Roizman and Pellett 2001). Occasionally genes lack the TATA box.
Most genes in herpesviruses code for a single ORF, however, some have a second inframe initiation site (Chou and Roizman 1986; Markovitz, Filatov et al. 1999). The
majority of herpesvirus genes are not spliced. Herpesviruses can also produce noncoding
RNAs, of which the HSV-1 latency associated transcript (LAT) is an example (Roizman
and Pellett 2001). Herpesviruses encode a wide range (from 70-200) genes depending on
the species of virus, with HSV-1 encoding approximately 90 known gene products and at
least 84 transcriptional units participating in the production of proteins (Roizman, Knipe
et al. 2007).
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Herpes Virion Architecture
Herpes virus virions are composed of four structures: an electron-dense core (that
contains the DNA), surrounded by an icosadeltahedral capsid composed of proteins, a
protein-rich zone called the tegument, and an outer lipid envelope that contains
glycosylated protein spikes (Fig 1.2) (Roizman 1974). Herpes virions range from 120nm
to 300nm in diameter with the majority of this variability in size due to the makeup of the
tegument and the state of the envelope (i.e.; an envelope that is not intact will allow more
significant changes to the tegument during processing for electron microscopy) (Roizman
1974).

Figure 1.2: Herpesvirus virion structure. Virions of herpes viruses range from 120nm
to 300nm in diameter (Roizman and Furlong, 1974). A virion consists of: an electrondense core containing the viral genome, a protein capsid surrounding the core, an
amorphous, proteinaceous tegument around the capsid, and an envelope derived from
host cell membranes containing glycoproteins (Roizman and Furlong, 1974). Figure
from (Melancon, 2003).
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The Core
The core is the central-most structural component of a herpes virion, visible as an
electron-dense area in electron micrographs. This structure is composed of the virus
DNA packaged in the shape of a torus (doughnut) that has been shown in some herpes
viruses to be suspended by a proteinaceous spindle that attaches the DNA to the inside
surface of the capsid and contain a less-dense central cylinder (Falke, Siegert et al. 1959;
Furlong, Swift et al. 1972; Nazerian 1974). The toroidal structure is 50 nm high, with an
inside diameter of 18 nm and an outside diameter of 70 nm (Nazerian 1974). The
arrangement of the viral DNA in the torus is unknown. In a host-cell nucleus, the virus
DNA is arranged in a double-stranded circle (Roizman and Pellett 2001).

The Capsid
The capsid of all herpesviruses is composed of 162 capsomere proteins arranged
in an icosahedron with triangulation symmetry of T=16, icosadeltahedron. This protein
shell is approximately 15 nm thick and 126 nm in diameter and contains the DNA. The
capsid is made of seven proteins pUL6, pUL17, pUL18, pUL19, pUL25, pUL35 and
pUL38. The major capsid protein pUL19 (VP5) is the primary structural subunit of the
capsid. This protein is arranged in monomers of 5 or 6 copies, pentons or hexons
respectively. Of the 162 capsomeres, 150 are identical hexons with a copy of VP26
attached to the outer face (Baker, Jiang et al. 2006). Of the remaining 12 capsomeres, 11
are identical pentons situated at the 5 fold vertices (Zhou, He et al. 1995; Zhou, Chen et
al. 1999; Newcomb, Thomsen et al. 2003). The last capsomere is a cylindrical, portallike, structure made from 12 copies of the pUL6 protein (Newcomb, Juhas et al. 2001).
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This portal functions as the channel for DNA entry into the capsid during encapsidation
and for DNA release after infection. This portal is a cylindrical structure composed of
twelve pUL6 molecules and functions as a channel through which DNA is introduced
into and released from the capsid. Capsomeres make direct contact through the base of
the capsomere. In addition to the direct contact, there is another component of the capsid,
a heterotrimeric complex (triplex) that indirectly connects the capsomeres (Newcomb,
Homa et al. 1999). The triplex consist of two copies of VP23 and one copy of VP19C
and acts as a scaffold for the capsid proteins (Spencer, Newcomb et al. 1998). Another
protein scaffold for the capsid proteins is pUL26/26.5, however this protein is lost when
DNA is packaged into the core and is not present in mature virions (Homa and Brown
1997; Newcomb, Homa et al. 1999).
Three types of capsids (A, B and C) can be observed by electron microscopy.
While the outer structures of the capsid are the same, the state of the DNA in the virus
core and the presence of scaffolding proteins determines the types of capsids observed
(Homa and Brown 1997). “A” capsids have a significant lack of DNA and protein in the
capsid cavity due to failed DNA packaging. “B” capsids lack viral DNA but have the
scaffolding proteins. “C” capsids contain all the viral DNA and scaffolding proteins,
however, the presence of heterodimers of pUL17 and pUL25 on “C” capsids and not
mature virions suggests that additional modifications occur during packaging and/or
nuclear egress (Trus, Booy et al. 1996; Homa and Brown 1997; Cardone, Winkler et al.
2007).
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The Tegument
The tegument is a proteinaceous region of variable thickness that lies between the
capsid and envelope. In a mature HSV-1 virion, the tegument contains 24 proteins.
These proteins are pUL7, pUL11, pUL13, pUL14, pUL16, pUL21, pUL23, pUL36
(VP1/2), pUL37, pUL41, pUL46 (VP11/12), pUL47 (VP13/14), pUL48 (VP16), pUL49
(VP22), pUL50, pUL51, pUL55, pUS2, pUS3, pUS10, pUS11, ICP34.5, ICP0, and ICP4
(Mettenleiter 2004; Loret, Guay et al. 2008; Kelly, Fraefel et al. 2009). This layer
appears fibrous on negative staining in electron micrographs and can be asymmetrically
distributed (Morgan, Rose et al. 1959; Wildy and Watson 1962; Morgan, Rose et al.
1968). The asymmetrical distribution and thickness of the tegument appears to be
dependent on location in the infected cell, with more symmetrical arrangement in perinuclear virions and more asymmetry in virions in cytoplasmic vesicles (Falke, Siegert et
al. 1959). Extracellular virions also have asymmetric tegument, however, this may be a
time-dependent phenomenon with the tegument more symmetrically organized at early
times after egress (Grunewald, Desai et al. 2003; Newcomb and Brown 2009).
The tegument proteins are important in multiple stages of the virus life cycle.
They function in the early stages of infection by recruiting the molecular motors of the
cell to assist in entry and cellular transport and regulating viral and host gene expression,
as well as having functions later in infection in virion egress (Kelly, Fraefel et al. 2009).
The tegument has an ordered density surrounding the pentons of the capsid (Zhou, Chen
et al. 1999). This is possibly due to the VP1-3 protein, which is a 336 kDa protein
involved in nucleocapsid attachment to the nuclear pore and DNA release into the
nucleoplasm (Knipe, Batterson et al. 1981; Batterson, Furlong et al. 1983; Ojala, Sodeik
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et al. 2000). However, this protein is likely involved in multiple stages of the virus life
cycle and is not essential for DNA packaging, since null mutants still accumulate DNAfilled capsids in the cytoplasm of infected cells (Desai 2000). Only 4 of the 24 tegument
proteins are essential for growth in cell-culture (pUL36, pUL37, pUL48 and ICP4)
(Roizman and Knipe 2001b; Mettenleiter 2002b; Loret, Guay et al. 2008; Kelly, Fraefel
et al. 2009). Some tegument proteins are expressed in significantly, 1000 fold, greater
quantities than others and recent investigations of null mutant viruses have shown that
lack of one protein can often be compensated for by recruitment of other proteins (del
Rio, DeCoste et al. 2005).

The Envelope
The envelope is the outer covering of the virus. The envelope is a lipid bilayer
composed of altered cellular membranes that have the typical trilaminar appearance of
lipid bilayers (Falke, Siegert et al. 1959; Armstrong, Pereira et al. 1961; Epstein 1962;
Morgan, Rose et al. 1968). The envelope also contains numerous protruding
glycoprotein spikes as well as non-glycosylated transmembrane proteins and membraneassociated proteins (Roizman, Knipe et al. 2007).
HSV-1 specifies at least 11 different glycoproteins, including; gpUL27 (gB),
gpUL44 (gC), gpUS6 (gD), gpUS8 (gE), gpUS4 (gG), gpUL22 (gH), gpUS7 (gI), gpUS5
(gJ), gpUL53 (gK), gpUL1 (gL), gpUL10 (gM), and possibly gpUL49A (gN). These
glycoproteins are expressed in varying amounts and copy number of a specific
glycoprotein can exceed 1000 in a single virion. The glycoproteins form spikes and
protrusions from the envelope that are variable in length and orientation, however,
thereappears to be a systematic distribution of the glycoproteins suggesting a functional
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reason for their ordered arrangement (Grunewald, Desai et al. 2003). The envelope
glycoproteins gB, gD, gH and gL have been shown to be essential for virion entry into a
susceptible host cell. Non-glycosylated membrane proteins include pUS9, pUL20 and
pUL45. Glycoproteins are important in membrane fusion with susceptible cells and
mediate interactions with host cell membrane receptors and viral entry (Mettenleiter
2004). The envelope proteins interact in a complex manner to determine host-cell
tropism and initiate entry into host cells. This is evidenced by the interactions of pUL20
and gK and subsequent interactions with gB, the primary fusogenic protein (Chouljenko,
Iyer et al. 2009; Chouljenko, Iyer et al. 2010). Envelope proteins (notably gC) also play a
role in modulating the host immune response to infection (Roizman, Knipe et al. 2007).
Table 1.2: HSV structual proteins by location in the virion architecture.
Capsid
Tegument
Envelope
pUL6
pUL4
pUL1 (gL)
pUL18 (VP23)
pUL11
pUL10 (gM)
pUL19 (VP5)
pUL13
pUL20
pUL25
pUL14
pUL22 (gH)
pUL35 (VP26)
pUL16
pUL27 (gB)
pUL38 (VP19C)
pUL17
pUL43
pUL21
pUL44 (gC)
pUL36 (VP1/2)
pUL45
pUL37
pUL49.5 (gN)
pUL41
pUL53 (gK)
pUL46 (VP11/12)
pUS4 (gG)
pUL47 (VP13/14)
pUS5 (gJ)
pUL48 (VP16)
pUS6 (gD)
pUL49 (VP22)
pUS7 (gI)
pUL51
pUS8 (gE)
pUL56
pUS9
pUS2
pUS3
pUS10
pUS11
ICP0
ICP4
Table 1.2: Adapted from (Roizman, Knipe et al. 2007; Diefenbach, Miranda-Saksena et
al. 2008b).
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The Herpes Simplex Virus Lifecycle
For the herpesvirus lifecycle, like all biological cycles, circular and stepwise
progression through the cycle will bring one back to the selected start point. At its most
basic, the herpesvirus life cycle starting with a mature viral particle, begins with initial
attachment to a host cell membrane and is followed by fusion with the host cell
membrane, entry into the host cell, virion transport to the nucleus, production of viral
proteins and viral DNA, creation of progeny viruses and release as a mature virion from
the infected cell (Roizman 1974). For HSV-1 this initial infection is generally contained
within the oral mucosa. For the mucosal epithelial infection, this infection follows the
basic life cycle until cleared by the immune system. However, HSV-1 or 2 infections,
may enter the sensory neurons innervating the infected area and start a more complex life
cycle, involving much more distant transport to the nucleus (retrograde transport) and a
state of latency not observed in epithelial cell infections (Cunningham, Diefenbach et al.
2006; Saksena, Wakisaka et al. 2006). This latent state can result in life-long recurrent
infections (Whitley, Kimberlin et al. 1998b). In the next few sections, primarily an
infection lifecycle as observed in an epithelial cell will be discussed with the differences
in neuronal infection covered later.
Virus Attachment and Entry
Entry is a three-stage process involving interactions between the viral membrane proteins
and host-cell surface receptors. The gamut of membrane proteins on the surface of a
herpesvirus can determine the species and cell types that a virus can infect(Roizman and
Pellett 2001). The first stage of viral attachment and entry is initial virus attachment to a
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Figure 1.3: The Herpes Simplex Virus Life Cycle. Schematic cartoon of the overall
herpes virus life cycle showing entry, transport to the nucleus, DNA release, coordinate
gene expression, DNA replication and packaging, and virion egress. This schematic
demonstrates the envelopment/deenvelopment model of egress. Figure from (Melancon,
2003).
potential host cell. The second stage is interaction of cellular membrane receptors with a
viral protein that initiates the final stage of fusion of the two membranes and entry of the
viral capsid and tegument into the host cell’s cytoplasm.
Virus attachment begins with an interaction between viral proteins and the
glycosaminoglycan (GAG) chains of proteoglycans that are richly distributed on the
surface of mammalian cells (Spear 2004b). The viral proteins involved in this interaction
are predominantly gB and gC, which have a predilection for heparan sulfate as the
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proteoglycan of choice (Shieh, WuDunn et al. 1992; Spear 2004b). Interestingly, this
initial attachment step is reversible and while greatly assisting infection of the host cell, it
is not essential for virus entry or replication as cells lacking heparan sulfate can be
infected and gC deficient viruses can infect and replicate albeit at 10 fold lower
efficiencies than normal (Heine, Honess et al. 1974; Banfield, Leduc et al. 1995).
This initial attachment, while not essential, aids in the positioning of glycoprotein
D (gD) to start an irreversible reaction that will lead to virus-cell fusion. Glycoprotein D
interacts with its cellular receptors and as a result undergoes a conformational change that
activates the virus membrane-cell membrane fusion machinery. This fusion complex
involves multiple viral membrane proteins including: gB, gH/gI and recently discovered
interactions with gK and UL20 (Cai, Gu et al. 1988; Forrester, Farrell et al. 1992; Roop,
Hutchinson et al. 1993; Spear 2004b; Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al.
2010).

Binding and Entry Receptors
Cellular receptors of gD include: the herpesvirus entry mediator A (HVEM or
HveA), nectins, and 3-O-sulfated heparan sulfate (Fig 1.4) (Roizman, Knipe et al. 2007).
HveA is a member of the tumor necrosis factor (TNF) receptor family. This receptor is
present on many mammalian tissues and cell types, including leukocytes, T and B
lymphocytes, epithelial cells, and fibroblasts (Spear, Eisenberg et al. 2000; Spear 2004b).
However, this receptor is not present on neurons (Spear 2004b). The natural ligands for
this receptor include LIGHT and lymphotoxin-alpha (Mauri, Ebner et al. 1998). These
ligands are involved in immune signaling and may be involved in HSV interaction with,
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or evasion of, immune cells (Kwon, Kim et al. 2003). Studies have shown that HveA is
significantly involved in HSV infection of activated T-cells, however, the T-cell is not
thought to be a primary target of HSV and HveA has been shown to not be the primary
mediator of entry in other cells, so the significance of this interaction is uncertain
(Montgomery, Warner et al. 1996).

Figure 1.4: Herpes Simplex Virus entry receptors. The three classes of cell surface
receptors for HSV entry: the tumor necrosis factor (TNF) receptor family consisting of
HVEM, the immunoglobulin superfamily consisting of the nectins, and 3-O-sulfated
heparin sulfate. Figure from (Melancon, 2003).
Members of the immunoglobulin superfamily may also serve as receptors. Nectin1alpha (α) (HveC), nectin-1beta (β) (Herpesvirus-like Immunoglobulin receptor HIgR,
and nectin-2α (HveB) are members that can mediate HSV entry. Nectin-1α and nectin1β are expressed on epithelial cells, fibroblasts and neural cells, all cells that reside in the
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human tissue targets of HSV infection (skin, brain, and spinal ganglia), as well as
hematopoietic cells (Cocchi, Lopez et al. 1998; Cocchi, Menotti et al. 1998; Geraghty,
Krummenacher et al. 1998). Nectin-1α and β can mediate entry of all HSV-1 strains,
HSV-2, Pseudorabies virus (PrV) and bovine herpes virus 1 (BHV-1) (Geraghty,
Krummenacher et al. 1998). Nectin-2α can mediate the entry of HSV-2, PrV, and certain
mutants of HSV-1 but not wild-type HSV-1 (Warner, Geraghty et al. 1998; Lopez,
Cocchi et al. 2000). Nectin-1 and nectin-2 are also related to the poliovirus receptor
(Takai and Nakanishi 2003). Another member of the immunoglobulin family, the paired
immunoglobulin-like type 2 receptor PILRα has been shown to bind to gB for fusion of
the virus (Wang, Fan et al. 2009). PILRα is expressed on hematopoietic cells and some
non-hematopoietic cells yet it remains to be determined if this receptor is a significant
contributor to HSV infection of ocular, epithelial, or neuronal cells (Farooq, Valyi-Nagy
et al. 2010).
In the host organism, the nectins are intercellular adhesion molecules localized to
intercellular junctions (Takahashi, Nakanishi et al. 1999). The nectins are highly
conserved throughout mammals and are expressed in the target tissues of herpesviruses,
namely epithelial cells, fibroblasts and neurons (Takahashi, Nakanishi et al. 1999). The
nectins are also similar in respect to structure, function, and the ability to mediate HSV
entry across many species (Shukla, Dal Canto et al. 2000; Milne, Connolly et al. 2001).
The distribution of these receptors and importance in intercellular junctions suggests that
these proteins probably play a role in both virus entry and cell-to-cell spread (Roizman
and Knipe 2001b).
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3-O-sulfated heparan sulfates may mediate entry of HSV-1 and these
proteoglycans are broadly distributed on human cells (Shukla, Liu et al. 1999). In
addition to direct membrane fusion, HSV-1 may enter a cell by endocytosis depending on
the cell type. In non-neuronal cells, endocytosis may occur in a pH-dependent manner
(Garner 2003; Nicola, McEvoy et al. 2003) or pH-independent manner (Milne, Nicola et
al. 2005). However, in neurons entry has been proven only in a pH-independent
membrane fusion type process (Nicola, Hou et al. 2005).

Virus-to-Cell Fusion
The final stage of virus entry is fusion of the viral envelope with the host cell
membrane and release of the capsid and tegument into the host cell cytoplasm (Morgan,
Rose et al. 1968). In cell culture, gD, gB and gH/gL are essential for virus-to-cell fusion
and entry into a host cell (Sarmiento, Haffey et al. 1979; Ligas and Johnson 1988;
Forrester, Farrell et al. 1992). Glycoprotein D binding to cellular receptors likely induces
conformational changes in gB that activate the virus fusion machinery (Heldwein, Lou et
al. 2006; Roller, Dollery et al. 2008; Atanasiu, Whitbeck et al. 2010). Glycoproteins H, L
and K as well as the non-glycosylated membrane protein UL20 interact to assist and
modulate this fusion reaction (Spear 2004a; Chouljenko, Iyer et al. 2009; Chouljenko,
Iyer et al. 2010). For entry via an endocytotic pathway, the first stage of endocytosis
appears to occur independent of a gD receptor, however, the viral glycoproteins gB, gD,
gH/gL are necessary and low endosomal pH may assist in conformational changes
contributing to fusion (Nicola, McEvoy et al. 2003; Nicola and Straus 2004; Dollery,
Wright et al. 2011). While these two pathways may occur in the same cell using similar
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viral protein constituents, these pathways are spatially distinct. After the fusion of the
virus and target cell membranes, the viral capsid, containing the viral DNA, and some of
the tegument is released into the cytoplasm (Maurer, Sodeik et al. 2008). In studies of
PrV, pUL11, pUL47, pUL48, and pUL49 were lost from the capsid while pUL36, pUL37
and PUS3 remained with the capsid (Granzow, Klupp et al. 2005; Luxton, Haverlock et
al. 2005; Antinone, Shubeita et al. 2006; Copeland, Newcomb et al. 2009). The
progression of the virus through the cytoplasm to the nucleus may also involve two of
these remaining tegument proteins, UL36 and UL37 (Krautwald, Fuchs et al. 2009;
Roberts, Abaitua et al. 2009).

Host Protein Shutoff
As the virus progresses toward the host cell nucleus, the virus also begins the
inhibition of host cell protein synthesis. The virion host shutoff (VHS) comes from a
structural element of the tegument and does not require protein synthesis in the newly
infected cell (Nishioka and Silverstein 1977; Fenwick and Walker 1978; Nishioka and
Silverstein 1978b; Nishioka and Silverstein 1978a). VHS inhibits the production of host
cell proteins via two mechanisms; it inhibits synthesis and processing of host mRNA and
it speeds the degradation of mRNAs. These effects are applicable to the virus, however,
once viral protein synthesis is occurring, it is in an overwhelming amount that makes the
effect of VHS on host cell protein production much more significant (Roizman, Knipe et
al. 2007). VHS functions to induce the cleavage of mRNA and cause 5’ degradation of
mRNA (Elgadi, Hayes et al. 1999; Karr and Read 1999). VHS also forms a complex
with the translation factor eIF-4H, to decap cellular mRNA from the 5’ end (Roizman
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and Knipe 2001b). Since VHS activity does not rely on production of de novo synthesis
of viral proteins, VHS preferentially targets cellular mRNA early in infection and may
facilitate the transition of viral gene expression through the A, B and C genes as it
accumulates and shortens the life of viral mRNA (Kwong and Frenkel 1987; Oroskar and
Read 1987). Although VHS accumulates late in infection, it does not degrade viral
mRNA, likely due to an interaction between VP16 and VHS at late times during infection
that blocks the degradation of RNA by VHS (Lam, Smibert et al. 1996). It is likely that
this interaction halts the VHS function so that progeny virions may be assembled and
released as mature infectious virions.

Virion Transport to the Host Cell Nucleus
After fusion of the viral envelope and deposition of the capsid and some of the
tegument into the cytoplasm, the capsid and some of the tegument are transported to the
cell nucleus. One of the tegument proteins that does not disassociate from the capsid is
VP16 (α-tiff). This tegument protein is actually transported along with the capsid to the
nucleus. The capsids are transported to the nuclear pores along microtubules by the
molecular motors dynein and members of the kinesin protein superfamily (KIFs) (Sodeik,
Ebersold et al. 1997; Dohner, Wolfstein et al. 2002; Garner 2003; Diefenbach, MirandaSaksena et al. 2008b; Lyman, Curanovic et al. 2008). Some experiments have shown that
microtubules adjacent to the cell plasma membrane are disrupted following entry, which
suggests that normal microtubule formations are likely altered by the capsid and
tegument proteins effects on microtubules (Ward, Avitabile et al. 1998). Additional
specifics of microtubule motor transport of HSV will be covered later in the section
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detailing transport in neurons. After transport, capsids accumulate at the nuclear pore
complexes. Capsid binding to the nuclear pore complexes can be prevented with
antibodies to parts of the nuclear transport machinery (Ojala, Sodeik et al. 2000). Once
close to the nucleus, capsids seem to dock to the nuclear pores and the capsid is
destabilized and DNA is released, or extruded, from the capsid into the nucleus (Sodeik,
Ebersold et al. 1997; Ojala, Sodeik et al. 2000). The tegument protein VP1/2, encoded by
the UL36, gene is involved in this process through interactions with the nuclear pore
complex (Batterson, Furlong et al. 1983; Batterson and Roizman 1983; Ojala, Sodeik et
al. 2000). Temperature sensitive HSV-1 mutants of UL36 cannot release DNA into the
host cell nucleus (Knipe, Batterson et al. 1981; Batterson and Roizman 1983). The
pUL25 capsid protein has been shown to interact with nucleoporins CAN/Nup214 and
hCG1and also binds to the pUL6 portal protein and the tegument protein pUL36
(Batterson, Furlong et al. 1983; Cardone, Winkler et al. 2007; Newcomb, Booy et al.
2007; Jovasevic, Liang et al. 2008; Roberts, Abaitua et al. 2009). It is likely that these
proteins play a coordinated role in capsid-nuclear pore binding and viral DNA release
into the nucleus.

Gene Expression in Infected Cells
Once the viral DNA has penetrated the host-cell nucleus, the HSV infection
begins in earnest with the expression of viral proteins and eventual synthesis of viral
DNA. During the infection, HSV-1 expresses greater than 80 gene products in an
organized pattern and timing of these proteins. Proteins can be broken into three groups
in terms of relative timing of expression; these are in order of expression: alpha (α), beta
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(β), and gamma (γ) (Honess and Roizman 1974). Transcription of viral DNA occurs in
the nucleus and the virus uses the host RNA polymerase II for transcription of viral genes
(Alwine, Steinhart et al. 1974; Costanzo, Campadelli-Fiume et al. 1977). Upon entry into
the host cell, the tegument protein VP16 is released from the tegument and binds to the
host cell factor C1 and this complex enters the nucleus and binds to Oct-1 (Katan, Haigh
et al. 1990; Kristie and Sharp 1990). This complex is a transactivator of α genes (La
Boissiere, Hughes et al. 1999). Shortly after a cell is infected, HSV-1 DNA enters the
nucleus and localizes to cellular ND10 structures, where VP16 causes the transactivation
and transcription of the α genes giving VP16 the name (α-TIF) for the α gene
transactivating factor (Post, Mackem et al. 1981; Ishov and Maul 1996; Maul, Ishov et al.
1996). Viral α gene expression peaks at about 2-4 hours post infection. There are six α
genes (ICP0, ICP4, ICP22, ICP27, ICP47 and Us1.5 and five of these can stimulate β
gene expression (Fig 1.5). ICP4 is required for all viral gene expression after the α genes
and it also down regulates some α genes, including self down regulation and ICP0, as
well as the gene products of ORF P and ORF O, which are pre-α genes (Clements,
Watson et al. 1977; Dixon and Schaffer 1980; Kristie and Roizman 1984; Faber and
Wilcox 1986; Godowski and Knipe 1986; Kristie and Roizman 1986; Gelman and
Silverstein 1987; Muller 1987). ICP0 is a non-specific transactivator that can induce α, β,
and γ genes (Everett, Orr et al. 1991). The expression of HSV-1 β genes, whose primary
functions are viral DNA replication and nucleotide metabolism, peaks from 4-8 hours
after infection (Roizman and Knipe 2001b). The β genes are further subdivided by the
timing of expression into β1 genes, which are expressed directly after α genes, and β2
genes, which are expressed somewhat later (Roizman and Knipe 2001b). The final
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group, the γ genes, peak after viral DNA replication has already begun. These genes
require the presence of ICP4, ICP27 and ICP8 for efficient transcription. The γ genes
predominantly include structural proteins, glycoproteins and tegument (Roizman and
Knipe 2001b). The HSV-1 C genes are subdivided similarly to the β genes, with γ1 genes
being expressed earlier, even as early as during α gene expression (and are sometimes
therefore called “leaky-late”); however, expression peaks after DNA replication. The γ2
genes are not expressed until after DNA replication has begun (Wagner 1985).
Glycoprotein K is a typical example of the γ2 genes.

Figure 1.5: Map of the complex coordinate gene expression in Herpes Simplex
Virus. 1) α-TIF, from the tegument activates initial transcription of α genes. 2)
Autoregulation of gene expression. 3) Activation of β gene expression by α genes. 4)
Activation of γ gene expression by α and β genes 5) γ genes stop expression of α and β
genes late in infection (Roizman and Knipe, 2001).
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Viral DNA Replication
After entry of the viral DNA into the nucleus, the linear DNA forms a circle using
the DNA ligase and XRCC4, a DNA repair protein, that then acts as the template for
DNA synthesis (Strang and Stow 2005; Muylaert and Elias 2007). DNA replication
begins after β genes are expressed and translated. Some of the β gene protein products
assemble at the ND10 nuclear structures, in punctate prereplicative sites, where the viral
DNA has already localized (Ishov and Maul 1996; Uprichard and Knipe 1996). The
rolling circle of replication starts at the origins of replication using the origin binding
protein (pUL9) (Elias, O'Donnell et al. 1986; Olivo, Nelson et al. 1988). UL9 binds to
the viral DNA replication origin sites, unwinds DNA, and recruits ICP8, the ssDNA
binding protein. Then these proteins recruit the remaining proteins in the helicaseprimase complex and the DNA polymerase into a replisome (Muylaert, Tang et al. 2011).
Then the replication of viral DNA begins, initially as a theta structure, then progresses to
a rolling circle form by the replisome that generates leading and lagging strands of
replicated DNA (Skaliter, Makhov et al. 1996) and eventually creates many head-to-tail
concatamers (Jacob, Morse et al. 1979). The concatamers of viral DNA are contained in
replication compartments consisting of viral DNA and replication complexes (Quinlan,
Chen et al. 1984). Seven viral proteins are necessary for viral DNA replication: the DNA
polymerase (UL30), the DNA polymerase accessory protein (UL42), the origin-binding
protein (UL9), the single-stranded DNA binding protein (ICP8) and the helicase-primase
complex (composed of UL5, UL8 and UL52) (Purifoy, Lewis et al. 1977; Conley, Knipe
et al. 1981; Challberg 1986; Wu, Nelson et al. 1988). It is likely that host cell factors and
enzymes such as DNA ligase and topoisomerase II are also necessary. Although only
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one origin of replication is necessary for the replication of viral DNA, there are three
possible origins of replication: oriS (present in two copies) and oriL (Frenkel, Locker et
al. 1976; Locker, Frenkel et al. 1982; Mocarski and Roizman 1982; Stow 1982; Vlazny,
Kwong et al. 1982; Weller, Spadaro et al. 1985; Knopf, Spies et al. 1986; Lockshon and
Galloway 1986; Deb and Doelberg 1988).

Capsid Assembly and DNA Packaging
During DNA replication, the γ genes are transcribed and the proteins are made in
the cytoplasm of the infected cell. The capsid components of the virus must be then be
transported back to the nucleus for assembly. The triplex proteins (two copies of VP19C
and one VP23) are brought into the nucleus already assembled in the cytoplasm, since
VP23 does not transport into the nucleus alone (Nicholson, Addison et al. 1994; Rixon,
Addison et al. 1996). The major capsid protein (VP5) is transported into the nucleus with
the triplexes or a scaffolding protein pre-VP22a (Roizman, Knipe et al. 2007). The
UL26/UL26.5 genes are responsible for multiple proteins involved in capsid formation
and assembly. These proteins are the result of two overlapping genes and multiple
cleavage forms of the UL26 gene. Pre-VP22a, the major scaffolding protein for capsid
formation is the product of the UL26.5 gene and the UL26 gene is responsible for VP21,
another scaffolding protein, and VP24, a protease that cleaves the major scaffold protein
(Roizman, Knipe et al. 2007). Once the capsid and scaffold proteins are in replication
compartments in the nucleus, the remainder of capsid assembly occurs. Assembly likely
begins at the portal ring, that is made from 12 copies of the pUL6 protein (Newcomb,
Homa et al. 2001; Newcomb, Juhas et al. 2001). The VP5 and pre-VP22 complexes self
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assemble, likely guided by the self-assembling nature of the pre-VP22a and guided by
alignment with the portal ring. As more pentons, hexons and triplexes are brought
together the capsomeres form into a sphere-like procapsid (Newcomb, Homa et al. 1996;
Baines 2011). Once this procapsid is formed, the viral DNA is loaded into the procapsids
by a three-part enzyme, the product of the UL28 gene (Beard, Taus et al. 2002). This
enzyme is also responsible for the cleavage of the replicated viral DNA concatamers into
single unit monomers of the viral DNA ready for packaging into the capsids. During the
DNA packaging process, the scaffold is also removed by the protease action of VP24
which allows the procapsid to assume a more stable and resilient icosahedral shape
(Newcomb, Homa et al. 1996).
Three types of capsids have been identified for HSV; A, B, and C capsids. All
three capsid types are formed of similar pentons, hexons and triplexes and are
approximately 120 nm in diameter (Gibson and Roizman 1972; Newcomb, Trus et al.
1993). C-capsids are capsids that have gone through maturation fully as described and
can proceed to become infectious viruses after egress. B-capsids contain VP21, VP22a,
and VP24 but do not contain viral DNA (Gibson and Roizman 1972; Newcomb, Trus et
al. 1993). A-capsids contain no scaffolding proteins and no DNA and are thought to be
an aborted attempt at DNA packaging (Sherman and Bachenheimer 1987; Newcomb,
Homa et al. 1996).

Virion Egress
To complete maturation of the virus and make an infectious particle, the
encapsidated virion must acquire the tegument and envelope and exit the infected cell.
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Two models are currently considered for this process. The first model has the virion
acquire its final tegument and final envelope as it buds through the nuclear membrane
and the mature virus particle exits the cell through the secretory pathway. The alternate
model involves acquisition of a primary envelope as the encapsidated virion passes
through the nuclear membrane followed by deenvelopment and final tegumentation and
envelopment occurs in the trans-golgi network (Roizman, Knipe et al. 2007).
For either model, two viral proteins appear to be involved in the process of
primary egress from the nucleus; pUL31, a nuclear phosphoprotein embedded in the
nuclear membrane of infected cells (Reynolds, Ryckman et al. 2001; Fuchs, Klupp et al.
2002), and pUL34, a protein in inner and outer nuclear membrane of infected cells that
uses a C-terminal membrane anchor (Klupp, Granzow et al. 2000). For both models, the
first step for virion egress terminates with the virus enveloped and present in the
perinuclear space between the two nuclear membranes (Vlazny, Kwong et al. 1982).
Furthermore, the inner nuclear membrane is bound by a protein-rich nuclear lamina and it
appears that this layer must be disrupted to allow intranuclear capsids access to the inner
nuclear membrane (Scott and O'Hare 2001). The viral proteins of UL31 and UL34 can
bind, reorganize and destabilize lamin A/C, which is the primary component of the
nuclear lamina (Reynolds, Liang et al. 2004a; Reynolds, Liang et al. 2004b; SimpsonHolley, Baines et al. 2004). The UL11 protein has also been shown to increase the
efficiency of this stage of envelopment, however it does not appear to be essential
(Baines and Roizman 1992; MacLean, Dolan et al. 1992).
Once this primary envelopment occurs via budding through the inner nuclear
membrane, the two models diverge. In the first model, the virion is basically complete at
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this point and, while some maturation may still occur, the virion retains its envelope and
tegument from this envelopment stage and exits the cell via the secretory pathways
(Darlington and Moss 1968; Johnson and Spear 1982; Johnson, Webb et al. 2001b;
Baines, Parsch et al. 2004). This exit strategy takes advantage of the continuity of the
perinuclear space with the endoplasmic reticulum and secretory paths.
In the alternate model, the enveloped virion in the perinuclear space must deenvelope from its primary envelope as it fuses with the outer nuclear membrane (Fig 1.6).
The virion is de-enveloped and loses some, or all, of its tegument as the virion enters the
cytoplasm (Enquist, Husak et al. 1998; Mettenleiter 2000). Re-envelopment then occurs
in the cytoplasm, specifically in the trans-Golgi network (TGN), compartments where
additional tegument is also added (Roizman, Knipe et al. 2007). This has been termed a
“de-envelopment, re-envelopment” model. The majority of evidence currently supports
the latter model. By electron microscopy, primary enveloped particles have been shown
fusing with the outer nuclear membrane and unenveloped, cytoplasmic virions have been
shown budding into cytoplasmic vesicles (Gershon, Sherman et al. 1994; Granzow,
Klupp et al. 2001; Mettenleiter 2002b). The lipid composition and ultrastructural
appearance of the extracellular virions resembles the cells plasma membrane rather than
the nuclear membranes (van Genderen, Brandimarti et al. 1994). Furthermore, UL31 and
UL34 proteins are present in perinuclear virions, but are not able to be detected in
extracellular virions. While, the tegument proteins of UL46 and UL49 genes are present
in cytoplasmic or extracellular virions but are not found in perinuclear virion particles
(Klupp, Granzow et al. 2000; Mettenleiter 2002b; Reynolds, Wills et al. 2002).
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The major argument against the “de-envelopment, re-envelopment” model,
currently, is the lack of a defined mechanism for de-envelopment. Glycoproteins
involved in the fusion machinery of the virus do not affect this pathway, as shown by
experiments with deletion mutants (Cai, Person et al. 1987; Jayachandra, Baghian et al.
1997; Steven and Spear 1997; Granzow, Klupp et al. 2001). Current investigation
focuses on the possibility of redundant pathways including multiples of the glycoproteins
or as yet unidentified players in this interaction.
In the “de-envelopment, re-envelopment” model, capsids acquire tegument
proteins as they pass through the nucleus and cytoplasm, likely in the manner of proteinprotein interactions with the capsid and other tegument members (Mettenleiter 2002b).
The tegument is composed of at least 15 different proteins in HSV. While initially
thought to be structureless, the tegument has been shown to possess some icosahedral
structure in its inner-most layer around pUL36, a large tegument protein that interacts
with the major capsid protein, VP5, (Machtiger, Pancake et al. 1980; McNabb and
Courtney 1992; Newcomb, Trus et al. 1993; Zhou, Chen et al. 1999; Mettenleiter 2002b).
The tegument likely plays a structural role, linking the capsid to the envelope, and has
important functions in the early phase of infection, through the actions of the tegument
proteins UL41 (vhs), UL48 (α-tiff), and Us3 (a protein kinase) (Mettenleiter 2002b;
Roizman, Knipe et al. 2007). While a lack of UL36 or UL37 tegument proteins ceases
virus maturation, this maturation can proceed without UL13, US3, UL41, UL46, UL47,
or UL49 (Rafield and Knipe 1984; Purves, Longnecker et al. 1987; Desai 2000; Desai,
Sexton et al. 2001; Klupp, Granzow et al. 2001; Roizman and Knipe 2001b; Mettenleiter
2002b). Therefore in cultured cells, while many tegument components are not necessary,
the tegument in its full form likely contributes to an efficient infection in the host.
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The final stage of production of an infectious particle involves acquisition of a
mature virion envelope and exiting the host cell. After tegumentation of the virion in the
“de-envelopment, re-envelopment” pathway, the HSV-1 capsid must bud into the system
of cytoplasmic vesicles called the Trans-Golgi Network (TGN) (Fig1.6). This network is
a collection of Golgi-derived endosomes. This final envelopment stage is not well
characterized (Mettenleiter 2002b). It is likely that this step requires some interactions
between the outer layer of the tegument and some of the viral membrane proteins that
will be resident on the mature virion. Deletion of glycoproteins E (gE) and I (gI) or gM
does not affect the formation of mature virions in pseudorabies virus (PRV-an
alphaherpesvirus closely related to HSV) or HSV. However deletion of all three
glycoproteins inhibits virus spread (and by extension production of mature virions) in
PRV but not HSV (Enquist, Husak et al. 1998; Brack, Dijkstra et al. 1999; Browne, Bell
et al. 2004). Simultaneous deletion of gD, gE and gI causes an envelopment defect in
HSV (Farnsworth, Goldsmith et al. 2003). However, any multiple glycoprotein deletion
may also destabilize other tegument or envelope interactions that may appear as solely an
envelopment defect.
The most dramatic secondary envelopment effects are observed with gK or
pUL20 deletions, in which there is marked accumulation of unenveloped and aberrantly
enveloped capsids in the infected cell cytoplasm with corresponding decreases in
extracellular infectious virus (Jayachandra, Baghian et al. 1997; Foster, Melancon et al.
2004b). In the normal course of infection, this final step of envelopment is proposed to
be followed by final egress of the virus from the host cell via the normal cellular
secretory transport machinery, resulting in a new, extracellular, infectious virus.
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Figure 1.6: Schematic of HSV-1 virion morphogenesis and egress in the deenvelopment/re-envelopment model. (I) Mature capsids bud through the inner nuclear
membrane into the perinuclear space. (II) De-envelopment of perinuclear virions at the
outer nuclear membrane. (III) Re-envelopment of cytoplasmic capsids by budding into
Trans-Golgi-Network derived cytoplasmic vesicles. (IV) Final egress to the extracellular
space. Figure from (Melancon, Luna et al. 2005).
Latent Infection
Latent infection is more of an alternate pathway in the virus life cycle rather than
a stage of the life cycle. The signals that push a herpes virus into a latent infection rather
than a typical lytic infection are poorly characterized, however, latency and reactivation
are well-documented phenomena clinically (Roizman, Knipe et al. 2007). In herpes
viruses, latent infection generally follows a primary infection and spread in some tissue
type with latency occurring in a secondary tissue. Herpesviruses tend to favor latency in
one or a few cell types depending on the family of herpesvirus. For HSV-1 primary
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infection is generally in a mucocutaneous epithelial tissue with the latent infection
occurring in the sensory ganglionic neurons that innervate this tissue. This is followed by
periodic reactivations and subsequent reoccurrence of clinical symptoms at the tissues of
initial infection. Latency in HSV is characterized by the viral DNA being held in the
host-cell nucleus, in a circular episome form, associated with the nucleosomes and near
total silencing of gene expression. The latency-associated transcripts (LATs) are
expressed giving multiple RNA species through splicing (Roizman, Knipe et al. 2007).
Reactivation generally occurs following some type of neuronal or primary infected tissue
stress; including UV radiation, intense heat, trauma or others, or a systemic stress and/or
immunocompromise to the individual infected. Once this occurs, the infection cycle
follows in a manner similar to that described above. Latency will be covered in greater
detail later in this chapter in sections pertaining to neuronal infection.

HSV Glycoproteins and Their Putative Functions
Herpes simplex virus type-1 encodes and uses at least eleven virally encoded
glycoproteins and possibly a twelfth in the mature, wild type virion: gB,
gC, gD, gE, gG, gH, gI, gJ, gK, gL, gM, and potentially gN (UL49.5). HSV-1 also has
multiple non-glycosylated, but still membrane associated proteins: pUL20, pUS9,
pUL24, pUL43, and pUL34. Herpesvirus membrane and membrane-associated proteins
function in multiple important roles; virus fusion to a potential host cell, virus entry via
host cell membrane fusion, virion morphogenesis, egress from the nucleus and infected
cell, cell-to-cell spread and virus-induced fusion of host organism cells (Roizman and
Knipe 2001b; Mettenleiter 2002b; Mettenleiter 2002a; Spear and Longnecker 2003;
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Spear 2004b). At least 11 membrane proteins are present on the surface of the virion
envelope (Roizman, Knipe et al. 2007). These proteins are vitally important in the virus
life-cycle as they are the first component of the virus that interacts with the host cell that
will be infected and can shape the interactions available to the virus both in the already
infected cell (egress, morphogenesis, and immune interactions) and the prospectively
infected cell (i.e.: cell tropism, virus-cell fusion and entry).

Glycoprotein B (pUL27)
Glycoprotein B (gB) is the product of the HSV-1 UL27 gene. This gene encodes a
904 amino acid (aa) protein that exists in its mature form in the viral envelope as a
homotrimer. This glycoprotein has a single cytoplasmic domain of 696 aa that has
multiple N-glycosylation sites, a short, 69 aa transmembrane domain and a 109 aa
carboyxterminal cellular domain (Claesson-Welsh and Spear 1986; Claesson-Welsh and
Spear 1987; Highlander, Goins et al. 1991; Spear 1993; Laquerre, Person et al. 1996;
Whitley 2001a). Resolution of the crystal structure has shown that it possesses features
of class I, in the form of an α-helical coiled-coil core, and class II, in the form of
extended β hairpins with hydrophobic tips, viral fusion proteins (Heldwein, Lou et al.
2006). The β hairpin structures are homologous to the Vesicular stomatitis virus (VSV)
G fusion protein and studies have shown that the hydrophobic tips of the loops are vital
for HSV-1 gB function in fusion (Hannah, Heldwein et al. 2007). Glycoprotein B is
highly conserved among many herpesviruses and in HSV-1 this protein plays an
important role in virus induced cell fusion, as the suspected primary virus-cell membrane
interactor (Spear 2001; Spear 2004b). HSV-1 deletion mutants of gB cannot enter cells
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(Cai, Person et al. 1987). The role of gB in membrane fusion can also be demonstrated
by amino acid substitution or truncation mutations of the carboxyl terminus that result in
extensive fusion (Bzik, Fox et al. 1984; Cai, Gu et al. 1988; Cai, Person et al. 1988;
Baghian, Huang et al. 1993; Gage, Levine et al. 1993).
Glycoprotein B is part of the four glycoprotein group, gB, gD, gH, and gL,
necessary for cell fusion in transient co-expression assays and carboxyl truncations of gB
result in extensive fusion in this system (Foster, Melancon et al. 2001; Haan, Lee et al.
2001; Klupp, Fuchs et al. 2002; Pertel 2002). These proteins appear to operate in a
sequence with gD in Phase I, gH/gL in Phase II, and gB in Phase III f fusion (Gianni,
Fato et al. 2006; Subramanian and Geraghty 2007).

Glycoprotein C (pUL44)
Glycoprotein C (gC) is the product of the HSV-1 UL44 gene. This gene encodes
a 511 aa protein that is a precursor of gC (Frink, Eisenberg et al. 1983). This protein has
a single 453 aa extracellular domain, with a 23 aa transmembrane domain and a short
cytoplasmic tail of 10 aa (Homa, Purifoy et al. 1986). In the mature form, found in the
envelope, gC has heavy N-linked and O-linked glycosylation (Wenske and Courtney
1983). While not necessary for infection, gC increases efficiency of infection and can be
found in over 1000 copies on the virus surface (Ruyechan, Morse et al. 1979).
Glycoprotein C can cause initial binding of the virus to host cell heparan sulfate at the Nterminal 120 aa binding site (Tal-Singer, Peng et al. 1995). HSV-1 gC can increase
binding by nearly 10-fold to host cells. HSV-1 gC also contributes to the viral infection,
in the host, by binding to the complement component C3b (Friedman, Cohen et al. 1984;
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Eisenberg, Ponce de Leon et al. 1987; Huemer, Larcher et al. 1993; Huemer, Nowotny et
al. 1995). This can function to protect the virus from the effects of complement mediated
neutralization (Lubinski, Wang et al. 1998; Lubinski, Wang et al. 1999). This is an
important virulence factor in the natural infection and gC deficient mutants can
demonstrate 5000 fold titer loss due to the rapid inactivation from complement (Kotwal,
Isaacs et al. 1990; Isaacs, Kotwal et al. 1992; Friedman, Wang et al. 1996; Sahu, Isaacs et
al. 1998). Glycoprotein C also carries a second domain that blocks the complement
component C5 from binding to C3 providing a second block on the potential complement
neutralization of HSV (Roizman, Knipe et al. 2007).

Glycoprotein D (pUS6)
Glycoprotein D (gD) is the product of the HSV-1 US6 gene. This gene encodes a
394 aa multifunctional protein. Glycoprotein D has a 315 aa extracellular domain with
three sites for glycosylation (Watson, Weis et al. 1982; McGeoch, Dolan et al. 1985).
This protein also has short transmembrane anchoring, 22 aa, and cytoplasmic, 32 aa,
domains (Minson, Hodgman et al. 1986). This glycoprotein is very important to
attachment, and by extension, and fusion/entry of the virus, serving as a ligand for all
known cellular entry receptors, including HVEM, nectin-1, nectin-2 and others (Spear,
Eisenberg et al. 2000). This protein is necessary or virus entry and cell-to-cell fusion. At
the extracellular N-terminus of the protein, there is an immunoglobulin like hairpin loop
that contains the binding sites for all entry receptors other than nectin-1 and this small
area also determines the ability to bind to nectin-2 (Carfi, Willis et al. 2001; Spear and
Longnecker 2003; Yoon, Zago et al. 2003; Zago and Spear 2003). Potential host cells
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that express gD are also resistant to infection by initiating endocytosis and degradation of
the virus; however gD expression alone in some cells can cause a pH-dependent cellular
fusion (Campadelli-Fiume, Arsenakis et al. 1988; Campadelli-Fiume, Avitabile et al.
1988; Johnson, Burke et al. 1990).

Glycoproteins E (pUS8) and I (pUS7)
Glycoprotein E (gE) and glycoprotein I (gI) are the products of the HSV-1 US8
and US7 genes, respectively. The US8 gene encodes a 550 aa protein, while the US7
gene encodes a 390 aa protein (Lee, Para et al. 1982; Longnecker, Chatterjee et al. 1987).
In the mature virion, these proteins are present in a heterodimer, containing one copy of
each protein. This heterodimer can mediate cell-to-cell fusion in epithelial and neuronal
tissues; however, neither is necessary for virus entry and infection (Johnson and Feenstra
1987; Mettenleiter, Schreurs et al. 1987; Neidhardt, Schroder et al. 1987; Johnson, Frame
et al. 1988; Kudelova, Kostal et al. 1991; Card, Whealy et al. 1992b; Jacobs, Mulder et
al. 1993a; Whealy, Card et al. 1993; Balan, Davis-Poynter et al. 1994a; Kritas, Pensaert
et al. 1994; Mulder, Jacobs et al. 1994; Cohen and Nguyen 1997; Tirabassi, Townley et
al. 1997; Dingwell and Johnson 1998; Kimura, Wang et al. 1998; Tirabassi and Enquist
1998). In very permissive cells that do not form tight cell junctions, the heterodimeric
complex is not necessary for cell-to-cell spread (Mettenleiter, Zsak et al. 1987; Zsak,
Zuckermann et al. 1992; Dingwell, Brunetti et al. 1994; Dingwell, Doering et al. 1995;
Tirabassi, Townley et al. 1997; Wisner, Brunetti et al. 2000). Furthermore, this complex
is not necessary for infection of the apical surface of a cell by extracellular virus
(Mettenleiter, Zsak et al. 1987; Dingwell, Brunetti et al. 1994). However, this complex is
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necessary for spread in synaptically connected neurons (Whealy, Card et al. 1993;
Mulder, Jacobs et al. 1994; Dingwell, Doering et al. 1995; Babic, Klupp et al. 1996b;
Tirabassi, Townley et al. 1997; Tirabassi and Enquist 1998).
This protein complex appears to be specifically designed to assist in cell-to-cell
spread at host cellular junctions. Viruses with the wild-type gE/gI complex preferentially
sort daughter virions to the lateral cell surfaces and cell junctions of infected cells, while
gE deletion mutants allow the accumulation of increased numbers of daughter virions in
the supernatant, infected cell cytoplasm, and infected cell apical surface (Alconada,
Bauer et al. 1996; Kimura, Wang et al. 1998).
The gE/gI complex also has a high affinity for the Fc portion of immunoglobulin
G, which suggests a host immune evasion component to this complex. In the natural
infection, this serves as a virulence factor, as this can disrupt antibody-dependent cellular
cytotoxicity and prevent immune targeting of the virus or infected cell (Eberle, Dubreuil
et al. 1995).

Glycoprotein G (pUS4)
Glycoprotein G (gG) is the product of the HSV-1 US4 gene. The US4 gene
encodes a 283 aa protein. The function of gG is not precisely known, however, this
glycoprotein has been shown to be non-essential for viral entry or infection. No
phenotypic abnormalities are recognized in single gG deletion mutants in culture and the
absence of gG only causes minimal attenuation of the virus in vivo (Atkinson, Barr et al.
1978). Using polarized cells in culture and in vivo infection of corneal epithelial cells,
the gC binding to these cells was defective in gG deletion mutant viruses (Tran, Kissner
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et al. 2000). It is possible that this protein is involved marginally or has redundant
functions to another glycoprotein in assisting the binding and entry of the virus at the site
of primary infection. Also, during the infection gG is incorporated in the nuclear and
cytoplasmic membranes, suggesting a possible role for gG in nuclear egress, however
deletion mutants are not defective for nuclear egress, suggesting a possible redundancy in
this instance as well (Frame, Marsden et al. 1986; Sullivan and Smith 1987).

Glycoproteins H (pUL22) and L (pUL1)
Glycoprotein H (gH) and glycoprotein L (gL) are the products of the HSV-1
UL22 and UL1 genes, respectively. The UL22 gene encodes an 838 aa protein, while the
UL1 gene encodes a 224 aa protein (Roizman, Knipe et al. 2007). Glycoprotein H has a
singular 785 aa extracellular domain with 21 aa transmembrane domain and a short, 14
aa, C-terminal cytoplasmic tail. In the mature virion, these glycoproteins exist as a
heterodimer. Since this complex is essential for viral entry and infection, both of these
glycoproteins are essential (Roizman, Knipe et al. 2007).
Glycoprotein L has a unique form in the mature virion, in that it is not embedded
in the membrane, but instead is dependent on the interaction with gH for incorporation
into the virion (Dubin and Jiang 1995). In fact, gH appears similarly dependent on gL for
its function since gH does not fold or process correctly in the absence of gL and gH
remains in the endoplasmic reticulum and self-aggregates in cells only transfected with
gH (Foa-Tomasi, Avitabile et al. 1991; Forrester, Sullivan et al. 1991; Roberts, Ponce de
Leon et al. 1991). Furthermore, in cells infected with gL-null virus or gH-null virus, the
alternate, or present protein, is in either case incorrectly processed and absent from the
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viral envelope (Hutchinson, Browne et al. 1992; Roop, Hutchinson et al. 1993). The
formation of the heterodimer requires no other viral proteins, suggesting a likely selfassembly or possibly the assistance of cellular components, however, gL is secreted into
the extracellular fluid since it has no membrane targeting sequence (Roop, Hutchinson et
al. 1993; Dubin and Jiang 1995).
Viruses lacking gH/gL are unable to enter cells, however, they can attach to the
cell surface and are essential proteins. Therefore the gH/gL complex appears to be
essential for later virus-cell membrane fusion and virus entry into cells.

Glycoprotein J (pUS5)
Glycoprotein J (gJ) is the product of the HSV-1 US5 gene. The US5 gene
encodes a 92 aa protein with a predicted signal peptide and a transmembrane domain
(Ghiasi, Nesburn et al. 1998). The precise function of gJ for the virus is not well known.
Deletion of gJ causes no observable changes in virus growth or phenotype in vivo or in
vitro and gJ deletion does not impair replication at the primary infection site or
progression to the nervous system in mice (Balan, Davis-Poynter et al. 1994a). In viruses
without gD or gJ, apoptosis of infected cells was not blocked as it would normally be in
an infected cell (Roizman, Knipe et al. 2007). The UL27.5 gene encodes a protein that
cross reacts to antibodies to gJ (Chang, Menotti et al. 1998). This protein accumulates in
the cytoplasm of infected cells but its function is also uncertain (Roizman, Knipe et al.
2007). It is possible that these two proteins have a redundant function.
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Glycoprotein K (pUL53)
Glycoprotein K (gK) is the product of the HSV-1 UL53 gene. The UL53 gene
consists of 1017 bases and encodes the 338 aa protein precursor to gK (Debroy, Pederson
et al. 1985; Pertel and Spear 1996). Glycoprotein K has two sites for N-linked mannose
glycosylation and is extremely hydrophobic (Hutchinson, Goldsmith et al. 1992;
Ramaswamy and Holland 1992). Glycoprotein K has been plagued with difficulty in
determining its form and function.
Previous experiments have suggested two forms for gK. The predicted forms
were a protein with four membrane-spanning domains with the N and C termini on the
extracellular side of the membrane or a protein with three membrane-spanning domains
and the C terminus located intracellularly (Debroy, Pederson et al. 1985; Ramaswamy
and Holland 1992; Mo and Holland 1997). More recent experiments in this laboratory,
Kousoulas laboratory LSU-SVM, have confirmed the four membrane spanning form of
the protein as the overwhelmingly likely mature form of the protein (Fig 1.7) (Foster,
Alvarez et al. 2003).
Originally, gK was determined to be necessary for viral replication in vivo,
however, that has since been shown to be incorrect although gK null viruses have a
greatly reduced ability to reproduce, due in large part to spread defects (MacLean,
Efstathiou et al. 1991; David, Baghian et al. 2008). One attempt at producing a gK
deletion mutant actually produced an insertion-deletion mutant with the N-terminal 112
aa of gK retained. The result was a syncytial phenotype with many aberrant
particles and and naked capsids trapped in the cytoplasm, which lead to the assumption
that gK was a preventer of abundant syncytia formation (Hutchinson and Johnson 1995;
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Hutchinson, Roop-Beauchamp et al. 1995). Later, a more precise deletion of gK provided
an actual gK null virus. This virus displayed a phenotype of severely impaired egress,
however, syncytia formation was not a noticeable feature of the gK-null phenotype
(Jayachandra, Baghian et al. 1997; Foster, Melancon et al. 2004a; Melancon, Luna et al.
2005).

Figure 1.8: Schematic of the expected structure of gK situated in the membrane.
Schematic shows locations of discrete domains and many characterized mutations.
Figure and mutation characteristics from (Dolter, Ramaswamy et al. 1994; Foster, Kraus
et al. 2003; Chouljenko, Iyer et al. 2009)
Some syncytial mutations are present in the non-glycosylated membrane protein
UL20 (Baines, Ward et al. 1991; MacLean, Efstathiou et al. 1991), the membrane protein
glycoprotein B (Bzik, Fox et al. 1984; Pellett, Kousoulas et al. 1985) and UL24 (Sanders,
Wilkie et al. 1982; Jacobson, Martin et al. 1989) however, the vast majority of syncytial
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mutations (especially those involving a minimum of deletions or substitutions) are
contained within gK (Ruyechan, Morse et al. 1979; Bond and Person 1984; Pogue-Geile,
Lee et al. 1984; Debroy, Pederson et al. 1985). The phenotype of syncytia formation
would strongly indicate the presence of gK in the membrane as either a binding protein or
a modulator of the primary fusion protein, gB.
A study of gK localization in the infected cell suggested that gK was located only
in the perinuclear space and only contained unprocessed carbohydrates, compatible with
a protein that does not pass through a Golgi-mediated maturation process or reach the
surface of the cell membrane (Hutchinson, Roop-Beauchamp et al. 1995). Many of the
earlier studies of the function of gK have occurred in transiently transfected cells and the
phenotype observed for mutations of gK are aberrant, with gK retained in the perinuclear
space or golgi, unless pUL20 is also transfected (Dietz, Klupp et al. 2000). It was later
shown that pUL20 and gK are dependent on one another for transport through the Golgi
network in a manner typical of wild-type virus (Fig 1.8) (Foster, Melancon et al. 2004b;
Melancon, Fulmer et al. 2007). As shown for PRV and later HSV, gK appears to rely on
the cotransfection of UL20 to restore processing of both proteins and to display their true
phenotype (Foster, Alvarez et al. 2003). The interactions between gK and gB were later
confirmed by the Kousoulas laboratory, showing that the amino terminus of gK,
particularly amino acids 31-68, modulates gB mediated, virus-induced cell fusion and
virion egress (Melancon, Luna et al. 2005; Chouljenko, Iyer et al. 2009).
Later glycoprotein K was shown to form a functional protein complex with the
non-glycosylated membrane protein UL20 that interacted physically with gB
(Chouljenko, Iyer et al. 2010). Furthermore, cleavage of the amino terminus of gK has
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also been shown to prevent viral entry into otherwise permissible cells (Jambunathan,
Chowdhury et al. 2011). Glycoprotein K along with its membrane partner pUL20 have
been demonstrated to participate in a hierarchical relationship with a protein complex of
the viral envelope that affects virion egress and envelopment (Chouljenko, Kim et al.
2012). It appears that gK and UL20 are intricately linked in the maturation and
development of the virus and gK appears to be involved in many aspects of the virus lifecycle including; envelopment, morphogenesis, entry and cell fusion.

Figure 1.8: Schematic of HSV-1 virion morphogenesis and egress hilighting the
areas of gK and UL20 function. Red arrows indicate the stages where gK and UL20
appear to function during egress. Figure from (Melancon 2003).
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Glycoproteins M (pUL10) and N (pUL49.5)
Glycoprotein M (gM) and glycoprotein N (gN) are the products of the HSV-1
UL10 and UL49.5 (or UL49A) genes, respectively. The UL10 gene encodes a 473 aa
protein, while the UL49.5 gene encodes a 91 aa protein (Baines and Roizman 1993). In
the mature virion, gM is an integral membrane protein with eight predicted, hydrophobic
transmembrane domains (Baines and Roizman 1993; MacLean, Robertson et al. 1993;
Babic, Klupp et al. 1996b). In cell culture, gM deficient viruses replicated at 10 to 20
fold lower titers with smaller plaque morphology than wild-type (MacLean, Efstathiou et
al. 1991; MacLean, Robertson et al. 1993). For gN, there are potential sites of O-linked
glycosylation and for the homolog of gN in Pseudorabies (PRV), an α-herpesvirus related
to HSV, the protein has been shown to be glycosylated in the mature virion (Jons,
Granzow et al. 1996).
For HSV, gN has been shown to be present in the virion and linked to the
tegument, however, it has not been shown to by glycosylated (Adams, Cunningham et al.
1998). Deletion of gN has shown that this protein is not essential for virus infection or
replication, with only a two-fold reduction in titers and no phenotypic plaque differences
in null mutants (Adams, Cunningham et al. 1998). Interestingly though neither protein is
necessary for the life cycle of the virus, both proteins are highly conserved though the
alpha-, beta-, and gammaherpesviruses and in many of these they form a dimeric
complex (Jons, Dijkstra et al. 1998; Lake, Molesworth et al. 1998; Wu, Zhu et al. 1998;
Mach, Kropff et al. 2000; Koyano, Mar et al. 2003). This may indicate redundancy or
partial redundancy in the functions of these proteins, requiring knock-out of multiple
proteins to determine their roles in the virus (Browne, Bell et al. 2004).
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While the exact mechanism of action is unknown, it appears that gM and gN work
together to inhibit virus induced cell fusion. It also appears that these proteins must work
together to cause this phenotype. In cellular fusion assays, gM and gN cause a decrease
in cell-cell fusion in experiments with the following: PRV gB, gD, and gH/gL, bovine
respiratory syncytial virus F protein, or with HSV-1 gB, gD, and gH/gL or Moloney
murine leukemia virus envelope protein. In these studies, the transfection of both gM and
gN reduced fusion while the transfection of only gM did not (Klupp, Nixdorf et al. 2000;
Koyano, Mar et al. 2003). This phenotype has even been shown to occur with human
herpesvirus 8 (Koyano, Mar et al. 2003).
Glycoprotein M has also been shown to be located in the nuclear membranes and
to be added to the viral particle as it passes through the nuclear membranes, possibly
indicating a role for gM in nuclear egress and/or increasing pathogenesis of virions
released during cell lysis, or those that do not undergo full transport through the Golgi
network (Baines, Wills et al. 2007).

Membrane Protein UL20 (pUL20)
The UL20 protein is a membrane protein of HSV-1 that is not glycosylated. The
ORF for this protein sits between the UL19 and UL20.5 genes and the expressed form is
situated on the complementary strand of the viral genome giving a 222 aa protein. The
UL20 protein was originally suspected to have two or three membrane spanning domains,
however, it was more recently predicted to have four membrane spanning domains with
the amino and carboxyl termini located cytoplasmically (McGeoch, Dalrymple et al.
1988a; McGeoch, Dalrymple et al. 1988b; Hofmann, James et al. 1993; Hirokawa, Boon-
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Chieng et al. 1998). Later this form of the protein in the mature virion was partially
confirmed at the same time that the dependence on UL20 for gK for proper trafficking
through the cell and maturation was established (Foster, Melancon et al. 2004a;
Melancon, Foster et al. 2004; Melancon, Fulmer et al. 2007). The interactions of gK and
pUL20 were covered in more detail in the above section on gK; the involvement of
pUL20 will be covered more briefly in this section.
During infection, gK and pUL20 are interdependent for proper processing and
localization of the proteins. The lack of either of these proteins causes the entrapment of
the other in the endoplasmic reticulum, while expression of both proteins together results
in these proteins being present in the TGN, cell membrane and on the surface of released
mature virions (Foster, Melancon et al. 2004b; Melancon, Fulmer et al. 2007).
Furthermore, these proteins generally colocalize in these areas, suggesting a functional
and physical linkage for these proteins (Foster, Melancon et al. 2004b; Melancon, Fulmer
et al. 2007). In the virus life-cycle, pUL20 appears to regulate virus induced fusion since
syncytia can be prevented in viruses with syncytial mutations in gB or gK if pUL20 is not
also expressed (Foster, Melancon et al. 2004b; Melancon, Fulmer et al. 2007).

Epidemiology of Herpes Simplex Virus
Typical infection of a healthy, not immunosuppressed, individual extremely rarely
results in a primarily fatal infection or contributes to a secondary infection that results in
death. This course of infection more typically results in a short duration of
mucocutaneous lesions, generally around the mouth, with latent disease established in the
trigeminal ganglia and lifetime recurrences with periods of shedding. These factors along
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with the age of the virus, likely a human (or human predecessor) pathogen for at least 810 million, contribute to the distribution of HSV-1 as endemic in developed and
underdeveloped countries worldwide (Black, Hierholzer et al. 1974; Black 1975;
McGeoch, Dolan et al. 1985; Gentry, Rana et al. 1988). Infection with HSV requires
intimate contact of mucosal surfaces or damaged skin in a susceptible individual with
someone who is shedding virus. Being an enveloped virus, HSV usually must be
transmitted directly or with little exposure to the environment. Enveloped viruses are
generally more susceptible to degradation of their infectiousness by interactions with the
environment (e.g.: UV radiation, dehydration, lipids, solvents, etc). Although some new
and old world monkeys can be infected with HSV-1 and some animals can be
experimentally infected, there are no known animal reservoirs or carriers of the virus.
There have, however, been reports of new world primates being naturally infected;
however, these are rapidly severe courses of disease and have not been established as a
true reservoir or reliable source of infection back into the human population (Costa,
Luppi et al. 2011).
New world primates are far more susceptible to HSV-1 infection than old world
primates. Reports of infection in primates, such as the gorilla (Gorilla gorilla),
chimpanzee (Pan troglodytes), bonobo (Pan paniscus), and white-handed gibbon
(Hylobates lar), indicate that the infection in old world primates usually follows the
typical course of infection similar to that found in immunocompetent humans with
lesions remaining on mucocutaneous tissues and not progressing to systemic infection
(Matz-Rensing, Jentsch et al. 2003). In new world primates and prosimians, the infection
is more similar to an aggressive infection found in immunocompromised humans
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(Schrenzel, Osborn et al. 2003). Although old world primates are generally less
susceptible, fatal systemic infections have been reported in the following new and old
world primates: marmosets (Callithrix penincillata), white-faced saki (Pithecia pithecia),
the common marmoset (Callithrix jacchus), the white-handed gibbon (Hylobates lar) and
the orangutan (Pongo pygmaeus) (Huemer, Larcher et al. 2002; Schmutzhard, Merete
Riedel et al. 2004; Kik, Bos et al. 2005; Landolfi, Wellehan et al. 2005). Most infections
in primates have occurred in pet, zoo, or research settings where primates have a greater
risk of exposure to a shedding human, however, naturally occurring infections can occur
in wild populations and are suspected to be the result of exposure to contaminated food
(Bruno, Liebhold et al. 1997; Juan-Salles, Ramos-Vara et al. 1997; Huemer, Larcher et
al. 2002; Matz-Rensing, Jentsch et al. 2003; Lefaux, Duprez et al. 2004; Costa, Luppi et
al. 2011). For HSV-1, humans are considered the reservoir for primate infections and
due to the nature of transmission, primate transmission to a human is extremely unlikely
and therefore, humans are considered the sole source of infection for other humans
(Whitley and Roizman 2001).

Mucocutaneous Infection
The frequency and duration of contact contributes significantly to the chance of
infection for a person (Whitley and Miller 2001). HSV-1 infection most often occurs by
5 years of age and is often fairly asymptomatic. The most common site of primary
infection is the mucosa of the lips and mucocutaneous junction around the mouth
(Whitley and Miller 2001; Whitley and Roizman 2001). After infection, virus is shed
from the mouth and feces for 7-10 days after infection (Amir, Nussinovitch et al. 1997).
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Fecal shedding is likely due to swallowed virus, as replication of HSV-1 in the
epithelium of the digestive tract has not been reported as a prominent feature of the virus.
By 4 to 7 days after neutralizing antibodies can be detected in the serum and these
antibodies peak at about 3 weeks after infection (Buddingh, Schrum et al. 1953).
Dissemination of HSV is often correlated with socioeconomic status with in some
underdeveloped countries having as much as 95% seroprevalence by age 15 (Black,
Hierholzer et al. 1974; Bader, Crumpacker et al. 1978). By 10 years of age the estimated
seroprevalence in the United States is about 50% and about 70% in Europe and at 60
years of age both populations are at 70% to 85% depending on the study (Nahmias, Lee
et al. 1990; Looker and Garnett 2005; Fatahzadeh and Schwartz 2007).
Due to the nature of HSV-1 being primarily acquired orally and HSV-2 primarily
acquired genitally, seroprevalence to HSV-1 is found in greater numbers and at an earlier
age than HSV-2, in which the seroprevalence increases after the age of the onset of
sexual activity (Nahmias, Lee et al. 1990; Fleming, McQuillan et al. 1997). While HSV1 is usually an oral infection and HSV-2 is a genital infection, there are increasing reports
of both viruses at the alternate sites, however, genital infections with HSV-1 tend to be
less severe and have a lower frequency of recurrence (Kalinyak, Fleagle et al. 1977;
Reeves, Corey et al. 1981; Corey, Adams et al. 1983).
The hallmark of HSV-lifecycle is infection of sensory neurons where the virus
establishes a latent infection for the life of the host (Whitley, Kimberlin et al. 1998a).
However, alternate forms of a herpes simplex infection include: neonatal infection,
disseminated infection, herpes gladiatorum, encephalitic infection, and ocular infection.
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Neonatal Infection
Neonatal infections with HSV occur at a rate of 1 in 3000 deliveries and 1500
cases per year in the United States (Nahmias 1983; Nahmias 1989; Brown, Wald et al.
2003). Neonatal infections may occur via in utero, intrapartum or postnatally with
intrapartum the most common and postnatal infection occurring in 10% of cases (Whitley
1994; Fatahzadeh and Schwartz 2007). Congenital infection with herpes simplex is rare
and often results in myriad developmental abnormalities in the brain (Jones 1996;
Whitley and Roizman 2001). Perinatal infection is much more common and may result
in isolated disease and clearance or systemic disease and encephalitis (NoAuthor 1998;
Fatahzadeh and Schwartz 2007). Neonatal herpes was shown to involve the skin, eye,
and mouth in approximately 42% of cases and generally a treated infant will resolve the
disease and recover normally (Whitley, Corey et al. 1988; Kimberlin, Lin et al. 2001).
Neonatal infections that result in encephalitis and/or disseminated disease and are
often fatal with disseminated disease reaching 60% mortality even in treated infants
(Fatahzadeh and Schwartz 2007). In the case of neonatal herpes encephalitis, mortality is
lower than for disseminated disease, but the brain develops normally in less than half of
these infants following recovery (Thompson and Whitley 2011).

Disseminated Infection
Disseminated herpes simplex infection is the result of either neonatal infection or
immunosuppression in an adult. The immunosuppressed state has a greater risk for virus
reactivation with aberrant spread of the virus to the internal organs including; the brain,
liver or lungs (Ramsey, Fife et al. 1982). The clinical significance of this disseminated
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spread is severe and the disease can be fatal even with therapy (Meyers, Flournoy et al.
1980; Siegal, Lopez et al. 1981; Ramsey, Fife et al. 1982).

Herpes Gladiatorum
Herpes gladiatorum is infection through damaged or abraded skin in a location
that is not the typical mucocutaneous exposure (Fatahzadeh and Schwartz 2007). The
incidence of this type of herpes infection is directly related to the potential for exposure
in a shedding individual, with wrestlers, or athletes of similar unprotected contact sports,
being especially susceptible (Fatahzadeh and Schwartz 2007).

Herpetic Encephalitis
The encephalitic form of disease with herpes simplex viruses is more attributable
to the state of the patient rather than the strain of the virus. When compared to
mucocutaneous infection, herpes simplex encephalitis is a rare event in the
immunocompetent person, however, in neonates the primary infection may result in
encephalitis and in immunocompromised adolescents and adults, the primary or recurrent
infection can result in encephalitis (Fatahzadeh and Schwartz 2007). While rare in the
healthy adult, herpes simplex encephalitis is still a significant cause of encephalitis in
humans, as the most common cause of infectious encephalitis world wide and responsible
for over 10% of the 7.3 million hospitalizations for encephalitis from 1979-1988 in the
US (Stahl, Mailles et al. 2011).
HSV encephalitis usually causes fever, headache, neurologic deficits, and
personality and cognitive disorders and has a 70% fatality rate when untreated (Wald and
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Corey 2007). When untreated, surviving patients rarely return to a fully normal
neurologic state and even some treated patients have persistent neurologic deficits (Wald
and Corey 2007). HSV or inflammation resulting from HSV has also been implicated in
the development of Alzheimer’s disease (Honjo, van Reekum et al. 2009).

Ocular Infection
Whether through primary ocular infection, such as may occur with herpes
gladiatorum or intimate contact, or recurrence resulting in spread through the trigeminal
ganglia, HSV may cause ocular disease as well. Ocular HSV is one of the most common
infectious causes of blindness in developed countries, with estimates of the incidence of
herpes ocular disease ranging from 4.1 to 20.7 cases per 100,000 in developed
countries(Liesegang, Melton et al. 1989b; Liesegang 2001). An estimated 400,000
people in the United States have had herpes simplex ocular disease, with about 50,000
new or recurrent cases occurring yearly (NoAuthor 1998).

Pathogenesis of Herpes Simplex Virus
Herpes simplex virus is an enveloped, double-stranded DNA virus that must
infect a target cell and replicate in that cells nucleus to complete its life cycle. Other than
research settings, HSV is nearly entirely a human pathogen, with person-to-person
contact responsible for the spread of the virus (Whitley 2001a). Herpes simplex virus is
unable to penetrate heavily keratinized layers of the skin, therefore, initial infection
occurs at mucous membranes, such as the lips or oral cavity, or at areas of abraded skin
for HSV-1 and generally the genital tissues for HSV-2 (Roizman, Knipe et al. 2007). For
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HSV-1, the initial infection and first round of virus replication typically occurs in the
orolabial mucosa (Roizman, Knipe et al. 2007). After this initial round of infection, the
virus spreads in subsequent rounds of infection, through this tissue and into sensory
neurons innervating the infected tissue. For HSV-2 this is the dorsal root ganglia in the
sacral spinal area and for HSV-1 this is typically in the trigeminal ganglia (Bastian,
Rabson et al. 1972; Baringer and Swoveland 1973; Whitley 2001a).
The most common clinical form of the disease consists of a short to moderate
duration of lesions at the initial site of infection, possibly with fever and generalized
symptoms. Following this, the virus having infected sensory neurons, establishes a latent
infection for the life of the host that results in periodic recurrences at or near the site of
initial infection with generally reduced severity from the initial infection (Bastian,
Rabson et al. 1972; Baringer and Swoveland 1973; Roizman, Knipe et al. 2007).
Alternate, and less common, sequelae to the initial infection include the development of
ocular disease, disseminated disease and neurologic disease. With the exception of those
arising from neonatal infections; disseminated, neurologic, and ocular disease are more
common for HSV-1 than HSV-2 (Roizman, Knipe et al. 2007). Individuals with reduced
immune capability, such as neonates, people concurrently infected with HIV, or people
with other causes of immune suppression are at greater risk for these alternate
manifestations of the infection (Fatahzadeh and Schwartz 2007).
At the site of initial mucosal infection, infected cells exhibit enlargement of the
cell with condensation of the chromatin in the nucleus. Sometimes cellular chromatin is
visibly moved to the periphery of the nucleus with formation of intranuclear inclusion
bodies (Whitley 2001a). Once the cell goes fully into a lytic phase, the there is
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degradation and fragmentation of the nucleus and disruption of the plasma membrane.
Occasionally cells will fuse the plasma membranes forming multinucleated giant cells
(Pugh, Dudgeon et al. 1955; Wheeler and Abele 1966; Terezhalmy, Tyler et al. 1979). In
the infected dermis there is an intense inflammatory response that may be complicated by
secondary bacterial or fungal opportunistic infection. Immune cellular response due to
the erosion of the mucosal surface and surface bacteria and fungi is often mixed with
polymorphonuclear cells, macrophages, lymphocytes and plasma cells (Pugh, Dudgeon et
al. 1955; Wheeler and Abele 1966; Terezhalmy, Tyler et al. 1979). If infected neurons
enter the lytic phase of infection, they appear similar to infected epithelial cells although
multinucleate giant cells are very rare (Dudgeon 1969). Neurons that enter the latently
infected state may appear normal. In neuronal tissues, the immune reaction is generally
restricted to lymphocytes and plasma cells with some macrophages. In mucosal tissues,
usually the intensity and duration of the cellular destruction and inflammation decreases
with recurrent infections (Whitley 2001a).

Mucocutaneous Infection
As stated above, primary infection with HSV-1 usually occurs in the orolabial,
glossal, gingival or buccal mucosa. This infection is often accompanied by one or more
of the following symptoms: vesicular or ulcerative lesions, localized pain and edema,
fever, and sore throat (Amir, Nussinovitch et al. 1997). The primary infection can
frequently be asymptomatic or of insufficient clinical significance to be reported as well
(Whitley and Roizman 2001). When symptomatic in children, the clinical course is
usually 2 to 3 weeks long with temperatures ranging from 101 F to 104 F. In young
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adults, the primary infection can produce pharyngitis at the initial stage of the oral
infection and tonsillectomy is often the treatment of choice when this occurs
(Langenberg, Corey et al. 1999). Occasionally the primary infection is complicated by
dehydration, likely due to an unwillingness to drink due to pain, and secondary bacterial
infection (Langenberg, Corey et al. 1999).
With HSV-1, recurrent disease is frequently more noticeable with marked pain,
burning, tingling or itching as a prodromal event (Spruance, Overall et al. 1977; Spruance
and Crumpacker 1982; Spruance 1984). These symptoms are usually short, six hours or
less, and are followed by formation of vesicles and the typical cold sore within 24-48
hours (Spruance, Overall et al. 1977; Spruance and Crumpacker 1982; Spruance 1984).
Pain is generally most intense at the beginning of the cold sore formation with the pain
resolving over 4-5 days and lesions resolving in approximately 7 days (Segal, Katcher et
al. 1974; Ship, Miller et al. 1977). Reactivation can occur for a number of reasons
including: trauma to the local area of initial infection, fever, exposure to UV radiation
and stress (Segal, Katcher et al. 1974; Ship, Miller et al. 1977; Spruance, Freeman et al.
1991). The frequency of reactivation varies greatly among individuals, with a study
reporting that approximately 30% of seropositive individuals experience recurrent
infections with 40% of these having at least one recurrence per year (Wald and Corey
2007). HSV-1 can also be detected on the orolabial mucosa of seropositive individuals
even without clinical disease, suggesting that recurrence, shedding, and possibly
transmission, can occur as an asymptomatic, subclinical, event (Koelle and Wald 2000;
Fatahzadeh and Schwartz 2007).
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In HSV-2 the primary infection usually occurs in the genital epithelial or mucosal
tissues. Generally with HSV-2, the most severe symptoms are associated with the
primary infection and are characterized by macules and papules that turn into pustules
and ulcers with lesions and viral secretion lasting about three week (Corey 1982; Corey,
Adams et al. 1983). It appears that previous exposure and immunity to HSV-1 may
mitigate HSV-2 infection, by decreasing the severity of the primary infection (Kaufman,
Gardner et al. 1973; Corey 1981; Allen and Rapp 1982).
Clinical recurrence in HSV-2, unlike HSV-1, is typically less severe than the
initial infection with asymptomatic shedding or milder pain, the development of vesicles,
and shedding of the virus lasting less than 10 days total (Adams, Benson et al. 1976).
However, with HSV-2 recurrence seems to be more frequent with several recurrences
occurring per year and the possibility of transmission during asymptomatic or
symptomatic disease (Corey 1982; Corey, Adams et al. 1983).

Neonatal Infection
Neonatal HSV infections occur at a rate of approximately 1 in 3000 births with an
estimated 1500 cases of neonatal HSV per year in the United States (Nahmias 1983;
Nahmias 1989; Brown, Wald et al. 2003). Neonatal infections may occur in utero,
intrapartum or postnatally with intrapartum the most common and postnatal infection
occurring in 10% of cases (Whitley 1994; Fatahzadeh and Schwartz 2007). Congenital,
in utero, infection is rare with HSV but is often severe when it occurs (Jones 1996;
Whitley and Roizman 2001). In utero infection causes cutaneous lesions, scars and
chorioretinitis and can cause multiple developmental abnormalities including:
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microcephaly, lissencephaly, hydranencphaly and microphthalmia (Hutto, Arvin et al.
1987). Intrapartum infection accounts for 75-80% of cases (Whitley 2001a). HSV-2 is
often the culprit in intrapartum infection, although HSV-1 infection may also occur, when
the fetus is exposed to maternal genital secretions during delivery or in the post-natal
period from the mother or other infected individuals (Whitley 2001a; Wald and Corey
2007).
In cases of herpes encephalitis in the neonate, HSV-1 usually has a better
prognosis than HSV-2 (Toth, Harder et al. 2003). The risk of fetal infection is directly
related to the type of maternal genital infection at the time of delivery, with a
transmission risk of approximately 30% if the mother has a primary infection and 3% or
less risk of transmission to the fetus if the mother has a recurrent infection at the time of
delivery (Brown, Benedetti et al. 1991). Risk of fetal infection is increased in the
intrapartum period with closer proximity of a primary maternal infection to the time of
delivery and with increased disruption or trauma to the mucocutaneous tissues (Nahmias,
Josey et al. 1971; Parvey and Ch'ien 1980; Brown, Wald et al. 2003). Risk of
transmission is reduced with maternal seroconversion prior to delivery and with
caesarean delivery (Brown, Wald et al. 2003; Johnston, Magaret et al. 2008).
HSV infection in newborns can result in disseminated disease, central nervous
system disease, or cutaneous disease. The type of disease is a result of the site and extent
of viral replication. Infection of the newborn may result in isolated cutaneous disease,
systemic (disseminated) disease, or encephalitis (NoAuthor 1998; Fatahzadeh and
Schwartz 2007). Neonatal herpes was shown to involve the skin, eye, and mouth in
approximately 42% of cases and generally a treated infant will resolve the disease and
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recover normally (Whitley, Corey et al. 1988; Kimberlin, Lin et al. 2001). Without
antiviral therapy, 25% of infants with only cutaneous disease still had neurologic
developmental delays (Whitley, Nahmias et al. 1980; Kimberlin, Lin et al. 2001).
Neonatal infections resulting in disseminated disease or encephalitis are much more
severe. Even with antiviral therapy, in one study there was 57% mortality for cases of
disseminated disease and 15% mortality for cases of encephalitis in infants (Whitley,
Arvin et al. 1991). In this same study none of the infants with cutaneous disease died and
94% developed normally neurologically (Whitley, Arvin et al. 1991). While mortality is
less in cases of infant with encephalitis versus disseminated disease, there are
developmental abnormalities in more than half of these infants following recovery
(Thompson and Whitley 2011). In the previously mentioned study, one year following
recovery 36% of infants that had encephalitis and 59% of the infants surviving
disseminated disease were developing normally (Whitley, Arvin et al. 1991).
Infants with cutaneous or disseminated disease usually present within the first 1012 days of life (Kimberlin, Lin et al. 2001). Cases of encephalitis in neonates usually
present slightly later, at 2-3 weeks after birth (Kimberlin, Lin et al. 2001). Cutaneous
vesicles may be seen with all presentations of neonatal HSV infection but are frequently
resolved by the time of presentation with more severe disseminated or encephalitic
disease (Kimberlin, Lin et al. 2001; Thompson and Whitley 2011). With central nervous
system infection and disseminated disease the initial symptoms are often non-specific,
including fever or fluctuating temperature, respiratory distress, lethargy, inappetance,
hypotension, shock, disseminated intravascular coagulation, apnea, and shock (Thompson
and Whitley 2011). Disseminated disease often involves many of the visceral organs
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including lungs, liver, adrenal glands, skin, eyes, and often the brain (Thompson and
Whitley 2011). Severe pneumonitis, hepatitis, and coagulopathy are common
complications of disseminated disease in neonates (Thompson and Whitley 2011).
Lesions in the central nervous system of infected neonates are similar to those described
later for adults with the exception that brainstem involvement appears to be less common
in the neonate (Chu, Kang et al. 2002; Pelligra, Lynch et al. 2007). In the cerebrospinal
fluid, there is mild to moderate pleocytosis, consisting predominantly of mononuclear
inflammatory cells and normal to decreased protein levels (Koskiniemi, Vaheri et al.
1980; Cinque, Cleator et al. 1996).

Ocular Infection
A less frequent, however, very serious manifestation of HSV infection is herpetic
ocular disease. Ocular disease with herpes simplex virus is usually due to HSV-1. Even
at a prevalence of 149 cases per 100,000 people per year, corresponding to less than 1%
of people exposed to the virus, HSV is the leading infectious cause of blindness in the
United States with an estimated 400,000 people in the United States with herpes simplex
ocular disease and approximately 50,000 new or recurrent cases occurring yearly
(Liesegang, Melton et al. 1989b; NoAuthor 1998; Liesegang 2001; Tullo 2003).
The ocular manifestation of HSV is usually a result of spread of primary disease
through the branches of the trigeminal ganglion rather than primary infection of the
ocular area (Tullo, Easty et al. 1982; Theil, Derfuss et al. 2003; Tullo 2003; Pepose,
Keadle et al. 2006). While a primary ocular infection could result from mechanical
transmission to the eye, ocular herpetic disease is usually the result of recurrent, or more
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accurately multiple recurrences, following a primary infection in the normal route.
Superinfection, or infection with a second strain after previous exposure to the virus and
incomplete immune protection, may account for some of the cases of ocular disease and
recent studies suggest that this phenomenon may be more common than previously
thought (Remeijer, Maertzdorf et al. 2002). In either case, after superinfection or
multiple recurrences or reactivation events, the tissues of the eye, including the cornea
and adjacent epithelial tissues, become infected and subsequent reactivations can cause a
progressive degeneration of the cornea eventually leading to blindness (NoAuthor 1998;
Liesegang 2001).
More rare causes of herpetic ocular disease can occur with primary or recurrent
infection that involves the innervation of alternate structures in the eye; e.g.: those
structures innervated by a nerve that is not part of the trigeminal. Reactivation of latent
HSV, possibly from earlier localized or CNS infection, from the ciliary or superior
cervical ganglion or Edinger-Westphal-nucleus can result in herpes infection in the iris
(Pepose, Leib et al. 1996; Labetoulle, Kucera et al. 2000). Furthermore, reactivation of
HSV from the suprachiasmatic or paraventricular nuclei or any other
infection/reactivation event causing encephalitis can result in retinitis or retinal necrosis
and spread of infection to the surrounding tissues (Gentry, Lowe et al. 1988; Atherton
2001). Following this round of replication, the trigeminal ganglion, which innervates the
sensory structures around the eye can be infected and contribute to later bouts of more
traditional recurrent herpetic eye disease.
With recurrent bouts of herpes keratitis, the cornea can become opaque leading to
blindness and sometimes the cornea is replaced with a corneal transplant. Herpes may
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spread from the patient’s latently infected trigeminal ganglia to the new cornea and can
even cause primary graft failure (Cockerham, Krafft et al. 1997; De Kesel, Koppen et al.
2001; Tullo 2003). Less commonly, a person without herpes keratitis may receive a
transplant cornea that is harboring latent or persistent HSV and following a flourishing
infection in the transplant, the patients previously naïve trigeminal ganglia (Easty,
Shimeld et al. 1987; Gordon, Romanowski et al. 1991; Kaye, Lynas et al. 1991). This
has recently lead to investigations into the possibility of non-neuronal sources of latency
for HSV (Farooq and Shukla 2011).
Primary infection or recurrent shedding causes herpetic ocular disease in one or
both eyes. The lesions of ocular infection with HSV include: blepharitis, conjunctivitis,
dendritic or epithelial keratitis (superficial infection of the cornea), stromal keratitis (deep
infection of the cornea), anterior uveitis, iridocyclitis, and retinitis (NoAuthor 1998;
Liesegang 2001). These conditions can cause blindness through progressive
inflammation and opacity of the cornea or more directly through destruction of the retina
(NoAuthor 1998; Liesegang 2001). On the surface of the cornea, the infection usually
begins as focal point that spreads to a web-like (dendritic) pattern (Maudgal and
Missotten 1978). Pathologically, on the surface of the cornea, there are erosions and
ulcerations of the epithelium with necrosis and inflammation by polymorphonuclear
inflammatory cells, lymphocytes and plasma cell, sometimes with syncytial cells and
intranuclear inclusions (Maudgal and Missotten 1978; Metcalf and Reichert 1979).
These surface lesions may also be complicated with secondary bacterial or fungal
infections.
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As the lesions progress deeper to stromal keratitis, there is inflammation of the
corneal stroma by polymorphonuclear inflammatory cells, lymphocytes, plasma cells and
macrophages (Metcalf and Reichert 1979). Necrosis, neovascularization, fibroplasia and
full-thickness penetration may also be observed (Metcalf and Reichert 1979). The
infection can progress to deeper eye tissues and cause infection and inflammation of the
anterior chamber, iris and retina (Holland, Togni et al. 1987; Liesegang 2001; David,
Baghian et al. 2008). Lesions can even progress to full-thickness necrosis of the retina
with mixed inflammatory infiltrates and herpes particles detectable in the cell layers of
the retina, including the retinal pigment epithelium (Holland, Togni et al. 1987;
Liesegang 2001). Acute necrosis of the retina in people is rare but more frequently
observed in young patients when it occurs (Liesegang 2001).
Another possible consequence of herpetic ocular disease is hypoesthesia, or loss
of sensation, in the cornea due to destruction or degeneration of sensory trigeminal nerves
(Keijser, van Best et al. 2002). This can cause a decrease in tear production and resulting
dry eye with increased chances for corneal abrasion, inflammation, secondary infection
and even stimulation of additional herpetic recurrence (Keijser, van Best et al. 2002;
Tullo 2003).

Central Nervous System Infection
Central nervous system (CNS) infection with herpes simplex virus encephalitis is
a rare event in the immunocompetent adult, however, in neonates the primary infection
may result in encephalitis and in immunocompromised adolescents and adults, the
primary or recurrent infection more frequently results in encephalitis (Fatahzadeh and
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Schwartz 2007). Although rare compared to oral mucosal infection, HSV-1 is one of the
most common and potentially severe causes of sporadic encephalitis in adults (Lakeman
and Whitley 1995). Herpes simplex encephalitis can happen to any age person, has no
seasonal variability and is one of the most common causes of infectious encephalitis with
an estimated incidence of 1 in 250,000 to 1 in 1 million people per year (Skoldenberg,
Forsgren et al. 1984; Whitley and Schlitt 1991). From 1979-1988, herpes simplex
encephalitis was the most common cause of infectious encephalitis in the US and was
responsible for over 10% of the 7.3 mission hospitalizations for encephalitis (Khetsuriani,
Holman et al. 2007; Stahl, Mailles et al. 2011). HSV-2 is a more common cause of
encephalitis in neonates, but HSV-1 is a far more common cause of herpes encephalitis in
older age groups, accounting for 90% of cases (Ito, Watanabe et al. 2000).
Infection of the central nervous system most likely occurs via spread of the virus
from the primary site of infection, usually mucous membranes, through the nerves that
innervate these tissues, usually the trigeminal or olfactory nerves (Arduino and Porter
2008). This spread can occur following the primary infection or more frequently during a
recurrence, after latency has been established. HSV encephalitis usually causes fever,
headache, neurologic deficits, and personality and cognitive disorders and has a 70%
fatality rate when untreated (Wald and Corey 2007). Herpes encephalitis has also been
associated with senile-plaque-like beta amyloid deposits in the brain that are associated
with the development of dementia and Alzheimer’s disease (Honjo, van Reekum et al.
2009; Miklossy 2011).
Clinically, herpes encephalitis can present with altered consciousness, nonspecific or randomly localizing focal neurologic deficits, focal seizures, and personality
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or behavior changes (Cinque, Cleator et al. 1996). These lesions generally refer to the
areas of the brain involved; however, there is no specific pattern for herpes encephalitis
(Cinque, Cleator et al. 1996). Prior to full onset of symptoms, there is often a prodromal
phase consisting of aphasia, fever, headache, nausea, and visual deficits that may
continue until presentation (Cinque, Cleator et al. 1996). In the most severe, or untreated,
cases, the disease can be rapidly progressive with severe cerebral edema, necrosis of vital
brain structures, and death within 7 to 14 days (Cinque, Cleator et al. 1996).
CNS lesions of herpetic encephalitis include aseptic meningitis and acute
encephalomyelitis either with or without necrosis (Dudgeon 1969). Herpes cases
involving solely aseptic meningitis appear to be rare (Dudgeon 1969). Cases with aseptic
meningitis often have few lesions with only infiltration of the meninges infiltrated by
mononuclear inflammatory cells and a slight increase of mononuclear inflammatory cells
in the cerebrospinal fluid (CSF) (Dudgeon 1969; Koskiniemi, Vaheri et al. 1980;
Skoldenberg, Forsgren et al. 1984). Cases with encephalitis or encephalomyelitis range
from moderate to severe with possible extensive cortical necrosis (Stahl, Mailles et al.
2011). Generally the temporal lobes are the most frequently affected in a bilateral,
random, asymmetrical pattern (Dudgeon 1969; Stahl, Mailles et al. 2011). The frontal
and parietal cortices are less commonly involved, however, all the brain can become
involved (Stahl, Mailles et al. 2011). In cases of encephalitis/encephalomyelitis, the early
CSF shows a mild to moderate increase in mononuclear cells with normal or slight
increases in protein (Dudgeon 1969; Koskiniemi, Vaheri et al. 1980; Skoldenberg,
Forsgren et al. 1984). Later, especially with necrosis, the CSF can show markedly
increased protein and red cells as well (Dudgeon 1969).
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Microscopically, herpes encephalitis lesions are characterized by focal to massive
necrosis with hemorrhage and edema of the gray matter sometimes with intranuclar
inclusions (Dudgeon 1969; Booss and Kim 1984). Neutrophils may be present in areas
of necrosis and microglial infiltration, microglial nodules and perivascular cuffing is
observed (Dudgeon 1969). Although lesions are often confined to the cortex, lesions can
progress to the basal ganglia, lobar white matter, and the brainstem (Chu, Kang et al.
2002; Ueda, Miyasaki et al. 2003; Ono, Manabe et al. 2009). In the end stages there is
gliosis and astrocytosis and there may be persistent post infectious encephalomyelitis,
movement disorders, atypical pain syndromes, neurologic deficits and epilepsy
(Schmutzhard 2001; Simmons 2002). HSV encephalitis may be diagnosed via PCR of
brain biopsy tissue or CSF, ELISA of CSF, or viral isolation from brain biopsy tissue
(Cinque, Cleator et al. 1996).

Infection in an Immunocompromised Host
Rather than being a distinct clinical appearance, primary or recurrent infection of
an immunocompromised person follows pattern similar to those observed in healthy
individuals with the exception that the infections are more severe, more common, have
greater spread, and are more likely to develop into serious illness (Fatahzadeh and
Schwartz 2007). Immune suppression may be due to immunotherapy, metabolic
disturbances, malnutrition, or concurrent disease, such as acquired immunodeficiency
syndrome (AIDS) or immune system neoplasia. In these patients, HSV infections may
develop progression from the oral mucosa to severe disease involving the esophagus,
gastrointestinal (GI) tract or respiratory tract (Montgomerie, Becroft et al. 1969;
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Korsager, Spencer et al. 1975). In the case of recurrence of oral mucosal disease, the
disease may spread extensively in the mouth, on the tongue and along the GI tract
resulting in a disease that is more painful and takes significantly longer to heal, up to 6
weeks or more (Whitley, Levin et al. 1984; Cohen and Greenberg 1985; Epstein,
Sherlock et al. 1990; Woo, Sonis et al. 1990). The incidence of reactivation can range
from 60-95% in seropositive patients that receive immunosuppressive therapy for bone
marrow transplant (Arduino and Porter 2008). The most common complication in
immunosuppressed patients is severe, progressive, chronic mucocutaneous infection with
recurrent infection leading to disseminated disease or CNS infection occurring rarely
(Whitley, Levin et al. 1984; Whitley and Roizman 2001). When disseminated disease or
CNS infection occurs it is similar to the conditions previously described. In the
immunocompromised patient, HSV-1 is the prominent culprit, however, HSV-2 has been
reported to cause meningoencephalitis in immunocompromised patients (Linnemann,
First et al. 1976; Gateley, Gander et al. 1990).

Treatment and Prevention of HSV Infection
Generally the two broad strategies for control of an infectious agent are some type
of preventative measure and then treatment of infected individuals. In the case of HSV,
whether type 1 or 2, prevention has been difficult to accomplish. The ideal mechanism
for prevention would be a vaccine that prevents the development of infection past a mild
mucocutaneous course of infection, eliminating spread to the nervous system and
possible recurrence. No vaccine has produced this level of protection to date (Roizman,
Knipe et al. 2007). Vaccination may also be used in a therapeutic sense rather than a
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prophylactic sense to prime the immune system to limit the severity and duration of
clinical symptoms in primary or recurrent infection (Stanberry 2004).

Vaccines
Attenuated live strains, killed virus, viral subunits, and genetically modified,
attenuated viruses have all been attempted. Attenuated live strains tended to produce
infection at the site of infection as well as recurrent disease later (Roizman, Knipe et al.
2007). Killed virus vaccines have been unreliable at producing a decrease in the
symptoms of recurrent infection versus placebo (Whitley 2001a). These vaccines have
also been unable to provide substantial increases in neutralizing antibody titers or
complement fixation of virus to defend against primary infection (Roizman, Knipe et al.
2007). Subunit vaccines utilize viral proteins without the DNA component to prevent the
vaccine from causing an infection. Typically subunit vaccines have provided little
mitigation of symptoms in the already infected and no definitive protection for the
unexposed (Roizman, Knipe et al. 2007). A recent subunit vaccine has had some success
with the mitigation of symptoms and prevention of primary infection.
Two somewhat similar HSV-2 based vaccines have recently been used in large,
well controlled studies (Roizman, Knipe et al. 2007). They both contain a modified
recombinant form of glycoprotein D, while one also contains a modified glycoprotein B
(Wilson, Fakioglu et al. 2009). The vaccine containing only the gD modification has
been shown to be protective versus primary infection as well as able to mitigate
symptoms of recurrence in latently infected women, however, no discernable effect was
observed in men (Roizman, Knipe et al. 2007; Wilson, Fakioglu et al. 2009). Given the
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similarity in the two vaccines, the difference may lie in the adjuvant, which in the more
efficacious vaccine induced T helper-1 rather than T helper-2 immune responses
(Roizman, Knipe et al. 2007; Wilson, Fakioglu et al. 2009). The gender difference in this
vaccine needs to be examined to provide a more efficacious vaccine; however, given the
poor status of HSV vaccines to date this progress is promising.
Construction of a recombinant (genetically modified), attenuated, live vaccine
strain of the virus is the most likely method to produce a vaccine that both limits the
course of recurrent disease in the latently infected and prevents primary infection.
Currently some strains with limited replication characteristics have been attempted as
possible vaccine strains, however, limited replication can have negative consequences on
the development of a robust immune response (Dudek and Knipe 2006; Roizman, Knipe
et al. 2007). Development of vaccine strains that allow sufficient replication to induce an
immune response while preventing the establishment of latency are likely the best
candidates for an effective vaccine (Whitley, Kern et al. 1993; Roizman, Knipe et al.
2007).

Isolation
Another prevention strategy is to eliminate contact with seronegative individuals
when seropositive individuals are shedding virus. Prevention using this strategy is
difficult due to asymptomatic shedding. Asymptomatic shedding has been reported for
HSV-2 and one study found that 33% of people were asymptomatic at the time of
infection of their partner (Mertz, Schmidt et al. 1985; Barton, Wright et al. 1986). For
asymptomatic shedding of HSV-1 in the oral cavity, one study found that as much as
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70% of the population may shed HSV-1 at least once per month with many of these
shedding six times per month without symptoms (Miller and Danaher 2008). Amounts of
viral DNA that can be detected decrease during antiviral therapy, however, detectable
DNA is still shed without symptoms during this therapy (Koelle and Wald 2000).
Clearly the virus can be transmitted to a seronegative individual without the knowledge
of the carrier.

Therapeutics
Therapeutic antivirals that can reduce the symptoms and duration of primary and
recurrent infection are available for HSV. The nucleoside analogs such as acyclovir,
ganciclovir, famciclovir and valacyclovir have specific activity against HSV. The first
nucleoside analog used effectively to treat HSV was acyclovir (Elion 1977). In general
these are analogs of the nucleoside guanosine, or are converted by cellular or viral
enzymes to analogs of guanosine, that can substitute for guanosine in DNA replication
(Wilson, Fakioglu et al. 2009). In these cases the deoxyribose sugar ring is altered or
replaced by another molecular structure. For acyclovir this is specifically a non-ring,
linear structure. Acyclovir enters the cell in this form and is phosphorylated to
acycloguanosine-monophosphate by viral thymidine kinase (Coen and Richman 2007). It
is then converted to the tri-phosphate form by cellular kinases and acycloguanosine-3P
competes with GTP in DNA synthesis (Coen and Richman 2007). It inhibits the viral
DNA polymerase and since the sugar end of acyclovir cannot be used to link the next
nucleotide, it terminates the DNA strand replication (Furman, St Clair et al. 1984). Viral
DNA polymerase also appears to be unable, or poorly able at best, to do any proof
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reading/removal of the acyclovir. This is because the HSV DNA polymerase is
irreversibly inactivated when it attempts to use the acyclovir-triphosphate (Furman, St
Clair et al. 1984). Acyclovir and the other guanosine analogs appear to have a higher
affinity for viral kinases and viral DNA polymerase thereby making them have a more
potent anti-viral effect than an anti-cellular enzyme effect (Fyfe, Keller et al. 1978). The
oral bioavailability of acyclovir is low, therefore other forms of guanosine analogs and
pro-drugs, such as famciclovir and ganciclovir were created with greater flexibility in
dosing (Coen and Richman 2007). Acyclovir and related compounds are fairly
efficacious in limiting the severity of herpetic disease, however, resistant strains have
developed (Bacon, Levin et al. 2003; Coen and Richman 2007). In cell culture, acyclovir
can be used to establish a quiescent/latent infection state, therefore, it is likely that drugs
like acyclovir may provide some measure of help in maintaining the latent state in
sensory neurons (Danaher, Jacob et al. 1999).
Another inhibitor of DNA replication, and HSV antiviral compound, is foscarnet.
This is a pyrophosphate mimic that can directly inhibit the action of the DNA polymerase
by substituting for pyrophosphate (Coen and Richman 2007). This compound will also
inhibit RNA polymerase. Foscarnet does not require the viral thymidine kinase for
activation and is therefore active versus acyclovir resistant viruses (Wilson, Fakioglu et
al. 2009). Since this compound is not as specific for HSV, it also possesses action
against cellular polymerases and is more toxic (Wilson, Fakioglu et al. 2009). Cidofovir
is a nucleoside analog, similar to acyclovir, however it uses cellular enzymes to be
phosphorylated to an active form and, therefore, can be used versus acyclovir resistant
strains (Wilson, Fakioglu et al. 2009). Since both foscarnet and cidofovir are more toxic

76	
  

and effective against acyclovir resistant viruses, these are generally administered only in
cases of resistance (Wilson, Fakioglu et al. 2009).

The Host Neuron and its Role in HSV Infection
Basic Neuron Structure
The anatomic structure of a typical neuron is composed of the cell body (soma)
that contains the nucleus, an axon (which is the long tubular process that traverses the
distance between the soma and the axon terminals, dendrites (which are multiple weblike projections of processes and synaptic bulbs (King 1994). Most neurons are
multipolar with axons and dendrites projecting in multiple directions and dendrites
coming directly off the soma. Sensory neurons, the primary neuronal target of HSV, are
pseudounipolar with a single process that bifurcates to make the axon running to the
receptors at one end and axonal termini at the other with the soma situated in the middle
(King 1994). In a sensory pseudounipolar neuron, the dendrite extends to the innervated
site and acts electrophysiologically like a dendrite bringing sensory stimuli toward the
cell body (Zaichick, Bohannon et al. 2011). However, in other respects the structural
composition, functional elements, and directionality of microtubules of this structure are
more similar to an axon (Enquist, Husak et al. 1998; Zaichick, Bohannon et al. 2011).
The synapse is formed from a synaptic bulb (a bulge in the axon terminus), the synaptic
cleft and the post-synaptic structure being acted upon (dendrites, other axons or neuron
cell bodies). The synaptic cleft is lined by the pre-synaptic membrane (part of the bulb
which releases neurotransmitters) and the post-synaptic membrane (where
neurotransmitters are bound and elicit their function) (King 1994). The synapse is an
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attractive target for entry of a virus as there is abundant turn-over of membranes due to
the vast recycling associated with release and reuptake of neurotransmitters (Salinas,
Schiavo et al. 2010). For HSV specifically, nectin-1 is located at the synaptic junction
for sensory neurons (Salinas, Schiavo et al. 2010).

Retrograde and Anterograde Transport
To discuss neuronal axonal biology and transport functions a few terms must first
be defined. First directionality of transport within a neuron must be considered.
Retrograde transport is defined as transport from the axon terminus/ends of dendritic
processes toward the nucleus/cell body. Anterograde transport is the opposite, transport
from the nucleus/cell body to the axon terminus/ends of dendritic processes. When
referring to a single neuron, this system is fairly straightforward. However, occasionally
these terms are used to refer to the overall direction of travel from the point of a whole
system that contains arcs of multiple neurons. In this case, retrograde transport refers to
the overall movement toward the central nervous system (CNS), the brain or spinal cord.
In this context, anterograde transport refers to movement from the CNS toward the
peripheral tissues of the animal. Therefore, due to the architecture of neuronal pathways
and individual neurons, retrograde transport at the level of the overall animal may require
brief anterograde transport on an individual neuron level.
The axon is a long, tubular structure in which the majority of transport within
neurons occurs. The axon is made predominantly of microtubules surrounded by the
plasma membrane and contains abundant transport molecules, proteins, enzymes, and
organelles that are being transported. Axons are myelinated by Schwann cells (a type of
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glial cel) in the peripheral nervous system (PNS) and by oligodendroglial cells in the
CNS with unmyelinated axons being supported and surrounded in groups in the PNS
(King 1994). The axon structure is vital to the function of transport of molecules within
the neuron.
Interestingly, intracellular transport is highly conserved among neurons and nonneuronal cells. Transport along axons occurs primarily along a scaffold of microtubule
rails. These are made of heterodimers of alpha and beta tubulins and are approximately
25 nm in diameter (Hirokawa 1998; Hirokawa and Takemura 2005). Although, transport
mechanisms are conserved, microtubules have polarity and in axons they run in the same
direction while in dendrites and other cell types they may run in multiple directions. In
axons, the plus end is directed to the periphery; which means that in axons anterograde
transport is always directed toward the plus end and retrograde transport toward the
minus end (Baas, Deitch et al. 1988; Burton 1988; Sharp, Yu et al. 1995). In epithelial
cells the minus ends are oriented toward the apical surface of the cell and in fibroblasts
they radiate around the nucleus in various directions (Hirokawa, Noda et al. 2009).
Transport within axons is accomplished by two types of molecular motors. One is the
kinesin superfamily of proteins (KIFs) and the other is dynein. Both of these proteins
transport a large variety of molecules and, although they use different mechanisms to
specify what molecules are transported, they both use ATP hydrolysis to drive transport
(Hirokawa, Noda et al. 2009). Dynein forms a dynactin complex with multiple subunits
to bind various molecules while KIFs use a wide variety of proteins in the family to
accomplish binding and transport of varied proteins, enzymes and organelles (Vallee,
Williams et al. 2004; Hirokawa, Noda et al. 2009).
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Comprehensive analysis of mammalian genomes have found 45 KIF genes with
38 expressed in the brains of mice (Miki, Setou et al. 2001). There are 3 broad catagories
of KIFs; N-kinesins with the motor domain near the amino terminus, M-kinesins with the
motor near the middle and C-kinesins with the motor near the carboxy terminus
(Hirokawa and Noda 2008; Hirokawa, Noda et al. 2009). N-kinesins have plus directed
motor activity and C-kinesins have minus motor activity. The majority of kinesins are Nkinesins with KIFs responsible for all anterograde transport currently identified (other
than diffusion) and dynein responsible for the majority of retrograde transport (Miki,
Setou et al. 2001; Gennerich and Vale 2009; Hirokawa, Noda et al. 2009). A few of the
best characterized kinesin superfamily proteins and their known cargos will be listed.
KIF1A has been shown to transport synaptic vesicle precursors containing
synaptophysin, synaptotagmin and Rab-3A and binds its cargo through a pleckstrinhomology domain (Okada, Yamazaki et al. 1995; Klopfenstein, Tomishige et al. 2002).
KIF1Bbeta seems to share many functions with KIF1A and this was not a unique instance
of some redundancy in these proteins (Hirokawa and Noda 2008). KIF1Balpha is a
monomer used for transport of mitochondria (Nangaku, Sato-Yoshitake et al. 1994).
KIF5 is a dimeric motor that consists of 3 subtypes (A, B, and C) that can form tetramers
with KIF light chains. KIF5 has been shown to transport mitochondria, neurofilaments,
syntaxin, syntabulin, GAP-43, synapsin and likely c-jun NH2-terminal kinase interacting
proteins (which serve as scaffolds for MAP kinases (Hirokawa and Noda 2008). KIF5
can also play a role in retrograde transport (Hirokawa and Noda 2008).
The previous examples are of fast axonal transport, however, there is a second set
of transport functions described as slow axonal transport. Generally slow axonal
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transport carries structural proteins, like tubulins and neurofilaments, or glycolytic
enzymes (Hirokawa and Noda 2008). KIF5 is the primary currently identified mediator
of slow anterograde transport (Hirokawa and Noda 2008). There is increasing evidence
that slow and fast transport actually occur at similar rates of forward progress, just that
slow anterograde movement has pauses of significantly greater duration than in fast
transport (Brown 2003). The determinants of what causes a pause, allows a return to
movement or determines the length of pauses are not well known (Brown 2003;
Hirokawa and Noda 2008). However, it appears that in slow axonal transport, there is a
distinct on- or off-track state and in the off-track state, neurofilaments pause for
prolonged periods of time without forward movement (Brown, Wang et al. 2005).
Furthermore, myosin Va may play a role in the length of pauses in the delivery of
neurofilaments by reducing time off-track (Alami, Jung et al. 2009).
Most of the retrograde transport that occurs in neurons, occurs via dynein. Less
specific details are known about dynein in axonal transport compared to the kinesin
superfamily. Dynein is a very large protein complex, 1.2 MegaDaltons (MDa), and is
composed of two heavy chains and multiple light chains (Gennerich and Vale 2009). The
motor action of dynein is performed by the heavy chains and the intermediate and light
chains perform cargo attachment functions (Hall, Song et al. 2010). The heavy chains of
dynein are encoded by a single gene and as few as two genes may encode the possible
dynein light chains (Pfister, Shah et al. 2006; Ha, Lo et al. 2008). These may be arranged
as isoforms to provide diversity of cargo binding domains. The intermediate chain of
dynein has at least 6 splice variants that appear to be preferentially expressed in various
neural tissues and appears to preferentially bind different tyrosine kinases (ie: TrK A or

81	
  

TrK B) (Pfister, Shah et al. 2006; Lo, Kogoy et al. 2007; Myers, Lo et al. 2007; Ha, Lo et
al. 2008). When considered simply, this disparity in complexity is likely due in part to
the vast amounts of molecular material that must be transported to the axon terminus
versus the much lower amount of material that needs to be transported back from the
terminus to the cell body. Cellular components and neurotransmitters that must be
recycled at the level of the cell body, must be transported in the retrograde direction.
However, there is substantial evidence that protein synthesis occurs at the nerve termini
and that there may be glial-neuronal cell signaling at protein and RNA levels at the axon
terminus (Giuditta, Chun et al. 2008). This is interesting in that it would provide a faster
response mechanism for the neuron to react at a local level, especially in long axons.
Neurons would need to react at the cell body level to signals for axonal growth and
development/regeneration. It is known that signaling endosomes do transport in a
retrograde fashion (Ha, Lo et al. 2008). Signaling endosomes are created and transported
when growth factors (such as neural growth factor NGF) or neurotrophic factors (such as
brain-derived neurotrophic factor BDNF) activate tyrosine kinases at the ends of neuronal
processes (Bhattacharyya, Watson et al. 2002; Delcroix, Valletta et al. 2003; Huang and
Reichardt 2003; Heerssen, Pazyra et al. 2004). Other cellular constituents such as
organelles are transported by the dynein motor complex as well (Vallee, Williams et al.
2004). Retrograde transport is also necessary for neuron survival and the plasticity of
axons (Ha, Lo et al. 2008).
One of the prime functions of anterograde transport is the delivery of
neurotransmitters/neurotransmitter precursors and synaptic vesicle constituents to the
synapse. The synapse is formed from the pre-synaptic membrane (where the
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neurotransmitters are released), the synaptic cleft, and the post-synaptic membrane
(where neurotransmitter receptors reside). Neurotransmitters are released in response to
the arrival of an action potential. The arrival of this action potential causes voltage gated
calcium channels to open. Ca2+ floods into the synaptic bulb (some release from stored
intracellular calcium storage may contribute) and this causes pre-synaptic vesicles to
release their neurotransmitter into the synaptic cleft (King 1994). Then the transmitter
binds to its receptor and causes its particular action.
Classically defined neurotransmitters include GABA (gamma aminobutyric acid)
(considered an inhibitory transmitter), glutamate (considered excitatory), acetylcholine
(functioning at the neuromuscular junctions), and dopamine and serotonin (which have
more complex functions in the central and peripheral nervous systems) (Kawaguchi
1997; Lee, Schmidt et al. 2001; Chase and Koelle 2007; Wang, Van Bockstaele et al.
2008; Dave and Bordey 2009). Neurotransmitters can also be classified as monoamines
(serotonin, dopamine, norepinephrine, epinephrine etc), amino acids (glutamate, GABA,
etc) and neuropeptides (endorphins, enkephalins, etc) (Kawaguchi 1997; Lee, Schmidt et
al. 2001; Chase and Koelle 2007; Wang, Van Bockstaele et al. 2008; Dave and Bordey
2009). Once the excitatory and/or inhibitory neurotransmitters are released, an action
potential is generated if a threshold of excitation is reached. This propagates as an
electrical signal along the axon. Once an action potential threshold is reached, these are
generally considered an all or none phenomenon with the action potential propagating the
entire length of the axon(King 1994). In many instances these neurotransmitters have
channels for reuptake and recycling at the synapse, which reduces the demand for novel
material from the cell body.
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Effects of Action Potentials on Transport
Action potentials are primarily a membrane effect, while axonal transport occurs
in the axonal cytoplasm. The majority of research appears to cover how axonal damage
alters impulses, delivery of molecules via axonal transport or neurotransmitter release or
recycling. However, there was some evidence that the mere generation of action
potentials may have an effect on the transport of molecules through the axon. It appears
that nerve impulse firing significantly reduced the retrograde transport of dynein in both
velocity and total distance traveled (Lardong, Maas et al. 2009). Also, firing of action
potentials altered the anterograde transport in axons. In one study of bullfrog dorsal root
ganglia, nerve stimulation decreased the overall fast axonal transport temporally, but did
not result in ultrastructural changes (Hammerschlag and Bobinski 1992). This was
interpreted as neurons increase transport when conduction is not occurring to replenish
the axon terminus (Hammerschlag and Bobinski 1992). Interestingly in neither study did
tetrodotoxin (which blocks action potentials by blocking ion channels) have an effect on
axonal transport (Hammerschlag and Bobinski 1992; Lardong, Maas et al. 2009).

Neuronal Transport as it Relates to HSV Infection
For HSV to complete its infectious cycle for a neuron, it must first come into
contact with the axonal processes of a neuron. Then the virus enters the neuronal cell via
pH-independent fusion of the viral envelope to the axonal process membrane (Qie,
Marcellino et al. 1999; Nicola, Hou et al. 2005). Viral fusion and entry are thought to
operate similarly to described earlier for non-neuronal cells using the coordinated
interactions of glycoproteins gD, gB, gH/gL, gC and possibly gK (Cai, Gu et al. 1988;
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Desai, Schaffer et al. 1988; Ligas and Johnson 1988; Hutchinson, Browne et al. 1992).
Some neurotropic viruses enter the neuron via endocytotic or clathrin mediated pathways,
including Canine Adenovirus type-2 (CAdV-2) and Rabies virus, and through neuron
specific sorting of endosomes can directly begin retrograde transport (Salinas, Schiavo et
al. 2010). Rabies virus transport has been demonstrated in an enveloped state and CAdV2 has been shown to be transported in intact endosomes (Salinas, Schiavo et al. 2010).
This may suggest a possible alternate, as yet undescribed, pathway for HSV that would
have implications for glycoproteins and the tegument proteins potential involvement in
early infection. After entry, the virus must be transported along the axon to the cell body
and eventually the nucleus. HSV has been shown to rely on the dynein/dynactin
molecular motor system using the microtubule network for retrograde transport in
fluorescence studies of viral transport in neurons and in studies using inhibitors or
destabilizers of dynein and the microtubule network (Topp, Meade et al. 1994; Bearer,
Breakefield et al. 2000; Dohner, Wolfstein et al. 2002). The exact interaction remains to
be determined for retrograde transport. Some proteins have been shown to bind dynein in
vitro including pUL34 and pUL9 (Diefenbach, Miranda-Saksena et al. 2008b). These
proteins are not present in the mature virion however, and may be used by the virus for
transport of materials during assembly (Diefenbach, Miranda-Saksena et al. 2008b).
Viruses lacking the pUL35 protein, or the capsid protein VP26, have been shown to have
greatly decreased retrograde transport in vivo, but in vitro retrograde transport to the
nucleus is retained, suggesting that functional redundancies or more complex interactions
may exist in this system (Desai, DeLuca et al. 1998; Antinone, Shubeita et al. 2006;
Dohner, Radtke et al. 2006). Since the envelope is shed during viral fusion to the neuron,
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it is assumed that interacting proteins will come from the capsid or tegument proteins
closely associated with the capsid. However, if the virus were to enter the neuron via
endocytosis it is unknown what role envelope proteins may play or if multiple pathways
exist to instigate retrograde transport.
Once the virus reaches the nucleus, the virus is likely to go latent, as discussed
earlier. During the reactivation of a latent infection or immediately if the virus stays in
the lytic phase, the viral components must be created and assembled to produce progeny
virus. This progeny virus is then transported in the anterograde direction to the axon
termini to be released and infect epithelial cells at the initial site of infection. The vast
majority of this process is considered to occur in the same manner as previously
described for non-neuronal cells. The mechanism of transport and the character of the
virion during transport in the anterograde direction is a highly controversial issue. Two
competing theories predominate, these are: 1) transport of the capsid containing the DNA
separate from the glycoproteins with final assembly occurring at the plasma membrane of
the neuron at the axon terminus, sometimes called the “unmarried model”; 2) transport of
a fully formed, enveloped virus that is created by budding through the TGN described
earlier, sometimes called the “married model” (Enquist, Husak et al. 1998). These two
models are in contention in large part due to disparate results from studies in two
alphaherpesviruses, Pseudorabies virus (PRV) and HSV-1 (Diefenbach, Miranda-Saksena
et al. 2008a; Liu, Goodhouse et al. 2008; Mettenleiter 2008; Mettenleiter, Klupp et al.
2009; Antinone and Smith 2010; Antinone, Zaichick et al. 2010; Maresch, Granzow et al.
2010; Osakada and Cui 2011).
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Since the N-kinesin members of the KIF superfamily (such as the prominent
members KIF1, KIF3, and KIF5) are the primary anterograde transporters in neurons, it is
likely that one of these molecules is the major molecular motor to transport herpes
viruses (Diefenbach, Miranda-Saksena et al. 2008b). Notably, since the exact character of
transport is unknown, little is also known about what components of the described
neuronal anterograde transport system are involved in the transport of herpes virions.
Although many viral glycoproteins have been implicated in efficient egress of virions
from epitheilal cells, the role of these proteins in neuronal egress has not been studied
extensively (Mettenleiter, Klupp et al. 2009). In PRV glycoproteins gE and gI are
required for anterograde transport, but not retrograde transport (Card, Whealy et al.
1992a; Jacobs, Mulder et al. 1993b; Babic, Klupp et al. 1996a; Johnson, Webb et al.
2001a; Brittle, Reynolds et al. 2004; Ch'ng and Enquist 2005). HSV-1 gE has been
reported to function in both retrograde and virus spread from epithelial cells to neurites
but it is not necessary for direct infection of neurites or retrograde transport in axons
(Balan, Davis-Poynter et al. 1994b; Saldanha, Lubinski et al. 2000; Wang, Tang et al.
2005; Brittle, Wang et al. 2008; McGraw and Friedman 2009).
Recently, the role of actin in herpes virus infection in neurons has been under
increased scrutiny. In the growing axon, actin directs the growth of the axon by
maintaining polarity in axonal growth cones (Roberts and Baines 2011). In the mature
neuron, actin still plays a role in maintaining polarity at the axon hillock, where it acts as
a buffer between the endoplasmic reticulum and cargoes that are destined for transport
along the axon (Roberts and Baines 2011). This would suggest that HSV necessarily
interacts with actin as it enters the nucleus during retrograde transport and as it leaves the
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nucleus for anterograde transport during a reactivation. Very recent work has suggested
that myosin Va, a molecular motor that interacts with actin, may bridge the gaps between
axonal transport and the nuclear membrane, but these models are early in development
and more work is necessary to confirm the hypothesis (Roberts and Baines 2011).

Latent Infection with HSV
While much is known about herpes viral latency, even more remains a mystery
regarding the exact mechanisms of latency and reactivation. Latent infection must first
be distinguished from chronic infection. In a chronic infection, a virus will express
proteins and produce a low level of infectious progeny that is shed continuously albeit in
amounts that may significantly wax and wane. In a true latent state, as defined for herpes
viruses, the viral DNA is held in a circular episome within the host cell nucleus and a
very slight level of DNA transcription occurs, however, there is no protein production
(Roizman, Knipe et al. 2007). During latency, HSV creates a latency-associated
transcript (LAT) from the viral DNA. The promoter for the encoded LAT is maintained
in acetylated histones, or active areas, of the host DNA (Kubat, Amelio et al. 2004). In
the latent stage of the infection, the lytic, or active infection, genes of HSV are
maintained in areas of heterochromatin, which are regions of host cell DNA that are
inactivated (Wang, Zhou et al. 2005). HSV DNA also avoids methylation by the host
nucleus that could inactivate the virus (Roizman, Knipe et al. 2007). During the latent
infection, the LAT is the only transcript expressed in abundance, however, very sensitive
assays can detect small amounts of transcription of lytic genes (Kramer and Coen 1995;
Kramer, Chen et al. 1998). This small expression of lytic genes may be a state of
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leakiness or abortive attempts at reactivation (Bloom, Giordani et al. 2010). The exact
reason for this expression is unknown. The LAT is an 8.3 kb sequence with several
splice variants, of which a 2.0 kb sequence is the most common (Farrell, Dobson et al.
1991). Through evaluation of mutant viruses, the LAT is associated with efficient
establishment of latency, reactivation, and blocking apoptosis (Farrell, Dobson et al.
1991). LAT deficient mutants have more significant pathology in the trigeminal ganglion
with more necrosis of neurons and greater mortality in mouse studies (Roizman, Knipe et
al. 2007). The LAT actually appears to have a protective effect for neurons that become
infected.
In the normal course of HSV infection, the virus replicates at the initial site of
epithelial infection and then infects the innervating sensory neurons. The virus travels in
the anterograde direction through the axon of the neuron to the nucleus and establishes a
latent infection. During the first 24-72 hours after infection of the ganglionic neurons,
expression of lytic genes and the LAT are observed, however, the lytic genes must be
rapidly suppressed to prevent a lytic infection, since neurons do not have an intrinsic
invulnerability to lytic infection (Kosz-Vnenchak, Coen et al. 1990; Kramer, Chen et al.
1998). Although an exact mechanism is unknown, it appears that CD8+ T cells play a
role in regulating infection in nervous tissue and there is a distinct lack of alpha gene
expression as latency is established (Roizman, Knipe et al. 2007). Furthermore, once the
latent state is established, less is known about the mechanism of maintenance of this
state. During latency, the LAT expression is maintained and HSV specific T cells are
preferentially maintained within neural tissues (Verjans, Hintzen et al. 2007).
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Once latency has occurred, the final characteristic of the virus is to reactivate out
of the latent state and cause a recurrent infection at the site of mucosal innervation via
retrograde transport. The mechanism of reactivation is not clearly defined. The
conditions that can cause reactivation have been described and include: any source of
local or systemic stress, such as UV radiation, trauma, surgery, excessive heat, another
infection, emotional stress, and hormonal imbalance (Roizman, Knipe et al. 2007). Once
this stress occurs, the lytic genes are moved from areas of heterochromatin to acetylated
histones, become active and begin a recurrent infection (Amelio, Giordani et al. 2006).
Viral proteins are created, viral DNA is replicated, and virions are assembled which can
then be transported to the site of initial infection (Roizman, Knipe et al. 2007). These
progeny virions can also move in the anterograde direction to second and third order
neurons progressing deeper into the central nervous system, although this is less common
(Roizman, Knipe et al. 2007). The final fate of the reactivated neuron is not clear.
Guaranteed destruction seems unlikely since areas of mucosal infection do not always
become anesthetized after many reactivations.
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CHAPTER II
THE HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) GLYCOPROTEIN K(gK) IS
ESSENTIAL FOR VIRAL CORNEAL SPREAD AND NEUROINVASIVENESS*

INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is an enveloped, double-stranded DNA
virus that is a ubiquitous pathogen of humans. When symptomatic, HSV-1 commonly
causes mucocutaneous lesions with acute encephalitis and ocular pathology occurring
less frequently (Whitley 2001). Although a less frequent manifestation of disease, ocular
HSV is one of the most common infectious causes of blindness in developed countries
with estimates of the incidence of herpes ocular disease episodes ranging from 4.1 to 20.7
cases per 100,000 in developed countries (Liesegang, Melton et al. 1989; Liesegang
2001). An estimated 400,000 people in the United States have had herpes simplex ocular
disease with about 50,000 new or recurrent cases occurring yearly (NoAuthor 1998).
Herpesvirus infection usually begins at a mucosal surface and from this site the virus
invades the ganglionic sensory neurons and can establish a latent infection for the life of
the host (Whitley, Kimberlin et al. 1998).
HSV-1 specifies at least 11 glycoproteins that are expressed in the infected cells
(Roizman and Knipe 2001). Glycoproteins B and C are primarily involved in initial
attachment of the virion to cell surface glycosaminoglycans by binding to heparan sulfate
(Laquerre, Argnani et al. 1998). Attachment is followed by fusion of the viral envelope
_______________________
* Material reprinted from Current Eye Research, 2008 May;33(5):455-467, The herpes
simplex virus type 1 (HSV-1) glycoprotein K (gK) is essential for viral corneal spread
and neuroinvasiveness,; David AT, Baghian A, Foster TP, Chouljenko VN, Kousoulas
KG., with permission from Informa Healthcare publisher of Current Eye Research.
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with cellular membrane receptors and viral glycoproteins B (gB), D (gD), H (gH) and
L(gL) (Furth, Whitbeck et al. 1997; Whitbeck, Peng et al. 1997; Warner, Geraghty et al.
1998; Krummenacher, Rux et al. 1999; Whitbeck, Muggeridge et al. 1999). These
glycoproteins have also been shown to be essential for viral entry and infectious virus
production (Wanas, Efler et al. 1999). Virus spread, a priori, occurs by either infectious
virions produced by cells that can then infect adjacent cells, or via inter-cellular
transmission of fully infectious virions facilitated by virus-induced cell fusion (syncytia
formation). Virus-induced cell fusion is mediated by viral glycoproteins expressed on
cell-surfaces, while gB, gD, gH and gL are necessary and sufficient to cause cell fusion in
the absence of virus replication (Davis-Poynter, Bell et al. 1994; Turner, Bruun et al.
1998; Muggeridge 2000; Pertel, Fridberg et al. 2001). Glycoprotein E (gE) may also
function to transport virions between cellular membranes by other than cell fusion
mechanisms (Dingwell and Johnson 1998; Wisner, Brunetti et al. 2000; Johnson, Webb
et al. 2001).
HSV-1 gK is essential for cytoplasmic virion envelopment, virion egress and
virus-induced cell fusion (Hutchinson and Johnson 1995). Recently, we have
demonstrated that gK physically binds to the UL20 membrane protein (Foster and
Kousoulas 2008). Furthermore, UL20/gK interactions are essential for their intracellular
transport, cell-surface expression and functions in cytoplasmic virion envelopment and
virus-induced cell fusion (Foster, Alvarez et al. 2003; Foster, Melancon et al. 2004a;
Foster, Melancon et al. 2004b; Melancon, Fulmer et al. 2007; Foster and Kousoulas
2008). HSV-1 gK is of particular importance to eye infections, because it has been
shown that it is involved in the exacerbation of eye disease, most likely, mediated by
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anti-gK humoral and cellular immune responses (Osorio, Cai et al. 2004; Mott, Osorio et
al. 2007; Mott, Perng et al. 2007; Osorio, Mott et al. 2007). Deletion of the gK gene
encoded by the pseudorabies virus (PRV) appeared to attenuate the virus, but did not alter
the ability of the gK-null virus to invade the central nervous system and cause clinical
eye disease (Flamand, Bennardo et al. 2001; Schwartz, Brittle et al. 2006; Ch'ng, Spear et
al. 2007). These results prompted the present work to assess the role of HSV-1 gK in
corneal spread and neuroinvasiveness. In contrast to previous findings with PRV gK,
work presented here, shows that HSV-1gK is essential for virus spread in the cornea of
mice and neuroinvasiveness.

MATERIALS AND METHODS

Cells and Viruses
The ocular and neural virulent McKrae strain of HSV-1 was obtained from Dr.
J.M. Hill (Louisiana State University Health Sciences Center, New Orleans, La). The UL
53 (gK) gene of HSV-1 McKrae was replaced with an EGFP gene cassette from plasmid
pEGFP-1 (Clontech, Pala Alto, Ca) under control of the human cytomegalovirus
immediate early gene promoter as described previously for the KOS ∆gK/GFP (Foster,
Rybachuk et al. 1998). Briefly, plasmid PTF9201 contains an EGFP gene cassette under
the human cytomegalovirus immediate early promoter control (HCMV-IE) within a DNA
fragment spanning the UL52-UL54 genomic region that lacks the UL53 gene (Foster,
Rybachuk et al. 1998). Plasmid PTF9201 was used in transfection followed by infection
with HSV-1 (McKrae) to isolate the McKrae-ΔgK/EGFP (MKΔgK) virus appearing as
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small fluorescent viral plaques under the fluorescence microscope. Individual viral
plaques were plaque-purified six-times before viral stocks were prepared in Vero or
VK302 cells. The resulting HSV-1 McKrae UL53 null virus is referred to as MK∆gK.
A rescued virus that was positive for both gK and GFP (MKgK) was constructed from
the MK∆gK, as described previously (Foster and Kousoulas 1999). See map of viral
mutations in Fig 2.1. African green monkey kidney (Vero) cells were obtained from
ATCC (Rockville, MD) and grown in Dulbecco’s modified Eagle Medium (DMEM)
supplemented with 7% fetal bovine serum (FBS) and antibiotics. The gK complementing
VK302 cell line (generously provided by Dr. David Johnson, Oregon Health Sciences
University) was maintained in Dulbecco’s modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and antibiotics (penicillin and
streptomycin). This cell line was used for generation of high titer MKΔgK viral stocks.
The properties of all virus recombinants were validated as described previously (Foster,
Rybachuk et al. 1998; Foster and Kousoulas 1999).

Mice
6-10 week old, female, Balb/c mice were used for all experiments and were
handled in accordance with the ARVO statement for the use of animals in ophthalmic and
vision research and Louisiana State University-School of Veterinary Medicine IACUC
regulations.
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Figure 2.1: Schematic of recombinant virus construction. (A) The top line represents
the prototypic arrangement of the HSV-1 (McKrae) genome with the unique long (UL)
and unique short (US) regions flanked by the terminal repeat (TR) and internal repeat
(IR) regions. (B) HSV-1 genomic map in relative map units. (C) An expanded genomic
region between map units 0.7 and 0.8 containing the UL52, UL53, and UL54 open
reading frames. (D) Diagram of the pSJ1723 plasmid (Jayachandra, Baghian et al. 1997),
which contains the UL52, UL53 and UL54 region of HSV-1 (KOS). (E) Plasmid PTF901
(Foster, Rybachuk et al. 1998) containing the CMV-IE-EGFP gene cassette in-place of
the gK gene, which was used to delete the gK gene and insert the EGFP gene cassette
within the HSV-1 (McKrae) genome.
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Plaque Morphology and Virus Replication Characteristics
For plaque morphology, confluent monolayers of Vero and VK302 cells were
infected at multiplicity of infection (MOI) of 0.001 with the MKgK and MK∆gK viruses
and were visualized by immunohistochemistry at 48 and 72 hours post infection (hpi). At
48 or 72 hpi, cells were fixed with ice-cold methanol. Immunohistochemistry was
performed with horseradish peroxidase-conjugated anti-HSV antibodies (Dako) and the
reactions were developed with NovaRed substrate (VectorLabs; Burlingame, CA).
To determine the kinetics of viral replication, cells were infected with the
MKΔgK, MKgK or the McKrae parental strain at MOI’s of 0.1 and 5. For McKrae
parental strain and the rescue strain, plates of Vero cells were used and for the MKΔgK
virus Vero and VK302 cells were used. Plates were prepared in triplicate and infections
were halted by freezing at 0, 3, 6, 9, 12, 24, 36, 48 and 72 hours post infection (hpi).
Plates were frozen, thawed and viral titers were determined for each time point by
standard plaque assay on VK302 cells (for the MKΔgK virus) or Vero cells (for the
parental and MKgK strains). Plaques were stained with crystal violet and visualized by
dissecting microscope. Growth curves show the result of the average of the triplicate
plates.

Mouse Eye Infections
Ocular infection with the rescued virus (MKgK) and wild type virus produced
similar results in terms of clinical and laboratory findings (data not shown); therefore, the
rescued strain data is presented since it serves as a better comparison to the gK null
mutant (MKΔgK). In studies in which mouse eyes are scarified, after anesthetizing the
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mice each cornea was scarified by four strokes vertically and four strokes horizontally of
a 25 gauge needle in a grid pattern. Then the designated viral inoculum, in 5 µl of
DMEM, was applied to the eyes with a micropipetter and the eyelids were gently held
shut for 30 seconds. For all studies, either 1.0 x 106 PFU of MKΔgK was inoculated into
each cornea or 2.5 x 104 PFU of MKgK was inoculated into each cornea. If not scarified,
mouse eyes were gently abraded by rubbing with sterile cotton swabs 10 times in
different directions.
For clinical lesion studies, mice were monitored daily for survival and the
degree of blepharitis, hyperemia and ocular discharge were recorded. These symptoms
were scored on the scale of 0-3, with 0 representing no symptoms and using the most
severe lesions in the group infected with the rescued McKrae strain as the scale of 3. For
direct observation of viral infection and spread in the eye, 2 groups of mice were
similarly inoculated (5 mice/group/time point). Mice were sacrificed at 12, 24, 48 and 72
hpi as well as 5, 7, 10 and 14 days post inoculation (dpi). The eyes of the mice were
excised and viral spread was tracked by direct observation under a Zeiss Stereo Lumar
fluorescence microscope and digitally photographed with an Axiocam color camera (Carl
Zeiss Inc, USA.). The extent of fluorescent plaques on the eye were scored on the
following 0-3 scale: 0 (No fluorescent foci observed), 1 (One or few (<12) pinpoint
plaques covering less than 5% of total visual surface or peripheral rim of connective
tissue), 2 (One or more plaques larger than pinpoint, or numerous pinpoint plaques,
covering 5-20% of the total visual surface or peripheral rim of connective tissue, 3
(greater than 20% of the visual surface covered with fluorescent plaques and/or iris
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involvement). Iris involvement was determined by fluorescent highlighting of iris tissue
structure.

Detection of Latent Virus in Trigeminal Ganglia Using PCR and In Vitro Tissue
Explants Cultures
Mice that survived the initial infection were sacrificed at 30-35 days postinfection. Mice were sacrificed via CO2 asphyxiation followed by thoracotomy. Then
trigeminal ganglia (TG) of the mice were excised. For determination of culture
reactivation, excised trigeminal ganglia were cultured as a whole for 5 days in six-well
plates in DMEM containing 10% bovine serum and antibiotics in a humidified incubator
at 37 degrees Celsius with 5% CO2 and 95% filtered room air. After 5 days, the TG were
triturated with a glass pipet and ganglion cells and media were placed on the Vero or
VK302 cell monolayers. Wells were monitored to study evidence of cytopathic effects
(CPE) indicative of virus reactivation. Every other day, half the media in each well was
passed to new plates with fresh monolayers and these were also monitored for CPE. This
process was repeated until a well had demonstrated CPE or for 12 days following plating
of the initial ganglion cells.
For viral DNA detection, a nested PCR methodology was used targeting the
UL30 gene. Mice surviving the clinical infection to 30 dpi were euthanized and the
trigeminal ganglia (TG) were harvested and frozen at -80C. TG’s were thawed and total
DNA from the TG was extracted using the Qiagen DNeasy blood and tissue kit (Qiagen,
CA, USA) per the manufacturer’s instructions. For non-scarified mice, TG DNA from
the right and left TG was harvested separately and any mouse positive by PCR in either
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or both ganglia was considered positive. For scarified mice, the right and left TG were
pooled for extraction.
The individual primers for the primary PCR reaction were : A) 5’CCTGGACAAG CAGCAGGCCGCCATC-3’; and B) 5’GCGCACCAGATCCACGCCCTTG-3’. The second step PCR utilized primers C) 5’CTCGGTGTACGGGTTCACGGGAGT-3’; and D)5’GATGGAGTCCGTGTCCCCGTAGATG-3’. The PCR product of A, B primers was
452bp, while the secondary PCR with primers C, D produced a 207bp DNA fragment.
These primers are HSV-1-specific diagnostic primers based on previously published
degenerate diagnostic UL30 primers (VanDevanter, Warrener et al. 1996). The
authenticity of individual PCR fragments was confirmed by DNA sequencing. The
FailSafe enzyme system with PCR premix E was used for all PCR reactions (Epicentre
Biotechnologies, Madison, WI, USA). Specifically, 1-10µl of extracted DNA was used
for the first step reaction and 1-10µl of the first step product was used in the second step.
The PCR products were then subjected to electrophoresis and stained with ethidium
bromide.
The positive control consisted of DNA extracted from McKrae virus stock.
Negative controls were TG DNA from mock infected mice as well as no template
controls. To determine the lower limit of sensitivity, serial dilutions of extracted viral
DNA mixed with equal volumes of negative mouse TG DNA were used. The lower limit
of detection occurred between 10 and 100 copies of viral DNA.
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Statistical Analyses
All following statistical analyses in this chapter were performed using
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego, California
USA.

RESULTS

Recombinant Virus Construction and Characterization
The construction of a HSV (KOS) recombinant virus in which the gK gene was
replaced with an EGFP gene cassette was described previously (Foster, Rybachuk et al.
1998). A similar strategy was utilized to construct the recombinant virus MK∆gK with
the gK gene deleted and replaced with a EGFP gene cassette (Fig. 2.1). In addition, the
rescued virus MKgK was constructed, in which the missing gK gene was replaced with
the wild-type gK gene, without affecting the adjacent CMV-IE-EGFP gene cassette.
Both viruses were extensively characterized by PCR diagnostics to ensure the absence of
any wild-type gK sequences from the MK∆gK virus and the restoration of the gK gene in
the MKgK virus (not shown). As expected, the MKΔgK virus formed extremely small
plaques on Vero cells composed of a maximum of 5-10 cells, while the MKgK virus
formed large plaques, which were indistinguishable from the prototypic McKrae virus.
MKΔgK virus plaques on the gK complementing cell line VK302 were rescued to nearly
the same size produced by the MKgK virus (Fig. 2.2: A-F).
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The replication kinetics of the MK∆gK and MKgK viruses was investigated in
Vero cells, as well as in VK302 cells that constitutively express gK at different MOI. The
MKgK virus appeared to replicate slightly slower than the wild-type McKrae virus,
however, both approached similar titers at late times post infection. The MK∆gK virus
exhibited approximately two logs (one hundred times) lower replication in comparison to
the McKrae and MKgK viruses. Replication of MK∆gK virus in the VK302
complementing cell line produced virus titers similar to those observed with the McKrae
and MKgK viruses (Fig. 2.3).

Figure 2.2: MK∆gK and MKgK plaque morphology. Confluent Vero (A, B, D, E) or
gK complementing VK302 cells monolayers (C, F) were infected with either the MKgKrescued virus, or the MK∆gK (gK-null) virus at an MOI of 0.001, and viral plaques were
visualized by immunohistochemistry at 48 (A, B, C) or 72 (D, E, F) hpi. All images are
taken at 200X magnification.
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Figure 2.3: Virus replication kinetics. Vero or VK302 cell monolayers were infected
with either MK∆gK, MKgK or McKrae viruses at MOI of 0.1 and virus titers were
obtained at different times post infection on either Vero or VK302 cells.
In Vivo Phenotypes and Clinical Disease Patterns of MKgK and MK∆gK Viruses in
the Mouse Eye Model System
Corneas are composed principally of a fairly thin epithelial layer resting on a
much thicker stromal layer composed primarily of collagen fibers. Corneas are typically
highly innervated tissues. To ensure that viral infections could access nerve endings
within the cornea, infections were performed with mild or more extensive scarification
(see Materials and Methods). MKgK viral infections produced viral plaques, which were
first visible by stereoscopic fluorescence microscopy at 12 hpi appearing as streaks of
multiple viral plaques. By 24 hpi viral plaques were spread substantially, and by 72 hours
viruses appeared to have spread to the iris. In mice infected after swab abrasion of their
corneas, fluorescent viral plaques were less numerous on the visual surface, but
qualitatively appeared to be overrepresented at the limbus in comparison to mouse eyes
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infected after needle scarification. In addition, at late times post infection, the iris of
mice infected after cotton swab scarification appeared to have less pronounced infection,
as evidenced by the substantial reduction in the number of fluorescent viral plaques (data
not shown).
Infected mice were monitored daily for clinical indicators of eye infection, such
as blepharitis, hyperemia and ocular discharge for 30 days post infection and the intensity
of the infection indicators were recorded on scale of 0-3. Typically, mouse eyes infected
with viruses after scarification were scored 0 when there were no symptoms of clinical
disease (Fig. 2.4: A). Eyes scored with a score of 1exhibited minimum blepharitis,
hyperemia, and ocular discharges at the medial canthus (Fig. 2.4: B). Eyes scored 2-3
exhibited progressively more severe clinical symptoms outlined above producing
ultimately crusting and complete occlusion of the eye (Fig. 2.4: C-E). The MKgK virus
produced severe disease in most mouse eyes (score 2-3), while few eyes were scored at
lower scores (score 1). The MK∆gK virus produced no significant clinical disease (score
0) in infection experiments even though approximately two logs higher virus titers of
M∆gK (1.0 x 106 PFU) were used than the MKgK virus (2.5 x 104 PFU) (Fig. 2.5: A).
Similar experiments were performed with the exception that mice eyes were abraded with
cotton swabs as opposed to needle scarified. Overall, peak clinical disease observed in
the unscarified mouse experiments was similar to that of the scarified experiments with
disease peaking within 7-9 dpi. Again, clinical disease was pronounced with the MKgK
virus, while the MK∆gK virus produced no disease symptoms. The only apparent
differences between the abrasion versus the more severe scarification results, were that in
the mildly abraded eyes, the resolution of clinical lesions was faster with an average
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return to normal conditions at approximately 14-16 dpi. In the more extensively scarified
eyes, many mice exhibited grade 1 lesions at much later times post infection (greater than
20 dpi) (Fig. 2.5: A, B).

Figure 2.4: Clinical disease progression. Mouse eyes were monitored for clinical signs
of disease as detailed in Materials and Methods. (A) Clinically normal mouse. (B) Lesion
with a score of 1 characterized by mild hyperemia, blepharitis and ocular discharge. (C)
Lesion with a score of 2 characterized by moderate hyperemia, blepharitis and ocular
discharge. (D and E) Lesion with a score of 3. (D) Picture shows severe hyperemia and
blepharitis. (E) The arrow indicates the position of the eye, which is completely covered
by a crust of ocular discharge. In figures B and C, arrows indicate accumulation of ocular
discharge near the medial canthus and lateral canthus respectively.
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Figure 2.5: Clinical lesion scores. Mice were infected ocularly with MKgK or MK∆gK
viruses. Ocular disease was based on a 0 to 3 scale for the parameters blepharitis,
hyperemia, and ocular discharge as described in the Material and Methods section. (A)
Graph shows the average clinical lesion scores in scarified mice on representative days 1,
2, 4, 7, 9, 11 and 14 following infection. (B) Graph shows the average clinical lesion
scores in non-scarified mice on the same days. Data are presented as the group mean of at
least 12 mice per group with error bars indicating the standard error. Bars denoted by an
* represent an average lesion score of 0 (The small positive bar is presented for visual
reference only). Error bars are not present on these bars since standard error is also 0.
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Mice were also monitored for survival for 30 days following inoculation.
Regardless of scarification status, all mice inoculated with the MKΔgK strain survived to
30 dpi (Fig 2.6: A, B). In scarified mice, 10 of the 30 mice inoculated with the rescued
virus died during the study with deaths occurring between 6 and 12 dpi (Fig 2.6 A). In
non-scarified mice, 8 of the 20 mice inoculated with the rescued virus died during the
study with deaths occurring between 4 and 15 dpi (Fig 2.6: B). Kaplan-Meier survival
curve analysis revealed a statistically significant difference in death rate for both scarified
and unscarified groups at a P=.001 (Fig 2.6: A, B). However there was no statistical
significance in the survival when comparing the mildly scarified with the more
extensively scarified groups that were inoculated with the rescue strain (Fig 2.6: C).

Figure 2.6: Mouse survival data after infection with recombinant viruses. (A-C) In
clinical lesion studies, mice were also monitored daily for survival to 30 days post
infection. (A) In scarified mice, 10 of the 30 mice inoculated with the rescued virus died
during the study with deaths occurring between days 6 and 12 post inoculation. All mice
inoculated with the gK-null strain survived. (B): In non-scarified mice, 8 of the 20 mice
inoculated with the rescued virus died during the study with deaths occurring between
days 4 and 15 post inoculation. All mice inoculated with the gK-null strain survived.
(C) There is no statistical difference between scarified or non-scarified groups when
inoculated with MKgK. (A, B) This shows a stastically significant difference in death
rate for both scarified and unscarified groups at a P=.001 (Fig 2.6: A, B) by KaplanMeier survival curve analysis. B and C continued on next page.
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Visualization of Viral Plaque Formation in Mouse Eyes
To study the degree of invasiveness and spread of viruses from the site of initial
ocular infection, mice were infected, following corneal scarification, with the MKΔgK or
MKgK viruses. All mice in each group were sacrificed at 12, 24, 48 and 72 hpi and 5, 7,
10 and 14 dpi. The eyes were excised intact and observed directly under an inverted
fluorescence microscope. 5 mice (10 eyes) /group/time point were examined and
representative pictures of the spread of fluorescent viral plaques at various time points are
shown (Fig. 2.7). MKgK produced viral plaques in mouse corneas that were easily
visible through direct observation of tissues using a fluorescent microscope as early as 12
hpi. These viral plaques increased substantially over time and appeared to spread to
mouse iris by 3-4 dpi (Fig. 2.7: F-J). In contrast, the MK∆gK virus, produced very small
plaques at 12 hours post infection, with an increasing number of viral plaques appearing
at 24 hpi. However, these viral plaques were substantially less visible at 48 hpi and all
mice in this group were devoid of viral plaques by four dpi (Fig. 2.7: A-E). These results
were consistent with virus isolation from eye swabs that revealed less than 10 viruses per
MK∆gK-infected eye, while MKgK-infected eyes yielded more that 1,000 plaque
forming units (PFU) per eye (not shown). The fluorescent plaques produced in mouse
eyes were also scored on a 0-3 point scale, average scores by day are shown (Fig. 2.8).
This graph and the previous pictures show that virus spread was markedly impaired in the
MK∆gK virus, with minimal plaque formation, smaller plaques and more rapid resolution
of plaques.
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Figure 2.7: Virus spread in mouse corneas. Spread and replication of MKgK versus
MKΔgK was studied in ocular infection of mice. The infected eyes in each group were
directly examined under an inverted fluorescence microscope. (A-E) Mouse eyes
infected with MK∆gK at 12hpi (A), 24hpi (B), 48hpi (C), 72hpi (D) and 5dpi (E). (A, C)
White arrows point to small plaques in these eyes. (F-J) Mouse eyes infected with MKgK
at 12hpi (F), 24hpi (G), 48hpi (H), 72hpi (I) and 5dpi (J). Figures are representative of 5
mice (10 eyes)/group/time point. All images were taken at 17-22X magnification.
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Figure 2.8: Graphical representation of virus spread. Mice were infected after
corneal scarification with the MK∆gK or MKgK viruses. Then the eyes of the mice were
excised and viral spread was tracked by direct observation under a fluorescence
microscope. Fluorescent plaque lesions were scored using a 0-3 scale described in
materials and methods. Bars represent the mean of 5 mice (10eyes)/group/time point.
Mice were sacrificed at 12, 24, 48 and 72 hpi and 5, 7, 10 and 14 dpi. Bars denoted by an
* represent an average lesion score of 0 (The small positive bar is presented for visual
reference only). Error bars are not present on these bars since standard error is also 0.
Determination of Virus Spread to the Trigeminal Ganglia
Typically, infection of mouse corneas with wild-type HSV-1 leads to transport of
virions in a retrograde fashion within neuronal axons and establishment of latency in
trigeminal ganglia. To determine the relative efficiency by which MKgK and MK∆gK
viruses reached the trigeminal ganglia, extracted ganglia were tested for the presence of
infectious virus by co-culture in Vero or VK302 cells. In these studies, mice were used at
least 10 days post complete resolution of clinical symptoms. In the scarified groups, 19
of 20 mice in the MKgK virus infected group had trigeminal ganglia that produced
infectious virus after coculture with Vero cells, while 0 of 20 mice in the MK∆gK group
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produced infectious virus (Table 2.1). In the non-scarified mice inoculated with the
MKΔgK virus, 0/12 trigeminal ganglia produced infectious virus after co-culture with
VK302 cells (Table 2.1). In contrast, 5/12 non-scarified mice that were inoculated with
MKgK virus produced infectious virus after co-culture with Vero cells (Table 2.1).
Additional testing was performed to detect the presence of viral DNA within
trigeminal ganglia of infected mice. In mice inoculated with MKgK without
scarification, HSV DNA was detected by PCR in 14/24 (58.3%) TG’s, corresponding to
9/12 (75%) mice (Fig 2.9, Table 2.1), while MKΔgK infections identified 0/24 TG
ganglia as PCR-positive corresponding to 0/12 mice (Table 2.1). In mice inoculated with
MKgK after scarification, HSV DNA was detected in the pooled TG by PCR in 19 out of
20 mice. In mice inoculated ocularly after scarification with MKΔgK, 3 of 20 mice were
PCR-positive for HSV-1 viral DNA (Table 2.1).

Figure 2.9: Nested PCR detection of viral DNA within mouse ganglia. Total DNA
was extracted from mouse ganglia and viral DNA was detected using a nested PCR
protocol (see Materials and Methods). Lanes 1-18 and 20-25 correspond to the right and
left TG, respectively, of 12 unscarified and MKgK-infected mice (24 lanes). Lanes 19
and 33 contain 2-Log DNA molecular mass ladder. Lanes 26, 27, 31 and 32 contain
negative controls. Lanes 28-30 contain positive controls.
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Table 2.1: Rates of Viral Latency, Reactivation, and Mouse Survival Data

Table 2.1: (* and +) There is a stastically significant difference between the two groups
at P<0.05. (#, **, ++, ##) There is a stastically significant difference between the two
identified groups at P<0.001. Fishers exact test for each pairing was performed using
GraphPad Prism version 4.0 for Windows.
DISCUSSION
We have shown previously that HSV-1 glycoprotein K (gK) is not essential for
viral entry into cells, but is essential for virus spread in cell culture, inasmuch as gK-null
viruses form very small viral plaques typically consisting of less than 10 infected cells
per plaque (Jayachandra, Baghian et al. 1997; Melancon, Luna et al. 2005). This viral
phenotype is produced because lack of gK drastically inhibits cytoplasmic virion
envelopment presumably occurring at trans-Golgi network (TGN) membranes (Foster,
Melancon et al. 2004a; Foster, Melancon et al. 2004b; Foster and Kousoulas 2008). A
similar viral phenotype has been also described for pseudorabies virus (PRV) indicating
that HSV-1 and PRV gK function in a similar fashion in viral morphogenesis and egress
in tissue culture (Klupp, Baumeister et al. 1998). In vivo work with PRV indicated that
although gK was essential for viral spread in cell culture, it was not essential for
159	
  

neuroinvasiveness (Flamand, Bennardo et al. 2001). Therefore, we undertook this study
to investigate whether HSV-1 gK was essential for neuronal infection and disease
causation in the mouse model system. We found that HSV-1 gK is essential for corneal
spread in the mouse eye, subsequent transmission and infection of the central nervous
system, and disease causation.
HSV-1 McKrae was isolated from a human ocular herpes infection (Kaufman,
Ellison et al. 1969) and it is highly virulent in mice and rabbits (Perng, Thompson et al.
1995; Perng, Chokephaibulkit et al. 1996; Halford, Balliet et al. 2004). The recombinant
virus MK∆gK was constructed to have a deletion of the gK gene, while at the same time
carrying a HCMV-IE driven EGFP gene cassette that enabled tracking of viral infection
using a fluorescence microscope. The rescued virus, MKgK was produced by rescuing
the gK gene, while leaving the EGFP gene cassette intact. The MKgK virus titers at 48
hours post infection were similar to the wild-type McKrae virus indicating that the
presence of the EGFP gene cassette constitutively expressing EGFP did not adversely
affect virus replication. However, it was noted that the MKgK virus appeared to replicate
slightly slower than the MKgK virus at earlier times post infection suggesting that EGFP
expression may had a mild negative effect on virus replication at early times post
infection.
HSV-1 virulent strains including HSV-1 McKrae can readily infect the mouse eye
via the cornea leading to efficient transmission to the central nervous system and
establishment of viral latency in the trigeminal ganglia. Following infection of murine
eyes with HSV-1, viral replication occurs initially in the corneal epithelium, and
subsequently the virus is transmitted via epithelial-neuronal interfaces to neurons.
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Virions are thought to move in the retrograde direction within neuronal axons to neuronal
bodies where they establish latency (Cunningham, Diefenbach et al. 2006; Diefenbach,
Miranda-Saksena et al. 2008). Infection of the CNS via the ocular route is very efficient
because the cornea is a highly innervated tissue with a high density of nociceptors per
square millimeter. Specifically, the human cornea is estimated to have more than 7,000
nociceptors per square millimeter (Muller, Marfurt et al. 2003). Thus, direct inoculation
of HSV-1 in the eyes of mice was predicted to have ample access to sensory neuronal
fiber endings innervating the cornea. Mild abrasion of the cornea with cotton swabs was
expected to expose neuronal endings innervating the cornea, while more aggressive
scarification of the cornea would be expected to give direct access of the virus to nerve
bundles in the sub-basal plexes underlying the epithelium of the cornea.
Apparently, constitutive expression of the EGFP gene did not significantly affect
viral replication in tissue culture. Similarly, viral plaques in mouse corneas were similar
to those produced by the wild-type McKrae strain (not shown). Infection of the mouse
eyes either with the cotton-swab or needle scarification protocols revealed that, in
comparision to the MKgK rescued virus, the MK∆gK virus was not able to efficiently
replicate and spread in mouse corneas despite the fact that a two log higher virus
inoculum of the MK∆gK virus was used and prepared in the complementing cell line
VK302. Specifically, MK∆gK was able to infect cells, as evidenced by the production of
small viral plaques that appeared to enlarge by 24 hpi; however those plaques were not
any more visible at later times post infection presumably because infected cells had been
eliminated. Clinical disease symptoms absolutely paralleled the observed infection
patterns with the MK∆gK infected eyes exhibiting no clinical signs at any time point
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following viral infection, while the MKgK rescued virus produced significant eye disease
by 4 dpi. This disease was characterized by severe hyperemia, blepharitis (thickening of
the eyelid), inflammation and ocular discharge. In addition, the MK∆gK virus did not
cause any mortality in the infected mice, while the MKgK virus produced significant
mortality, as well as clear signs of neurological damage characterized by visual
observation of hunched posture, ataxia, circling and seizures.
A priori, neuronal infection via the eye route should lead to efficient
establishment of viral latency in mouse trigeminal ganglia. Nineteen-of-twenty mice
infected with the MKgK-rescued virus released infectious virus after cocultivation of
mouse ganglia with Vero cells, and 19/20 mice contained viral DNA in their ganglia
detectable by PCR. Mice infected after cotton swab eye scarification appeared to have a
lower incidence of viral latency reduced by approximately 25% -50% taking into account
either PCR detection of viral DNA, or virus isolation, respectively. Infection of murine
eyes following either cotton swab or needle scarification revealed that the MK∆gK virus
was not able to efficiently establish latency as evidenced by the fact that only 3/20
ganglia were positive for viral DNA by PCR in the scarification model, while none of the
ganglia were positive in the cotton swab scarification model. The fact that no virus was
isolated from any ganglia in coculture experiments may be partly due to the inability of
gK-null viruses to efficiently egress out of infected cells.
Overall, these results strongly show that gK is essential for corneal spread,
neuroinvasion, and infection and establishment of latency in mice infected via the ocular
route. In this regard, this result is substantially different from those obtained with the
PRV system suggesting that HSV-1 and PRV may exhibit substantial differences in their
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requirements for neuroinvasion. In the PRV gK-null virus experiments, mice were
infected via the intranasal route. It is possible that infection via this route may access the
central nervous system more efficiently than the ocular route. However, additional
experiments in mice have revealed that the MK∆gK virus is also avirulent when
administered at relatively high titers (greater than 106 PFU) either via the intranasal or
intramuscular routes (not shown) suggesting that PRV and HSV-1 gK-null viruses use
substantially different mechanisms for neuroinvasion.
HSV-1 gK may be particularly important for the causation of ocular disease in
humans because it has been reported to exacerbate ocular disease mediated by anti-gK
humoral and cellular immune responses (Ghiasi, Cai et al. 1996; Ghiasi, Cai et al. 1997;
Mott, Perng et al. 2007; Osorio, Mott et al. 2007). Thus, gK is an important determinant
of both viral infectivity and ocular disease. The high probability that neuronal endings
were readily accessible in the mouse eyes after extensive scarification and the relative
lack of viral DNA in mouse ganglia argues for a role of gK in direct neuronal infection as
well as indirect transmission of virus from corneal epithelial cells to nerve endings. It is
also possible that the lack of gK may lead to the formation of defective tegumented
capsids, which are unable to move in a retrograde fashion. Additional in vitro and in vivo
experiments are needed to resolve the potential role(s) of gK in neuronal infectivity and
retrograde transport.
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CHAPTER III
A MUTANT HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) MCKRAE LACKING
THE GLYCOPROTEIN K (GK) GENE IS UNABLE TO BE TRANSPORTED IN
AXONS IN EITHER THE ANTEROGRADE OR RETROGRADE MANNER

INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is an important human pathogen that
typically causes mucocutaneous lesions in facial and genital epithelial/mucosal surfaces.
The hallmark of HSV-lifecycle is infection of sensory neurons where the virus establishes
a latent infection for the life of the host (Whitley, Kimberlin et al. 1998). HSV-1
neuronal infection can occasionally cause acute encephalitis (Kimberlin, Lin et al. 2001),
while ocular HSV-associated disease is one of the most common infectious causes of
blindness in developed countries (Liesegang, Melton et al. 1989; Liesegang 2001).
HSV-1 enters into neuronal cells via a pH-independent fusion of the viral
envelope with neuronal plasma membranes (Qie, Marcellino et al. 1999; Nicola, Hou et
al. 2005), while it can enter into a wide range of non-neuronal cells via either pHindependent or pH-dependent endocytosis (Milne, Nicola et al. 2005). Virus entry into
all cells involves the coordinated functions of glycoproteins gD, gB, gH, gL and gC (Cai,
Gu et al. 1988; Desai, Schaffer et al. 1988; Ligas and Johnson 1988; Hutchinson, Browne
et al. 1992). Viral glycoprotein gD binds to different cellular receptors including the
herpesvirus entry mediator (HVEM, or HveA), nectin-1 (HveC), or 3-O-sulfated heparan
sulfate (Montgomery, Warner et al. 1996; Geraghty, Krummenacher et al. 1998; Shukla,
Liu et al. 1999). Apparently, gB can also bind to additional receptors including paired
immunoglobulin-like type 2 receptor alpha (PILR-a), non-muscle myosin heavy chain
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IIA (NMHC-IIA), and myelin-associated glycoprotein (MAG) that function in virion
attachment and virus entry (Satoh, Arii et al. 2008; Arii, Goto et al. 2010; Suenaga, Satoh
et al. 2010). Binding of gD and gB to their cognate receptors is thought to trigger
sequential conformational changes in gH/gL and gB causing fusion of the viral envelope
with cellular membranes during virus entry, as well as fusion among cellular membranes
(Heldwein, Lou et al. 2006; Hannah, Heldwein et al. 2007; Connolly, Jackson et al.
2011).
Fusion of the viral envelope with cellular membranes causes deposition of the
viral capsid into the cytoplasm, which is subsequently transported to the cell nucleus
(Morrison, Stevenson et al. 1998; Morrison, Wang et al. 1998; Ojala, Sodeik et al. 2000).
This retrograde transport of capsids to the neurons is highly dependent on the cellular
microtubule network and mediated via, most likely, direct interactions by one or more
tegument and capsid proteins with the dynein motor and the dynein cofactor dynactin
(Kristensson, Lycke et al. 1986; Topp, Meade et al. 1994; Sodeik, Ebersold et al. 1997;
Dohner, Wolfstein et al. 2002), reviewed in (Diefenbach, Miranda-Saksena et al. 2008).
Infectious virus production is initiated in the nucleus of cells where capsids
assemble. The virus acquires an initial viral envelope by budding of capsids into
perinuclear spaces (Diefenbach, Miranda-Saksena et al. 2008; Mettenleiter, Klupp et al.
2009). Fusion of the viral envelope with the outer nuclear membrane is thought to
deliver partially tegumented capsids into the cytoplasm. These capsids acquire additional
tegument proteins before acquiring their final envelopes by budding into intracellular
vesicles, most likely, originating from the trans-Golgi network (TGN) (Mettenleiter 2002;
Mettenleiter 2004). Fully-matured virions are finally released through an exocytosis
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process that appears to involve the kinesin family of microtubular network-associated
motors reviewed in (Diefenbach, Miranda-Saksena et al. 2008; Mettenleiter, Klupp et al.
2009).
The mechanism of anterograde transport of alphaherpesvirus in neuronal cells is
highly controversial to a large extent because of disparate results obtained with
pseudorabies virus (PRV) and HSV-1. Two principle mechanisms of axonal transport
have been proposed: 1) independent axonal transport of viral glycoproteins and capsids
and assembly of the enveloped virions in the plasma membrane; 2) transport of fully
enveloped virions that have formed via budding of capsids into TGN-derived membranes
(Diefenbach, Miranda-Saksena et al. 2008; Liu, Goodhouse et al. 2008; Mettenleiter
2008; Mettenleiter, Klupp et al. 2009; Antinone and Smith 2010; Antinone, Zaichick et
al. 2010; Maresch, Granzow et al. 2010; Osakada and Cui 2011b).
A number of viral glycoproteins have been implicated in efficient egress of
virions from infected non-neuronal cells (Mettenleiter, Klupp et al. 2009). However, the
role of viral glycoproteins in both retrograde and anterograde neuronal transport has not
been extensively studied. PRV glycoproteins gE and gI are required for anterograde
transport, but not retrograde transport (Card, Whealy et al. 1992; Jacobs, Mulder et al.
1993; Babic, Klupp et al. 1996; Johnson, Webb et al. 2001; Brittle, Reynolds et al. 2004;
Ch'ng and Enquist 2005). HSV-1 gE has been reported to function in both retrograde and
virus spread from epithelial cells to neurites (Balan, Davis-Poynter et al. 1994; Saldanha,
Lubinski et al. 2000; Wang, Tang et al. 2005; Brittle, Wang et al. 2008). Experiments
with neuronal cultures in microfluidic chambers revealed that HSV-1 (gE) was not
required for direct infection of neurites, however, it enhanced transmission of virus from
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epithelial cells to neurites. In addition, gE-null virions that entered into neurites did not
exhibit any defect in retrograde axonal transport (McGraw and Friedman 2009).
HSV-1 gK is a structural component of the virion particle and functions in virus
entry into epithelial cells (Foster, Rybachuk et al. 2001; Jambunathan, Chowdhury et al.
2011), cytoplasmic virion envelopment, virion egress and virus-induced cell fusion
(Hutchinson, Roop-Beauchamp et al. 1995). In infected cells, gK is found in a functional
complex with the membrane protein UL20 (Foster and Kousoulas 2008). UL20/gK
interactions are essential for their intracellular transport, cell-surface expression, and
functions in cytoplasmic virion envelopment and virus-induced cell fusion (Foster,
Alvarez et al. 2003; Foster, Melancon et al. 2004a; Foster, Melancon et al. 2004b;
Melancon, Fulmer et al. 2007; Foster and Kousoulas 2008). Recently, we showed that
HSV-1 gK and UL20 physically bind to gB and gH and modulate gB-mediated
membrane fusion (Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 2010). Also, we
reported that gK was essential for virus spread in the cornea of mice, neuroinvasiveness
and establishment of latency into ganglionic neurons (David, Baghian et al. 2008). In
this report, we utilize a microfluidic chamber to show that gK is required for infection of
neurites and retrograde and anterograde transport in neurons.

MATERIALS AND METHODS
Cells and Viruses
African green monkey kidney (Vero) cells were obtained from the American
Type Culture Collection (Rockville, MD, USA) and grown and propagated in Dulbecco’s
modified Eagle Medium (DMEM) supplemented with 7% fetal bovine serum (FBS) and
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antibiotics. The gK complementing VK302 cell line (generously provided by Dr. David
Johnson, Oregon Health Sciences University, Portland, OR, USA) was maintained in
Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and antibiotics. This cell line was used for generation and maintenance of
McKrae ∆gK viral stocks. Vero and VK302 cells were used to determine the replication
characteristics (plaque morphology) for parental McKrae virus and all recombinant
viruses used in these experiments. The clinical ocular isolate and neuroinvasive strain of
HSV-1 (the parental wild-type), McKrae strain, was obtained from Dr. J. M. Hill
(Louisiana State University Health Sciences Center, New Orleans, LA, USA) (Fig 3.1:A).

Construction of Recombinant Viruses
The construction methodology of mutant viruses for this experiment is essentially
similar to the techniques that were previously described to create KOS strain mutants
(Jayachandra, Baghian et al. 1997; Foster, Rybachuk et al. 1998; Foster and Kousoulas
1999; David, Baghian et al. 2008). McKrae virus with deleted UL53 (gK) gene (∆gK;
(Fig 3.1: B)) was constructed using the ICP27-null (d27-1) virus and plasmid pSJ1724, as
described previously for the HSV-1 (KOS) ∆gK virus (Jayachandra, Baghian et al. 1997).
The ICP27-null virus has 1627 base pair (bp) of UL54 gene deleted, but contains a
complete UL53 gene. Plasmid pSJ1724 has a 1068 bp deletion in UL53, but has an intact
UL54. Recombination between homologous regions of d27-1 virus and plasmid pSJ1724
resulted in the ∆gK virus. This virus does not contain an EGFP cassette and is designated
in this paper as ΔgK/GFP-. This ∆gK virus was rescued (R/GFP-) (Fig 3.1: C) by
transfecting Vero cells with PCR amplified fragments of UL53 gene from wild-type
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HSV-1 (KOS) strain followed by infection with the ∆gK virus (Jayachandra, Baghian et
al. 1997). The UL 53 (gK) gene of HSV-1 McKrae was replaced with an enhanced green
fluorescence protein (EGFP) gene cassette under control of the human cytomegalovirus
immediate early gene promoter (CMV-EGFP) (Foster, Rybachuk et al. 1998). Briefly,
The CMV-EGFP cassette was cloned into the plasmid pSJ1723 to create plasmid
pTF9201 as described previously (Foster, Rybachuk et al. 1998; David, Baghian et al.
2008). Plasmid PTF9201 contains an EGFP gene cassette under the human
cytomegalovirus immediate early promoter control (HCMV-IE) within a DNA fragment
spanning the UL52–UL54 genomic region that lacks the UL53 gene. Plasmid PTF9201
was used in transfection followed by infection with HSV-1 (McKrae) to isolate the
McKrae-∆gK/EGFP virus (Fig. 3.1: D) designated ∆gK/GFP+, appearing as small
fluorescent viral plaques under the fluorescence microscope (Foster, Rybachuk et al.
1998; David, Baghian et al. 2008). The McK ∆gK/EGFP virus was rescued using
plasmid pTF9105, which contains a complete UL53 gene from the HSV-1 (KOS) strain
creating the virus designated R/GFP+ (Fig. 3.1: E) (Foster and Kousoulas 1999).

Animals
Adult female Sprague-Dawley rats, 15-18 days pregnant, were used (Charles
River, Wilmington, MA). All procedures were approved by the Louisiana State
University-School of Veterinary Medicine Institutional Animal Care and Use Committee.
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Figure 3.1: Schematic representation of mutant viruses. The top line represents the
prototypic arrangement of the HSV-1 genome with the unique long (UL) and unique
short (US) regions flanked by the terminal repeat (TR) and internal repeat (IR) regions.
(A) McKrae wild type. (B) McKrae parental strain with deletion mutation of gK and
without the EGFP cassette (ΔgK/GFP-). (C) Rescue of the gK deletion in the virus (B)
without the EGFP cassette (R/GFP-). (D) McKrae parental strain with deletion of the gK
gene by replacement with an EGFP cassette (ΔgK/GFP+). (E) Rescue of the virus in (D)
with preservation of the EGFP (R/GFP+).
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Dorsal Root Ganglion Primary Neuron Culture
Dorsal root ganglia (DRG) neurons were cultured under conditions that were
adapted from those described previously for culturing sympathetic superior cervical
ganglia-derived neurons (Liu, Goodhouse et al. 2008). Additional modifications were
adapted from previously
described culture conditions for dorsal root ganglia (Osakada and Cui 2011b; Osakada
and Cui 2011a). Specifically, ganglia were dissected from fetal Sprague-Dawley rats at
embryonic day
15-18. DRG were incubated at 37° C for 30 min in 250 mg/ml of trypsin (Worthington
Biochemical Corp., Lakewood, NJ). Trypsin was neutralized by incubating ganglia in
neuron culture media with 10% fetal bovine serum (FBS) and 1 mg/ml trypsin inhibitor
(Sigma Aldrich, St. Louis, MO) for 2 min. Ganglia were rinsed with fresh neuron culture
media and ganglionic neurons were gently triturated into a single-cell suspension using a
pulled-glass Pasteur pipette. Then cells were plated into one side of the microfluidic
neuron devices (Cat. number: SND450; Xona Microfluidics, LLC, Temecula, CA)
adhered to glass coverslips or the surface of 35mm plastic petri dishes. Glass coverslips
or 35mm plastic petri dishes were prepared for neurons by coating with Poly-D-Lysine,
molecular weight 75,000 to 150,000 Daltons, (Sigma Aldrich) dissolved in borate buffer
at 0.2mg/ml, incubated at 37° C for 48 hours prior to plating of neurons. Neuronal
devices were assembled by placing a standard neuronal microfluidic device firmly onto
the coverslip or petri dish to ensure a sealed barrier. Maintenance neuron culture media
consists of Neural Basal Media with B-27 supplement, at manufacturer’s recommended
concentration, (Invitrogen, Grand Island, NY). Media was supplemented with 50 ng/ml
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neural growth factor 2.5s (Invitrogen), 2% normal rat serum (Invitrogen), 1X Glutamax
(Invitrogen) and 0.2% Primocin (Invivogen, San Diego, CA). Once plated, neurons were
maintained in a humidified incubator at 37° C and 5% CO2 for the duration of all
experiments. To eliminate non-neuronal cells, 1 and 3 days post-plating, neuronal
cultures were treated with 4 mM cytosine β-d-arabinofuranoside (CAB) (Sigma-Aldrich)
in neuronal media for 24 hours. Neuronal culture media was changed every 48-72 hours
during the course of the experiment.

Infection of Neuron Devices
Neurons were allowed to grow for 10-14 days post plating until robust axonal
processes with abundant branching were observed on the axon side of neuron devices.
Once present, the neuronal devices were prepared for infection. For retrograde
infections, media was completely depleted from the wells of the axonal side of
microfluidic devices. Then on the neuron-soma-side of the devices, wells were filled to
maximum fluid capacity until a small meniscus formed in the neuronal culture media.
After establishment of the fluid pressure gradient, axonal side wells would be inoculated
with the virus at the concentration indicated in the results. Then, approximately 100
microliters of neuron culture media was placed in the infected wells to ensure mixing of
the virus into the central chamber containing the axons. Once the fluid pressure gradient
had been established media was only added to the soma side if necessary to combat
dehydration and maintain an obvious fluid level difference. In the case of anterograde
neuronal infection studies, the axonal side was co-plated with a monolayer of VK302 or
Vero cells. Briefly, these cells were trypsinized from a cell-culture flask, the trypsin was
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neutralized using 100% FBS, and an abundance of cells were plated on the axon side of
the microfluidic neuron devices using a media consisting of a 1:1 mixture of DMEM with
10% FBS and neuronal culture media. VK302 or Vero cells were seeded in devices and
allowed to grow for 24-48 hours to ensure a nearly confluent monolayer for experiments.
For anterograde infections, media was completely depleted from the wells of the neuron
soma side of microfluidic devices. Then on the axon/reporter cell side of the devices,
wells were filled to maximum fluid capacity. After establishment of the fluid pressure
gradient, soma side wells were inoculated with the virus at the concentration indicated in
the results. Then approximately 100 ml of neuron culture media was placed in the
infected wells to ensure mixing of the virus into the central chamber containing the
axons. Again, after establishment of the gradient, media was only added to the high side
(axon/reporter cell side in this case) to replace any loss due to dehydration.

Growth Curves on Neurons
To determine the kinetics of viral replication on ganglionic neurons, 24-well
plastic plates were plated with 175,000 ganglionic cells using the above described
harvesting protocol. Ganglionic neurons were infected with approximately a multiplicity
of infection (MOI) of 0.1 with each of the viruses. Plates were prepared in triplicate and
infections were halted by freezing at 0, 12, 24, 48 and 72 hpi. Plates were frozen, thawed
and viral titers were determined for each time point by standard plaque assay on VK302
cells (for the ΔgK viruses) or Vero cells (for the parental and rescue strains). Plaques
were stained with crystal violet and visualized with a dissecting microscope. Growth
curves show the result of the mean of the triplicate plates.
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Plaque Morphology
For fluorescent plaque morphology, confluent monolayers of Vero and VK302
cells were infected at MOI of 0.001 with the indicated viruses. EGFP fluorescence of
representative plaques was visualized and photographed at 72 hpi with a fluorescence
microscope (Olympus, Tokyo, Japan). For immunohistochemical plaque morphology,
cells were fixed with 10% formalin at 72 hpi (Melancon, Foster et al. 2004; David,
Baghian et al. 2008). Immunohistochemistry was performed with primary rabbit antiHSV antibodies (1:1000) (Dako, Carpinteria, CA) and the reactions were developed with
NovaRed substrate (VectorLabs; Burlingame, CA). Images were taken with an inverted
light microscope (Olympus) using relief contrast.

Visualization of Retrograde and Anterograde Infections
For direct observation by phase contrast of the viral infection, neuronal soma
sides and axon/reporter cell sides of devices were observed and imaged using an inverted
microscope (Olympus) and relief contrast. EGFP fluorescence was observed using the
same inverted microscope set for fluorescence. For immunofluorescent antibody analysis
of anterograde infections, microfluidic devices were fixed with cold 10% formalin. Then
the devices were incubated with blocking buffer (PBS containing 4% BSA and 2% goat
serum) for 1 hour at room temperature. Next the primary antibodies were added and
devices were incubated overnight at 4°C. Primary antibodies used were mouse
monoclonal anti-HSV glycoprotein C IgG2a (Virusys Corp., Taneytown, MD) diluted
1:3000 and mouse monoclonal anti-neurofilament IgG1 (Invitrogen) diluted 1:1000.
Next secondary antibodies, goat anti-mouse IgG1 conjugated to Alexafluor 488 and goat
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anti-mouse IgG2a conjugated to Alexafluor 594 (Invitrogen), both diluted to 1:1000 were
applied. All antibodies were diluted in PBS containing 2% BSA and 1% goat serum.
After 30 minutes devices were washed 5 times with PBS. The microfluidic neuron
devices were placed on ice and removed from the glass coverslips (per the
manufacturer’s instructions). Prolong Gold with DAPI (Invitrogen) was added to the
coverslips and cells were photographed with an inverted fluorescence microscope.

Sample Collection for PFU and Quantitative PCR (qPCR) Studies
For studies of viral DNA transmission and virus/viral DNA production neuronal
devices were sampled in the following manner. The low side (axonal side in retrograde
studies and somal side in anterograde studies) was always aspirated first. At the
appropriate time points, the media present in the low side wells was aspirated and
collected. Then, the sampled side was flushed with a small amount of media. Following
that, media from the higher side was collected and that side was flushed with a small
amount of media. Subsequently, the high side wells were filled with media and the
devices were frozen overnight. Devices were then thawed and the low side was flushed
with a small amount of media and this media was collected. Finally, the high side was
flushed and collected. This procedure allowed for maintenance of the fluid pressure
gradient by always keeping the gradient and allowed for collection of cell-associated
virus as well as any free virus in the media. At this point all samples were frozen. Later
these samples were thawed and used for analysis of PFU or viral DNA.
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Detection of PFU from Anterograde and Retrograde Infections
Samples of media collected from the neuronal devices were thawed and plated in
serial dilutions. The number of infectious virions in the media was determined by plaque
assay on appropriate (Vero or VK302) monolayers visualized with anti-HSV-1 rabbit
polyclonal antibody (Dako) developed with Nova Red (Vector Labs).

QPCR
For quantitative PCR, once thawed, samples were processed using the Qiagen
DNeasy blood and tissue kit (Qiagen, Valencia, CA) per the manufacturer’s instructions
to isolate DNA. qPCR was performed as described previously for Kaposi’s sarcoma
herpesvirus (KSHV) (Subramanian, D'Auvergne et al. 2008; Subramanian, Sehgal et al.
2010). Specifically, the primers and probe (6-carboxytetramethylrhodamine (TAMRA))
for the real-time PCR were designed to detect HSV-1 US6 (gD). Equal volumes of viral
DNA were used for TaqMan PCR 196 analysis. Purified plasmid containing the gD gene
was initially used to generate the standard curve. Samples were also tested and genome
numbers were determined using validated standards provided by the Path-HSV1-genesig
real-time PCR detection kit for Human Herpes Virus 1 (Herpes simplex type 1)
(PrimerDesign, LTD, South Hampton, UK).
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RESULTS

Replication Characteristics of Recombinant Viruses on Rat Dorsal Root Ganglionic
Neurons
We have previously described the construction of recombinant HSV-1
(McKrae) viruses constitutively expressing the enhanced green fluorescence protein
(EGFP) under the human cytomegalovirus immediate early promoter (HCMV-IE)
(David, Baghian et al. 2008). To determine the role of glycoprotein K (gK) in neuronal
replication, a complete set of recombinant viruses with intact or deleted gK genes were
constructed and studied. This set of viruses include: 1) the wild-type McKrae strain
compared to a mutant virus lacking the gK gene (∆gK/GFP-) and a virus in which the
deleted gK gene was rescued to wild-type (R/GFP-) (Fig. 3.1: A, B, C, respectively); 2) a
set of McKrae derived viruses that have a HCMV-IE-EGFP gene cassette replacing the
gK gene sequence (∆gK/GFP+) and a derivative virus that replaced the missing gK gene
and retained the HCMV-IE-GFP gene cassette adjacent to the gK gene (R/GFP+) (Fig.
3.1: D, E, respectively).
Infection of dorsal root ganglionic neurons with wild-type McKrae virus
resulted in rapid cytopathic effects exhibited as early as 12 hpi. Typically, neurons
appeared rounded up, swollen, while the overall number and length of axons present
before infection, appeared to be markedly reduced at early times after infection (not
shown). Wild-type-like McKrae virus as well, as wild-type-like virus produced after
rescue of the deleted gK gene, replicated with approximately equal efficiencies in the
presence or absence of the EGFP gene (Fig. 3.2: A, B). However, mutant viruses lacking
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the gK gene grown on either Vero, or the gK complementing cell line VK302 replicated
1-2 logs less efficiently than the parental McKrae viruses at late times post infection (Fig.
3.2: A, B).
All wild-type-like viruses (wild-type and gK-rescued virus) produced on
average similar size plaques on both Vero and VK302 cells (Fig. 3.3) (David, Baghian et
al. 2008). In contrast, gK-null viruses prepared in either Vero or VK302 cells produced
on average drastically smaller viral plaques on Vero cells. The gK-null defects were
efficiently complemented on VK302 cells, where gK-null viruses produced viral plaques
similar in size to the wild-type like viruses (Fig. 3.3). Examination of individual viral
plaques by fluorescence microscopy revealed that all viruses containing the GFP gene
cassette readily expressed EGFP (Fig. 3.3).

Microfluidic Multi-Chamber Device for Neuronal Transport Studies
A commercially available microfluidic device was used for neuronal transport
studies (see materials and methods). This device enables the physical separation of
neuronal somas and axon termini under virion impermeable conditions (Fig. 3.4: A). To
ensure that virions could not be passively transmitted from one chamber to the other,
control experiments were performed as follows: Vero cells were plated in wells on both
sides of the microfluidic chamber. Wells of one side were infected with R/GFP+ virus at
an MOI of 10. A hydrostatic pressure differential between the infected and uninfected
chambers was maintained by ensuring that the uninfected fluid levels were substantially
higher than those in the infected wells. The infected cells exhibited extensive
cytopathicity and expression of EGFP at 48 hpi. In contrast, uninfected cells did not
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exhibit any cytopathic effects, or fluorescence at 5 days post infection suggesting that
virions were unable to passively leak from the infected into the uninfected wells (Fig.
3.4:B)

Figure 3.2: Growth curves of HSV-1 (McKrae) and mutants on DRG neurons.
Approximately 175,000 ganglionic cells plated in 24 well plates were infected with the
parental McKrae strain, R/GFP+, ∆gK/GFP+ (Vero), ∆gK/GFP+ (VK302), R/GFP-,
∆gK/GFP- (Vero), or ∆gK/GFP- at an MOI of approximately 0.1. (A) Curves for the
three GFP+ viruses with the parental McKrae strain for comparisson. (B) Curves for the
three GFP- viruses with the parental McKrae strain for comparisson. Viral titers were
obtained at indicated time points post infection by standard titration plaque assay on Vero
or VK302 cells. PFU totals represent the mean of triplicate experiments and error bars
represent the standard error.
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Figure 3.3: Representative plaque morphologies of HSV-1 (McKrae) strain and
mutants on Vero and VK302 cells. Confluent Vero or gK complementing VK302 cells
monolayers were infected with the R/GFP+, ∆gK/GFP+ (Vero), ∆gK/GFP+ (VK302),
R/GFP-, ∆gK/GFP- (Vero), or ∆gK/GFP- at an MOI of approximately 0.001. Viral
plaques were visualized by immunohistochemistry at 72 hpi using rabbit anti-HSV-1
developed with Nova Red (Vector Labs) with contrast microscopy. Fluorescent plaques
from viruses with EGFP were observed using a fluorescence microscope at 72 hpi.
Plaques shown are representative of average plaque size observed. All images are taken
at 100X magnification.

185	
  

Figure 3.4: Microfluidic Neuron Device System. (A) Photograph of the neuron device
(Xona Microfluidics) that maintains a fluid pressure (left panel). Virus impermeable
barrier containing axons (middle panel). Side view schematic showing wells, main
central channel and microgroove barrier showing the maintenance of a fluid pressure
gradient (right panel). (B) Control experiment to test for system integrity. Phase contrast
and GFP fluorescence of infected Vero cells at 3 days post infection, and uninfected Vero
cells at 5 days post infection. During all 5 days the uninfected side wells were
maintained at a higher fluid level than the infected side wells.
Retrograde Transport of Virions
Retrograde transport of virions from infected neuronal endings to neuronal
somata was investigated. For retrograde studies, microfluidic chambers were seeded with
rat dorsal root ganglionic neurons on one side of the chamber. Neurons were allowed to
propagate axons across the microgroove barrier for 10-15 days, or until axons and
neuronal endings were visibly present across the barrier and the apposed chamber,
respectively (see Materials and Methods). The neuronal endings chambers were infected
with R/GFP+ and ∆gK/GFP+ viruses at an approximate MOI of 5. Progression of
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infection on the neuronal soma side of the microfluidic device was monitored daily using
a fluorescence microscope to detect EGFP expression. EGFP expression was readily
detected as early as 24 hpi in the R/GFP+, while infection with the ∆gK/GFP+ virus
failed to produce any EGFP expression, as late as 5 days post infection (Fig. 3.5).
Surprisingly, ∆gK/GFP+ virus grown on the VK302, gK complementing, cells failed to
be transmitted to the neuronal soma side of the microfluidic device, although an
occasional fluorescent cell was infrequently detected (approximately 100-1000-fold less
than the R/GFP+ ) (Fig. 3.5 F).
To determine whether infectious virions and/or viral DNA were transported in a
retrograde manner, neuronal termini chambers were infected with an MOI of
approximately 5. The number of viral genomes was obtained by quantitative PCR, while
the presence of infectious virus was assessed by determining viral titers on VK302 cells
as detailed in Materials and Methods. Generally, all virus stocks appeared to have a
genome to PFU ratio of less than 10 suggesting that most viral genomes were contained
within infectious virion particles (Fig. 3.6). The number of viral genomes detected on the
neuronal termini side of the device decreased by approximately 35% at 48 hpi and 45% at
72 hpi, respectively, while it did not decrease in wells infected with either the
∆gK/EGFP+ or ∆gK/EGFP+ produced in VK302 cells suggesting that the gK-null
viruses failed to enter into neuronal endings, unlike the wild-type-like virus. Comparison
of total PFU numbers revealed a time-dependent decrease of PFU remaining within the
neuronal endings chambers for all viruses. This PFU reduction was similar to decreases
in PFU obtained when viral samples were incubated for similar time periods at 37C
suggesting that it reflected a natural decay of viral infectivity over time (not shown).
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Examination of the number of viral genomes and PFU obtained from samples derived
from the soma side of the devices revealed that the R/GFP+ virus efficiently transported
and replicated in soma chambers producing maximum viral genomes and PFU at 72 hpi.
In contrast, both the ∆gK/EGFP+ and ∆gK/EGFP+ grown on VK302 cells failed to be
transported and replicate in soma chambers at 72 hpi (Fig 3.6.).

Figure 3.5: Infection of neuron cell bodies (Soma) via retrograde transport. Phase
contrast (A-C) and GFP fluorescence (D-F) of neurons. Axonal side of chambers (not
shown) were infected with ΔgK/GFP+ (VK302), ΔgK/GFP+ (Vero) and R/GFP+.
Neurons potentially infected with ΔgK/GFP+ (VK302 or Vero) were photographed,
using phase and fluorescence microscopy, at 5 dpi to allow ample time for retrograde
transport. Neurons infected with R/GFP+ were photographed, using phase and
fluorescence microscopy, at 2 dpi due to the presence of ample infected neurons. All
images were taken at 100X magnification.
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Figure 3.6: Determination of PFU and viral genomes recovered in retrograde virus
transport experiments. Viral DNA copy number determined by QPCR, and PFU,
determined by serial titration plaque assay are shown for samples recovered from the
axon and soma sides of devices infected in retrograde manner. Bars represent the mean
of 6 (DNA) or 4 (PFU) samples taken from devices at 2, 48, and 72 hpi as well as
corresponding volume samples of innocula taken at the time of infection (input). (A, B)
R/GFP+ infected. (C, D) ∆gK/GFP+ (Vero) infected. (E, F) ∆gK/GFP+ (VK302)
infected. Input bars are black. Bars representing the axon side (white) and soma side
(gray) are shaded to correspond to the sides in the schematic (top).
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Anterograde Transport of Virions
For anterograde studies, after seeding of microfluidic chambers and propagation
of axons, axonal side wells were co-plated with a monolayer of VK302 cells. Then,
neuronal somata were infected as described in the retrograde studies. Infection of the
neuronal side of the microfluidic chambers was also monitored daily by visualizing
EGFP fluorescence. All three viruses, R/EFP+, ∆gK/GFP+(Vero) and
∆gK/GFP+(VK302) infected neuronal somas efficiently, as evidenced by the strong
EGFP fluorescence (Fig. 3.7). However, only the R/GFP+ virus was transported in an
anterograde manner to the Vero reporter cells on the microfluidic chambers (Fig. 3.7).
Similar virus axonal transport experiments were performed, but this time the cells within
the soma and reporter sides of the microfluidic chambers were fixed and immune-stained
with antibodies specific for viral glycoprotein C (gC), nuclei, and neurofilament (neuronspecific stain) and viruses not expressing GFP were utilized (to allow multicolor
immunofluorescence). Cells in both the soma and reporter sides of the chambers
expressed relatively high levels of gC only when infected R/GFP- virus, while both
∆gK/GFP- (Vero) and ∆gK/GFP- (VK302) viruses expressed in gC in cells in the soma
side of the chambers, while no gC expression was detected on the reporter side of the
chambers (Fig. 3.8).
Anterograde transport of virions was also monitored by determining the number of
infectious viruses produced on the reporter side of the microfluidic chamber (Vero cells)
after infection of the neuronal soma sides, as well as determining the number of viral
genomes transmitted axonally to the reporter sides using QPCR. Infectious virions were
retrieved only in infections with the R/GFP+ virus. The relative number of infectious
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virions present at 72 hpi in somas appeared to decrease in comparison to input virus,
while the total number of viral genomes appeared to increase reflecting continued viral
replication within neuronal somata (Fig 3.9).

Figure 3.7: Anterograde infection and transmission. Anterograde infection and
transmission demonstrated by phase and fluorescence microscopy of the infected
neuronal side and uninfected reporter cell/axon side. Only the rescued virus was
observed spreading the virus in the anterograde direction to reporter cells.
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Figure 3.8: Anterograde infection and transmission via immunofluorescence of viral
proteins. Anterograde infection and transmission demonstrated by fluorescent
antibodies. Images are stained with anti-neurofilament antibody with Alexafluor 488
secondary (green), anti-HSV-1 gC with Alexafluor 594 secondary (red) and DAPI (blue).
Neuron sides of the microfluidic devices were infected with R/GFP-, ΔgK/GFP- (vero)
and ΔgK/GFP- (VK302). Only the rescued virus was observed spreading in the
anterograde direction to reporter cells as demonstrated by red staining indicating the
production of viral glycoprotein C in reporter cells.
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Figure 3.9: Determination of PFU and viral genomes recovered in anterograde virus
transport experiments. Viral genome and PFU numbers from the axon/reporter cell and
soma sides of devices infected in the anterograde manner. Bars represent the mean of 6
(DNA) or 4 (PFU) samples taken from devices at 72 hpi as well as corresponding volume
samples of innocula taken at the time of infection (input). (A, B) R/GFP+ infected. (C,
D) ∆gK/GFP+ (Vero) infected. (E, F) ∆gK/GFP+ (VK302) infected. Input bars are
black. Bars representing the soma side (white) and reporter cell side (gray) are shaded to
correspond to the sides in the schematic (top).
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DISCUSSION
HSV-1 gK functions as a protein complex with the membrane protein UL20 in
membrane fusion phenomena during virus entry and virus-induced cell fusion enabling
virions to enter into cells and spread into adjacent uninfected cells, respectively
(Jayachandra, Baghian et al. 1997; Melancon, Luna et al. 2005; Foster and Kousoulas
2008; Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 2010; Jambunathan,
Chowdhury et al. 2011). Previously, we showed that lack of gK prevented corneal spread
in mice, transmission of the gK-null virions to the central nervous system, and
establishment of latency. Here, we show that gK is essential for infection of free
neurites, and retrograde and anterograde transport in rat dorsal root ganglionic neurons in
culture, in agreement with the previous in vivo studies (David, Baghian et al. 2008).
Herein, we have chosen to work with the HSV-1 McKrae strain because this
virus was isolated from a human ocular herpes infection (Kaufman, Ellison et al. 1969)
and shown to be highly virulent in mice and rabbits (Perng, Thompson et al. 1995; Perng,
Chokephaibulkit et al. 1996; Halford, Balliet et al. 2004). In these studies we utilized a
set of recombinant viruses lacking gK gene expression in the presence or absence of
EGFP expression for comparative purposes, because constitutive expression of the EGFP
gene may alter viral replication characteristics (DeWire, Money et al. 2003). Wild-typelike viruses replicated to similar levels in the presence or absence of GFP expression in
ganglionic neurons. In contrast, gK-null virions reached maximum viral titers that were
1-2 logs lower than their corresponding wild-type-like viruses, while EGFP expression
did not adversely affect viral growth. These experiments indicated that EGFP expression
did not alter viral replication characteristics of these viruses.
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The relative size of viral plaques is an indication of the ability of the virus to
spread from infected to uninfected cells. Consistent with previous findings, the lack of
gK caused the production of substantially smaller viral plaques indicating a severe defect
in virus spread. EGFP expression did not have any effect on the gK-null defect in virus
spread.
Microfluidic devices separating axonal termini from neuronal somata have been
extensively used in herpes viral experiments to investigate the contribution of individual
genes in retrograde and anterograde axonal transport (Ch'ng, Flood et al. 2005; Feierbach,
Bisher et al. 2007; Liu, Goodhouse et al. 2008; Curanovic and Enquist 2009). We
exclusively utilized a commercially available microfluidic device (Xona Microfluidics,
LLC) originally developed from a collaboration between the Enquist laboratory
(Princeton Univ.) and the Jeon laboratory (Univ. of CA Irvine) (Liu, Goodhouse et al.
2008). It is particularly important in all studies using these devices that control
experiments are performed carefully to ensure that there is no leakage of fluids between
the device and the cover slip on which the device is placed. Therefore, methods utilized
in these studies were validated for obtaining appropriate sealed chambers prior to the
onset of each experiment. Furthermore, chambers were inspected to ensure that axons
were exclusively appearing within the device microgrooves.
Infections of chambers containing axonal termini showed that the wild-type-like
virus (R/GFP+) was readily transported to the somata containing chamber, while the gKnull virus ∆gK/GFP+ failed to be transported. Surprisingly, ∆gK/GFP+ virus grown on
the complementing cell line VK302 was also largely unable to be transported to the
somata containing chamber. This result suggests that expression of the HSV-1 (KOS)
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gK gene in VK302 cells may complement for infectious virus production in Vero,
however virions produced in VK302 cells may not be able to infect neuronal axons. We
have shown that the amino terminus of gK interacts with the amino terminus of gB, most
likely affecting the ability of gB to mediate fusion of the viral envelope with cellular
membranes during virus entry (Chouljenko, Iyer et al. 2009; Chouljenko, Iyer et al. 2010;
Jambunathan, Chowdhury et al. 2011). Comparison of the predicted amino acid
sequences of KOS and McKrae gB and gK reveal a number of amino acid differences
including amino acid changes within the amino termini of gB and gK. Furthermore, lack
of gK prevented entry via fusion of the viral envelope with cellular membranes
(Chowdhury, Naderi et al. 2012). Thus, it is conceivable that KOS gK cannot efficiently
complement the McKrae gK-null virus for entry into neuronal axons via fusion of the
viral envelope with neurites, because of altered interactions between KOS gK and
McKrae gB. It is important to note these experiments cannot differentiate whether
virions entered into neurons but were subsequently unable to be either transported or
replicated within somatas, since only GFP expression was monitored. In an attempt to
address this issue, the total viral genomes and infectious virions remaining within the
axonal termini-containing chambers were determined. In the inoculated chambers, viral
genome numbers appeared to decrease by up to 45% in the wild-type-like infections with
no comparable decrease observed with gK-null infections, possibly suggesting that the
gK-null virions were unable to enter into axons and be removed from the inoculated side.
This result was not corroborated by the PFU counts, most likely, because of the natural
decay of infectious virions at prolonged incubation at 37C. Despite the consistent
detection of few cells expressing GFP in infections with the ∆gK/GFP+ virus within
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somata, there were no infectious virions recovered from these chambers even at 72 hpi.
Collectively these results indicate that EGFP expression may be due to transport of DNA
fragments containing the EGFP gene cassette. These gene fragments may exist in the
original virus stocks used for infections, or produced after degradation of endocytosed
virions into neurons.
UL20 and gK are required for cytoplasmic virion envelopment and egress in
epithelial cells (Hutchinson, Roop-Beauchamp et al. 1995; Jayachandra, Baghian et al.
1997; Melancon, Luna et al. 2005). Furthermore, direct comparison of the role of gK and
UL20 in cytoplasmic envelopment, virion egress and infectious virus production with
similar functions provided by the carboxyl terminus of gD, gE, UL11, or gM have
revealed that gK and UL20 are more important than each of these proteins alone or in
combination (Chouljenko, Kim et al. 2012). In agreement with these known functions of
gK, lack of gK drastically inhibited transmission of virus from somata-containing
chambers to axonal termini embedded within VK302 cell monolayers. Neurons, unlike
epithelial or fibroblasts have an intricate distribution of cytoplasmic organelles within
somata and axons. Specifically, TGN derived-membrane vesicles migrate to synapses
and play important roles in synapse formation among neurons (Sytnyk, Leshchyns'ka et
al. 2004). Therefore, it is conceivable that cytoplasmic envelopment of virions occur
within both somata and via budding into TGN-derived vesicles proximal to synaptic
membranes.
Apparently, both ∆gK virions grown on Vero or VK302 cells appeared to infect
somata with approximately similar efficiencies indicating that lack of gK does not
substantially alter entry of the gK-null virions via infection of neuronal cell bodies.
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Neurons are known to express nectin-1, which binds gD and functions in virus entry
(Richart, Simpson et al. 2003; Simpson, Manchak et al. 2005). In agreement with these
published results, we readily detected nectin-1 expression in neuronal termini, axons and
somata (not shown). Thus, an altered distribution of nectin-1 between neurites and somas
are probably not responsible for the lack of gK-null virus infection of neuronal termini.
Nectin-1 is known to primarily mediate endocytosis of virions rather than fusion of the
viral envelope with cellular membranes (Milne, Nicola et al. 2005). Thus, it is possible
that virions enter into neurites primarily via membrane fusion suggesting that gK
functions in virus-cell membrane fusion utilizing cellular receptors other than nectin-1.
Herpes simplex virions have evolved a highly complex system for optimum
infection of neurons, the ultimate destination of the virus in the human host. It is
conceivable that virus entry into neuronal synapses via transmission of virus through
epithelial neuronal synapses, or via infection of axonal termini requires the presence of
gK. We hypothesize that gK, known to interact with the amino terminus of gB, may
modulate fusogenic activity of gB via specific gB cellular receptors. Lack of gK may
result in loss of critical regulatory functions provided by gK on gB to mediate fusion of
the viral envelope with synaptic membranes resulting in inability to enter into axons, or
entry and subsequent degradation of virions within lysosomal compartments. Direct
visualization of fluorescent virions via specially equipped fluorescent microscopes may
resolve these issues that will be addressed in future experiments.
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CHAPTER IV
CONCLUDING REMARKS
SUMMARY
Earlier work in our laboratory has shown that HSV-1 glycoprotein K (gK) is not
essential for virus entry into cells, but is essential for virus spread in cell culture.
Glycoprotein K-null mutant viruses form very small viral plaques typically consisting of
less than 10 infected cells per plaque (Jayachandra, Baghian et al. 1997; Melancon, Luna
et al. 2005). This phenotype is the result of gK’s critical role in cytoplasmic virion
envelopment presumably occurring at trans-Golgi network (TGN) membranes (Foster,
Melancon et al. 2004a; Foster, Melancon et al. 2004b; Foster, Chouljenko et al. 2008). A
similar viral phenotype had been described for pseudorabies virus (PRV) indicating that
HSV-1 and PRV gK function in a similar fashion in viral morphogenesis and egress in
tissue culture (Klupp, Baumeister et al. 1998).
In vivo work with PRV indicated that gK was essential for virus spread in cell
culture, but it was not essential for neuroinvasiveness (Flamand, Bennardo et al. 2001).
To investigate whether HSV-1 gK was essential for neuroinvasiveness and disease
causation, we performed the experiments detailed in chapter 2 of this dissertation. Using
a mouse eye model, we established that HSV-1 gK is essential for spread in the cornea
during primary infection. No clinical symptoms and very low levels of virus were found
in gK-null virus infected mouse eyes, which correlated well with data from cell culture,
in that HSV-1 can infect without gK but the infection is scant at best with no ability to
spread. For our studies, we used the McKrae strain of HSV-1. This strain was initially
isolated from a human ocular infection (Kaufman, Ellison et al. 1969). This strain is
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highly virulent in the eyes and neural tissues of mice and rabbits and, therefore, served as
an excellent standard to judge manipulations that resulted in reduced pathology (Perng,
Thompson et al. 1995; Perng, Chokephaibulkit et al. 1996; Halford, Balliet et al. 2004).
Following infection of mouse eyes with HSV-1, virus replication occurs initially
in the corneal epithelium, and subsequently the virus is transmitted via epithelialneuronal interfaces to neurons. Virions are thought to move in the retrograde direction
within axons to neuronal soma where they establish latency (Cunningham, Diefenbach et
al. 2006; Diefenbach, Miranda-Saksena et al. 2008). To determine the neuroinvasiveness
of the gK-null mutant virus, mice that were infected in the corneas were monitored for
survival and symptoms of neurologic disease. The eye is a good model for neural
transmission because the eye cornea is a highly innervated tissue with a high density of
nociceptors per square millimeter and thus, efficient, ready access to the nervous system
(Muller, Marfurt et al. 2003). Clinical disease symptoms absolutely paralleled the
observed infection patterns with the MK∆gK infected eyes exhibiting no clinical signs at
any time point following viral infection, while the rescued virus produced significant eye
disease by day 4 post infection. Furthermore, neuroinvasion was confirmed due to the
development of severe neurologic symptoms and death in rescue inoculated mice.
Significantly no clinical eye disease or neurologic symptoms were observed in the gKnull inoculated mice.
The final test of virulence and transmission was to determine whether the gK-null
viruses could cause retrograde spread to the sensory ganglia and establish latent infection
in the periphereal nervous system. With the efficiency of neuronal infection and
transmission in a scarification and direct inoculation system, any level of neuronal
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infection should result in latent infection. Thirty days after infection of the eyes,
trigeminal ganglia from infected mice were cultured to isolate reativated HSV-1. No
reactivation could be found in mice infected with the gK-null virus, but mice infected
with the rescue strain had abundant reactivation. To provide greater certainty, the
ganglionic tissues were also examined by PCR for HSV-1 DNA. HSV-1 DNA was very
rarely present in the ganglia of gK-null infected mice.
These results taken together, provide stong evidence for gK as a critical
determinant of spread, pathogenesis, neuroinvasion, and the establishment of latency.
These results are substantially different from the results reported for PRV. To better
characterize these disparate results, it was decided that this infection process should be
evaluated in a primary neuron cell culture system to eliminate confounding factors that
are present in animal models. To that end, a primary neuronal culture system was
developed. This system was developed using dorsal root ganglionic neurons from rats.
These ganglia provide sensory neurons, which are the primary neuronal target of HSV-1.
Use of neurons, allowed us to separate the phenomena of retrograde and anterograde
transport in a more definite way than is possible in a live animal model. This was
important because PRV glycoproteins gE and gI are required for anterograde transport,
but not retrograde transport (Card, Whealy et al. 1992; Jacobs, Mulder et al. 1993; Babic,
Klupp et al. 1996; Johnson, Webb et al. 2001; Brittle, Reynolds et al. 2004; Ch'ng and
Enquist 2005). And HSV-1 gE has been reported to function in both retrograde and virus
spread from epithelial cells to neurites but was not required for direct infection of neurites
or retrograde transport (Balan, Davis-Poynter et al. 1994; Saldanha, Lubinski et al. 2000;
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Wang, Tang et al. 2005; Brittle, Wang et al. 2008; McGraw and Friedman 2009). Clearly
these processes have different interacting proteins.
The experiments contained in chapter 3 use the primary neuronal culture system and our
gK-null mutant viruses to demonstrate that gK is a critical determinant in infection at the level of
the neurite/axonal process. Viruses without gK could infect and apparently replicate in neurons
that were infected at the level of the cell body, however, this virus could not be transported in the
anterograde direction or be released to infect adjacent cells. Although a number of viral
glycoproteins have been implicated in efficient egress of virions from non-neuronal cells, their
role in neuronal transport has not been studied extensively (Mettenleiter, Klupp et al. 2009). The
findings of this dissertation suggest a possible similarity between the role of gK in neurons and
non-neuronal cells. The infection phenotype observed in neurons recapitulates in many ways the
infection observed in non-neuronal cultures. Herpes simplex virions have evolved a highly
complex system for optimum infection of neurons, the ultimate destination of the virus. It is
conceivable that virus entry via transmission of virus through epithelial neuronal synapses, or
direct infection of axonal termini requires the presence of gK.
UL20 and gK are required for cytoplasmic virion envelopment and egress in
epithelial cells (Hutchinson, Roop-Beauchamp et al. 1995; Jayachandra, Baghian et al.
1997; Melancon, Luna et al. 2005). Lack of gK drastically inhibited transmission of
virus from somata-containing chambers to axonal termini embedded within VK302 cell
monolayers. Neurons, unlike epithelial or fibroblasts have an intricate distribution of
cytoplasmic organelles within somata and axons. Specifically, TGN derived-membrane
vesicles migrate to synapses and play important roles in synapse formation among
neurons (Sytnyk, Leshchyns'ka et al. 2004). Therefore, it is conceivable that cytoplasmic
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envelopment of virions occur within both somata and via budding into TGN-derived
vesicles proximal to synaptic membranes.

CURRENT AND FUTURE WORK
Neurons are known to express nectin-1, which binds gD and functions in virus entry
(Richart, Simpson et al. 2003; Simpson, Manchak et al. 2005). In agreement with these
published results, we have readily detected nectin-1 expression in neuronal termini, axons and
somata. In particular, nectin-1 appears to be expressed at or near the synapse of sensory neurons
(Salinas, Schiavo et al. 2010). Nectin-1 is known to primarily mediate endocytosis of virions
rather than fusion of the viral envelope with cellular membranes (Milne, Nicola et al. 2005).
However, HSV-1 is thought to enter the neuron via viral membrane fusion with the neuron
plasma membrane (Salinas, Schiavo et al. 2010). Therefore one area of interest is determining
the receptor constituents used by HSV-1 as it enters the neuron and the exact entry mechanism;
e.g. fusion versus endocytosis. The entry mechanism may have a significant impact on what
viral proteins accompany the capsid as it enters the neuron cytoplasm and eventually axon.
Following other work in this lab, this may require extensive investigation in the gB, gK,
UL20 interactions. Another area of interest for further investigation is a further refinement of the
exact domains that influence the virus’ ability to infect and be transported in neurons. These
domains may provide additional insights to the complex interactions of the envelope proteins the
domains responsible for neuroinvasiveness, morphogenesis, egress, and fusion are examined for
simultaneous functions and higher order interactions with other proteins.
As these properties of the virus are determined, this research may bring great advances
in the potential development of vaccine strains and safety mechanisms in viruses used for viral

210	
  

tumor therapy. The identification of the exact determinants of neuronal infection, transport and
eventual latency, if combined with the determinant for a robust immune reaction would enhance
the efficacy and safety of herpes viruses used for therapies or preventative vaccines.
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APPENDIX

DEVELOPMENT OF PRIMARY NEURON CULTURE

CELL SOURCES
I attempted to use a variety of different cells as sources for the primary neuronal
culture system. These included harvested cerebral cortical cells from mice, commercial
frozen cortical and ganglionic cells from mice and rats, harvested cortical cells from rats,
and harvested dorsal root ganglionic neurons from rats. In addition to the primary cells,
redifferentiation of neuroblastoma cell lines to a primary cell was attempted. The
greatest and most easily reproduced success was with the dorsal root ganglionic neurons
from the rat.
When evaluating these potential systems, three main factors were necessary for a
usable system for our experiments. The first factor was survival of the neurons in
sufficient quantity and density to provide a reasonable population for experimentation
and microscopic visualization. The second factor was the growth of axons of sufficient
length to allow the use of a culture system that could physically separate the neuron cell
body (soma) from the termini of axons (neurites) so we could separate anterograde and
retrograde transport. In practice this required an axon to grow to a length of at least 450
microns before the neuron would die from senescence in prolonged cell culture. The
third factor was the development of a robust network of axons and neurites on the axonal
side of the culture system that would provide a reasonable substrate for infection and
reporter cell co-plating.
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Redifferentiation of neuroblastoma cell lines is accomplished using retinoic acid
in varying doses to force the cells to go from an undifferentiated, tumor state to a
differentiated neuron. Using this system, we could get the neuroblastoma cells to achieve
a morphology more similar to a primary neuron rather than a tumor cell-line; however,
these were unsuitable for our experiments because the axons produced were not
consistently long enough to be placed in a chamber system that could isolate the axonal
processes from the cell bodies. In fact, the morphology of these neurons usually more
closely resembled the morphology of a cortical neuron with many short dendrites
surrounding the soma and very rare, short axons when they were present. Cultures of
cortical neurons, in all cases, were unsuitable for the same reasons. Although cortical
neurons consistently produce dense, hearty neurons the processes are uniformly of
insufficient length for the purposes of our proposed experiments. This was found with all
cortical neuron types, including: commercial, primary harvested, frozen and shipped rat
or mouse neurons as well as on-site harvested rat and mouse cortical neurons.
Ganglionic neurons harvested from mice in our lab were also unsatisfactory. This
is likely a technical problem that may be overcome; however, in my experience yields
were insufficient for our experiments. This is likely due to the extreme difficulty of
harvesting ganglionic neurons from the neonatal mouse, as the ganglia are very small and
difficult to visualize. Using the commercial, primary, frozen rat and mouse ganglionic
neurons was initially promising with decent density of neurons at plating. These neurons
seemed to lack viability as the duration of cultures progressed. Axonal growth was slow
and by the time axonal processes were nearing sufficient length, the density of neurons
was extremely poor.
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By far the most suitable cultures came from dorsal root ganglia of rats. These
ganglia are challenging to dissect for primary culture, but not prohibitively difficult like
mouse ganglia. One particular challenge to the harvest of a primary cell such as a
neuron; is that there is significant time lapse from euthanasia of the animal to removal of
the neural tissue and placement of this tissue in a media that will prevent cell death. In
these systems, animals are generally euthanized and then dissection proceeds to the
ganglia. After dissection, the ganglia must be enzymatically treated to achieve a single
cell suspension before addition to a growth medium for plating in a culture system. I
found two things to significantly enhance neuron survival, and therefore plating density,
during this stage. The use of a dissecting solution, composed of phosphate buffered
saline supplemented with 3.5 grams per liter of sucrose and 7 grams per liter of glucose,
for all stages of dissection and enzymatic dissociation greatly influenced neuron survival.
Also, whenever possible keeping the tissues to be dissected and the dissected ganglia
cold, as situated in a Petri dish over ice, was helpful. The method used to produce
consistent, robust cultures of rat dorsal root ganglia will be covered in more detail next.

PRIMARY RAT DORSAL ROOT GANGLIONIC NEURON HARVEST

Rats
Harvesting the ganglia of varying ages of rats was attempted. All attempts were
made ranging from embryonic to 7 days after birth. Neurons harvested from rats between
3 and 7 days after birth may give initial robust plating densities; however, these neurons
usually die during the second week of culture leading to insufficient axon growth and
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very poor neuron densities by the time neurons are ready for experimentation. For our
experiments we used Sprague-Dawley rats that had a gestation of 21-22 days. Dorsal
root ganglia (DRG) neurons from rats ranging from embryonic day 17 (E17) to 48 hours,
2 days, after birth (P2) provide suitable neurons for abundant plating densities and
sufficient survival times to allow for axon growth and experimentation. The only
difficulty with this age for harvest is that the spinal column has mineralized to a more
significant degree making removal of the ganglia more time consuming, which can
contribute to loss of cells if the dissector is not proficient. For my harvests, the ideal age
was day 15-16 of gestation (identified as E15-E16 pups). Any earlier and the tissues
were too soft to handle without major structural disruption. At E15-16, once the vertebral
column is dissected from the spinal cord, the spinal cord can be removed with the DRG
maintaining their attachment. Later than E16, the dissection of the vertebrae is easier due
to greater size and structure of the tissues but the DRG will separate from the spinal cord
unless careful and time-consuming dissection is performed. The DRG must be
individually separated from connections that hold them against the remaining spine.

Dissection and Processing
My preferred technique is as follows. First a pregnant rat is euthanized at day 1516 of gestation. The rat is rapidly dissected along the abdominal midline and the uterine
horns containing the E15-16 pups are placed in conical tubes containing dissecting
solution that are situated in an ice bath. The rat pups are dissected from the uterus as
needed and are otherwise left in the solution in the ice bath. Using a dissecting
microscope, individual rat pups are laid on their back and the ventral midline is incised
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with sharp-tipped micro-dissection forceps. These forceps are used to remove all the
thoracic and abdominal viscera from the pup. Then micro-dissection, spring scissors are
used to remove the tail at the pelvis. Then from the caudal to the cranial end of the pup,
one tip of the scissors is inserted into the spinal column and the lateral wall of all
vertebral bodies is cut. Care must be taken to avoid traumatizing the spinal cord
excessively. The best cut is made with the flat cutting axis of the scissors running
parallel to ribs and the scissors as low as possible to the level of the rib attachments,
without actually cutting the ribs. This will usually take several snips to travel the full
length of the spine. After making this cut from the tail to the cervical spine near the base
of the skull, the ventral floor of the vertebral bodies can be removed. During this process
rib attachments have usually separated from vertebrae. At this point, the spinal cord can
be visualized and the DRG should be visible as small, oval, lumps lying next to the spinal
cord between and alternating with the remnants of the vertebral bodies or ribs (Fig A.1).
For the next cut, the cutting axis of the scissors is directed perpendicularly to the
direction of the ribs. From the tail to the head, a cut is made longitudinally just lateral to
the spinal cord on both sides. The longitudinal cuts should run from the caudal to the
cranial extremity of the pup, cutting soft tissues and rib attachments just slightly lateral to
the vertebrae, where the DRG are situated, but leaving the DRG with the spinal cord.
Then the head is cut from the cervical spine with the scissors. Using two sets of microdissection forceps, the dorsal remnant of the spine is stabilized against the dissecting
surface with one hand while the spinal cord is gently pulled up using the other hand.
Using E15-16 pups should allow all DRG to be removed still attached to the spinal cord.
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At this point, the spinal cord with the attached DRG, is placed in a Petri dish
containing dissection solution that is on ice (Fig A.1). The dissection process can be
repeated to increase the number of ganglia. Care must be taken to balance a large harvest
with the time taken to remove the ganglia, as the percentage of neurons that will not
survive increases with increasing time to placement in media. I usually harvest between
10 and 15 pups, trying not to take longer than 90 minutes for the harvest step. Once
spinal cords with attached ganglia are collected in a petri dish, the individual ganglia are
dissected from the spinal cords using either micro-dissection scissors or a small scalpel
blade. Spinal cords are discarded. Using a glass pipette, ganglia are suctioned and
placed in a 15 ml conical tube with approximately 2 ml of dissection solution. Care must
be taken to prevent excessive adherence of ganglia to the sides of the glass pipette. Some
dissection protocols recommend pre-coating the inside of the glass pipette with serum
prior to suctioning a tissue that may adhere. I avoid this because serum is also used to
inactivate the trypsin that will be used to enzymatically digest the tissues in the next step.
I have found a quick pre-pipette of dissection solution can help. Also pipetting quickly in
multiple batches is preferable to allowing the ganglia to sit in the barrel of the pipette for
any length of time.
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Figure A.1: Pictures of primary neuron harvest from embryonic rat dorsal root
ganglia. For all pictures, rats at 4 days post birth were used to enhance visualization of
pertinent tissues. A: The spinal cord can be observed following the removal of the
ventral segments of the vertebral bodies. Black arrows designate the positions of the
DRG interspersed between the remnants of the attachments of the ribs and the remaining
vertebral body tissue. B: Higher magnification of the spinal cord, DRG, and vertebrae.
The position of the DRG are denoted by black arrows. Note DRG are slightly less shiny
and more translucent appearing than the adjacent bone and cartilage. C: A 35 mm petri
dish filled with dissection solution, containing several spinal cords that have been
removed with the DRG attached. At this magnification, DRG are just visible as small
nodules slightly protruding from the sides of the spinal cords. D: Higher magnification
of a segment of a spinal cord with DRG attached. White arrows demonstrate the DRG as
small nodules extending from the spinal cord.
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Once ganglia are in the conical tube, trypsin is added at a final concentration of
0.25 mg/ml. Ganglia are placed in a 37 degree Celsius water bath for 45 minutes,
swirling every 5 minutes to agitate. Trypsin may be diluted to stock concentrations using
dissection solution and stored for at least 6 months at -80 degrees Celsius. Once ganglia
have incubated for 45 minutes, allow to sink to the bottom of the tube by gravity for 1-2
minutes. Pipette off excess enzyme solution. The next step neutralizes trypsin, therefore,
leaving some is preferable to removing more than a few ganglia when removing the
enzyme solution. For neutralization of trypsin and plating of neurons, neuronal media
(recipe will be included later) supplemented with 10% fetal bovine serum (FBS) is used.
This will be referred to as plating media. Add approximately 2 ml of plating media to the
tube, swirl, and allow ganglia to settle by gravity for 1-2 minutes. Remove media by
pipetting and repeat this neutralization step twice more to ensure full rinsing and
neutralization of trypsin. Add the plating media to a final volume of 2 ml on the ganglia.
Using a glass Pasteur pipette, pipette up and down to agitate the ganglia to make a single
cell suspension. A fired, pulled pipette may be used for a more narrow diameter that will
provide greater turbulence and agitation but these are usually not necessary. The opening
of the pipette can be placed against the bottom of the tube to restrict flow and give greater
turbulence as well. The solution should rapidly become cloudy. At this stage the tissues
are very soft and should dissociate fairly easily with 10 or less pipettings. Neurons are
also fragile at this point and exceedingly vigorous pipetting can cause cell death.
Once a single cell suspension is achieved, a sample should be taken to count the
cell number. Use of a vital dye, such as Trypan Blue, can be used to count living cells in
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the 2 mls of plating media. While counting cells, centrifuge the neuron suspension to
form a pellet. Centrifuge at 400 times gravity or less for 5 minutes. Remove supernatant
taking care to not disturb the cell pellet. Resuspend the cells in a small amount of
residual media. Using the cell count obtained earlier, calculate the total number of live
cells and dilute to the desired plating concentration using plating media. I usually plate
between 60,000 and 100,000 cells, with 75,000 cells being a good average to achieve the
desired plating for our neuronal devices. It is important to note that not all of these are
neurons. Although I have not performed specific counts, I suspect half or less of the total
cell amount is neurons. From a harvest of the ganglia from 12 pups, I can usually
achieve approximately 4 million total live cells.
After dilution to the desired concentration, neurons may be plated. For our
neuron devices, the SND450 from Xona Microfluidics (more information in Materials
and Methods section of second data chapter), a pipetting volume of 12-15 microliters is
necessary for use with the device. The central chamber of interest only holds
approximately 1 microliter but it is impossible to pipette a single microliter in a manner
that fills the chamber without significant and disruptive air bubbles. Therefore, I plate at
a concentration of 5,000 cells per microliter. Allow the neurons to adhere to prepared
surface (instructions on preparing a substrate to follow) for 15 min to 1 hour, then fill
chambers of the neuron device with plating media.
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PRIMARY CULTURE
Neuron Medias and Maintenance
Unless otherwise specified, the neuronal media used is as follows (suppliers and
more information included in Materials and Methods of the second data chapter): Neural
basal media supplemented with 1 X B27 supplement, 1% Glutamax, 2% normal rat
serum, 2% Primocin and 50 nanograms per milliliter neural growth factor 2.5s. For the
plating and neutralizing media used during dissection, this media is further supplemented
with 10% FBS. I have found that plating with this media enhances neuron attachment,
survivability, and axon growth. Generally neurons grow best using a system of removing
half the current media and replacing with fresh, not full media changes. Therefore, the
only full media changes occur when adding or removing anti-mitotic agents. Twentyfour hours after plating, an anti-mitotic agent must be added to the culture. These agents
enrich the culture for neurons. All other cultured cell types will attempt to divide in
culture. The addition of these agents inhibits division causing the other cells (namely
astrocytes and glial cells with some fibroblasts) to die and be removed from the culture
with successive media changes. At 24 hours post plating, neuronal media, supplemented
with 5 micromolar cytosine-β-d-arabinofuranoside (CAB), is added to the culture. At 48
hours post plating, this media is removed and replaced with normal neuronal maintenance
media. At 72 hours post plating, neuronal media, supplemented with 2 micromolar CAB,
is added to the culture. At 4 days post plating, this media is removed and replaced with
normal neuronal maintenance media. Successive media changes all occur with
maintenance media, every 2-3 days depending on pH indicator color to determine
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metabolic state and needs. Unless necessary to maintain proper pH, only half of the
media should be changed.
With this plating strategy, large numbers of neurons are placed into the central
chamber (the area of interest) of the neuron devices. Primary neurons in cell culture tend
to aggregate especially when densely cultured. Neurons also tend to grow processes in
an attempt to build a significant network of interconnections with neighboring cells. A
serendipitous side effect of the anti-mitotic agents is that they will help prevent this
somewhat. Large numbers of neurons are also present in the wells. These neurons are
very dense and are more likely to cause aggregation of chamber neurons to the well than
contribute to the area of interest. To prevent this, the neurons in the device chambers can
be vacuumed out during the early media changes as long as care is taken to avoid
disrupting the central chambers. In practice, this seems to also stimulate additional
growth across the microgrooves to the axonal side of the chamber; likely as the neurons
attempt to find connections that would have been preferentially diverted toward the wells
if many neuron somata were in the wells. Once established, neuron cultures are rather
stable and will grow robust interconnected axons within 1-2 weeks post plating. At this
point they are ready for use in an experiment.
During the course of developing the culture system, maintenance media and
plating media went through many permutations. There are reports of various
neurotrophic factors enhancing axonal development, particularly in enhancing directional
growth. In my experience, the use of brain derived neurotrophic factor, glial cell derived
neurotrophic factor, and ciliary neurotrophic factor did not provide a substantial benefit
whether used individually or in combination. Anecdotally, I believe they may have
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enhanced directional axonal growth to some degree, however, this was not sufficient to
overcome the negative effects. It appeared that the use of these factors in concentrations
sufficient to stimulate some growth, also stimulated increased migration of cells through
the microgrooves. This is highly problematic, since it must be definitively determined
that these are not neurons or the integrity of the anterograde versus retrograde state of the
device is suspect. Some of these devices were tested and I was able to confirm neuron
migration post plating through the microgrooves (or possibly under the device as a
whole) as a consequence of this treatment. We also attempted to use varying
concentrations of neural growth factor to stimulate growth, as axons will tend to grow
toward the high side of a gradient. In the devices we were using this was similarly
dissapointing. Once again, there seemed to be minimal increase in directional axonal
growth with increased cellular migration to the non-plated side.

Reporter Cell Co-Culture
If a reporter cell culture is desired, to simulate an epithelial-axonal interface as
might be found in an animal, cell-line cultures may be co-plated over the axons. Once
the axon density on the axon side of the chamber is at the desired level, cells such as
Vero or VK302 cells may be co-plated. To plate these over the axons, cells grown to a
confluent monolayer are trypsinized as normal for splitting of the cells. Once trypsinized
and disrupted to a single cell suspension, trypsin is neutralized with 100% FBS. Then the
cells in the FBS are centrifuged to produce a cell pellet. Cells are resuspended, diluted in
media and plated by filling the wells of the axon side with this media. For the Vero and
VK302 cells that we use, one T-75 flask can be resuspended in 4 mls of media with about
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150 microliters of that used for plating per well (so 300 microliters for a device with two
wells on the axon side). The media used for this purpose is a one-to-one ratio of our
standard Vero cell media and neuronal media supplemented with a final concentration of
10% FBS. Our standard Vero or VK302 cell media consists of Dulbecco’s modified
eagle media supplemented with 20 micromolar HEPES buffer. Plated cells in the axon
chamber often do not grow well beyond the initial plating. To provide more access to
nutrients, cells in the wells may be suctioned out the day after plating, similar to neurons.

Setting up Neuronal Devices and Substrates for Plating Neurons
Neuron devices are commercially available polydimethylsiloxane chips that have
been shaped using laser lithography. These devices were described previsously in the
neuronal transport chapter. Briefly, when placed on a coverslip or Petri dish, they can
create a chamber with that allows culture of neurons and growth of axons to a second
chamber that is functionally impermeable to virus by diffusion. This type of chamber
allows the study of retrograde and anterograde transport separate from one another.
Neurons may be plated on glass coverslips or directly on plastic Petri dishes that will act
as the floor of these chambers. In either case neurons grow best with the least clumping
using a dual coating of poly-D-lysine and laminin. However, with a laminin coated
substrate, axonal growth seems more aggressive and neurons are much more likely to
penetrate under a neuron device. The virus impermeable barrier can only be guaranteed
if axons only grow through the device microgrooves and growth under the device as a
whole disrupts this barrier. Lysine only coated surfaces seem to have a failure rate of
about 10% when well prepared while laminin coated devices can reach 20-25% failure.

226	
  

To prepare a substrate, whether glass or plastic, poly-D-lysine, at a concentration
of 0.1-0.25 milligrams per milliliter in borate buffer, is placed on the substrate and
incubated at 37 degrees Celsius. For a lysine only coating, this is best done for 48 hours
prior to use. For a dual coating, lysine is allowed to coat the substrate for 24 hours. Then
the substrate is washed 5 times with sterile water and laminin, at a concentration of 0.01
milligrams per milliliter in borate buffer, is placed on the substrate for 24 hours at 37
degrees Celsius. After coating with either method, the substrate is washed 5 times with
sterile water and allowed to dry completely but not excessively. Ideally the substrate
should be assembled with the neuron device within 30 minutes of fully drying. Neuron
devices are prepared by treating with an ethanol soak followed by rinsing 5 times with
sterile water and fully drying. Once substrate and neuron device are dry, a device is
pressed very firmly onto the substrate to ensure a complete seal. It is recommended that
when using glass coverslips a very flat, sterile, surface is used, otherwise coverslips may
crack from unequal pressure during this step. Very aggressive pressure can help to make
laminin coated substrated less likely to fail; and in a recent experiment the failure rate
with extensive pressure was below 20%. Once the device and substrate are assembled,
they should be placed in a humidified incubator to prevent excess dehydration of the
laminin. Prepared devices should be plated with neurons the same day as they are
prepared but lysine coated devices can be used with some success after 1-2 additional
days if necessary. When devices are ready for an infection, as determined by sufficient
axonal growth and branching and reporter cell culture if desired, media levels must be
adjusted to maintain barrier. The side being infected should always have a lower fluid
level in the wells than the uninfected side. Removal of media with a media change for
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the “high” side is recommended at this time, since following the addition of virus, only
addition of media, not removal and change, is recommended to avoid accidental loss of
fluid pressure gradient. Media may be added to either side to combat dehydration as long
as gradient is maintained. See schematics of neuron devices with fluid pressure gradients
demonstrated (Fig A.2). A scale model of a cross section of a single microgroove with
representations of the sizes for the HSV virion particle, a typical dorsal root ganglionic
neuronal axon, and a typical dorsal root ganglionic neuronal soma are provided for
comparison (Fig A.3).
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Figure A.2: Microfluidic Neuron Device. A: Picture of a microfluidic neuron device
containing media in a 35mm Petri dish. B: Three dimensional wire-frame, side view
schematic of wells, central chamber and microgrooves of microfluidic device. The
microgrooves are 3 microns tall by 10 microns wide and 450 microns long. The central
chambers that connect same side wells (only one well from each side shown in this
schematic) are 100 microns high by 1.5 mm wide and 7 mm long. Wells are 8 mm in
diameter. C: Color schematic, top view, of a retrograde setup. D: Color schematic, top
view, of an anterograde setup with reporter cells on axon side of device.

229	
  

Figure A.3: Scale model of the cross section of a microgroove in a microfluidic
neuron device. Scale side view schematic of the cross section of a microgroove from a
microfluidic neuron device. The microgrooves are 10 x 3 microns (width x height) and
450 microns long. There are scale appropriate size examples of an average dorsal root
ganglion cultured axon with a diameter of about 1 micron and the range of the HSV virus
particle with a reported 120-300 micron diameter. For comparision, on the bottom: In
one study, that characterized cultured DRG’s, neuronal cell bodies ranged from 20-50
microns for the cell body diameter. The smallest of these soma diameters is represented
in this schematic.
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